00-PS Rheumatology-prelims-ccpp:prelims
27/3/08
13:06
Page iii
Problem Solving in
Rheumatology KEVIN PILE MB ChB, ...
288 downloads
3801 Views
2MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
00-PS Rheumatology-prelims-ccpp:prelims
27/3/08
13:06
Page iii
Problem Solving in
Rheumatology KEVIN PILE MB ChB, MD, FRACP Conjoint Professor of Medicine, University of Western Sydney, New South Wales, Australia
LEE KENNEDY BSc, MB ChB, MD, PhD, FRCP, FRCPE, FRACP Professor of Medicine, School of Medicine, Department of Medicine, James Cook University, Queensland, Australia
CLINICAL PUBLISHING OXFORD
00-PS Rheumatology-prelims-ccpp:prelims
27/3/08
13:06
Page iv
00-PS Rheumatology-prelims-ccpp:prelims
27/3/08
13:06
Page v
Contents Abbreviations vii
SECTION 1 1. 2. 3. 4. 5. 6. 7.
New Onset Painful Joints 1 An Acutely Swollen/Hot Joint 6 Painful Shoulders – Rotator Cuff and Frozen Shoulder 11 Tennis Elbow and Golfer’s Elbow 18 Carpal Tunnel Syndrome and Other Entrapment Neuropathies 21 Fibromyalgia Syndrome 27 Plantar Fasciitis 33 SECTION 2
8. 9. 10. 11. 12. 13.
Osteoarthritis
Causes and Prevention 39 Non-Pharmacological Treatment 45 Drug Treatment 50 NSAIDs – Gastric Side Effects and Protection 54 NSAIDs – Cardiac Complications 60 Joint Replacement Surgery 65 SECTION 3
14. 15. 16. 17. 18. 19. 20.
General Rheumatology and Soft Tissue Rheumatism
Rheumatoid Arthritis
Causes 71 Laboratory and Imaging Investigations 77 Managing Rheumatoid Arthritis at Onset 82 Evaluating the Response to Treatment 87 Pregnancy and Rheumatic Diseases 92 Diet and Arthritis 97 Polyarthritis in the Elderly 103 SECTION 4
Systemic Lupus Erythematosus, Sjögren’s Syndrome and Scleroderma
21. Antinuclear Factor 109 22. SLE – Risk Factors and Diagnosis 116 23. Monitoring and Managing SLE 122
00-PS Rheumatology-prelims-ccpp:prelims
vi
27/3/08
13:06
Page vi
Contents
24. 25. 26. 27.
Sjögren’s Syndrome 129 Raynaud’s Phenomenon 134 Assessing and Treating Scleroderma 139 Immunosuppressive Drugs 147 SECTION 5
Vasculitic Syndromes
28. Vasculitic Disease 153 29. Giant Cell Arteritis and Polymyalgia Rheumatica 159 30. Behçet’s Syndrome 165 SECTION 6 31. 32. 33. 34. 35. 36. 37. 38. 39.
Acute Back Pain 169 Chronic Back Pain 175 Psoriatic Arthritis 178 Asymptomatic Hyperuricaemia 184 Gout – Acute Attack and Beyond 189 Pseudogout – Investigation and Management 195 Joint and Bone Infections 199 Viral Arthritis 205 Rheumatological Complications of Diabetes 211 SECTION 7
40. 41. 42. 43. 44. 45. 46.
Back and Specific Joint Problems
Bone Diseases
Osteoporosis – Prevention and Lifestyle Management 217 Bisphosphonates for Osteoporosis – Which Agent and When? 222 Osteoporosis – Drugs Other Than Bisphosphonates 227 Male Osteoporosis 233 Glucocorticoid-Induced Osteoporosis 237 Paget’s Disease of Bone 241 Bone Complications of Renal Disease 246 SECTION 8
Muscle Diseases
47. Steroid myopathy 253 48. Inflammatory Myopathies 260 49. Muscle Complications of Statin Therapy 265 General index 271
00-PS Rheumatology-prelims-ccpp:prelims
27/3/08
13:06
Page vii
Abbreviations ABD ACE ACR ADAMTS ADFR
ADP ADR AMP ANA ANCA ANF AP AP-1 APPROVe APS AS ASC ATP B19 BASMI BMD BMI BP BPs C5 c-ANCA CCB CCTG CCL2 CCP CDSN CEP cGMP CHB CI
adynamic bone disease angiotensin-converting enzyme American College of Rheumatology a disintegrin and metalloproteinase with thrombospondin motif Activate, Decrease osteoclast activity, Free of treatment and Repeat adenosine diphosphate adverse drug reaction adenosine monophosphate antinuclear antibody anti-neutrophil cytoplasmic antibodies antinuclear factor alkaline phosphatase activator protein-1 Adenomatous Polyp Prevention on Vioxx study antiphospholipid syndrome ankylosing spondylitis apoptosis-associated speck-like protein adenosine triphosphate parvovirus B19 British Ankylosing Spondylitis Metrology Index bone mineral density body mass index blood pressure bisphosphonates fifth cervical segment cytoplasmic anti-neutrophil cytoplasmic antibody calcium channel blocker cytosine-cytosine-thymine-guanine monocyte chemoattractant protein1 (see also MCP-1) cyclic citrullinated peptide corneodesmin circulating endothelial precursor cyclic guanosine monophosphate congenital heart block confidence interval
CIM CK CKD CKD-MBD CLASS Clc-l CMC CNS CORE COX COX-1 COX-2 CPEO CPPD CREST
CRP CSS CT CTG CTGF CTS CTLA4-Ig CVD CXR D3 DC DD DEXA DHA DHEA DIL DIP DISH DLCO DM DM1
critical iIlness myopathy creatine kinase chronic kidney disease CKD-mineral and bone disorder Celecoxib Long-term Arthritis Safety Study chloride channel carpometacarpophalangeal central nervous system Continuing Outcomes Relevant to Evista cyclooxygenase cyclooxygenase-1 cyclooxygenase-2 Chronic Progressive External Ophthalmoplegia calcium pyrophosphate dihydrate Calcinosis; Raynaud’s phenomenon; Esophageal dysmotility; Sclerodactyly, Telangiectasia C-reactive protein Churg–Strauss syndrome computed tomography cytosine-thymine-guanine connective tissue growth factor carpal tunnel syndrome cytotoxic lymphocyte-associated antigen linked to immunoglobulin cardiovascular disease chest X-ray 1,25-dihydroxy-vitamin D3 dendritic cell Dupuytren’s disease dual-energy X-ray absorptiometry docosahexaenoic acid dehydroepiandrosterone drug-induced lupus distal interphalangeal diffuse idiopathic skeletal hyperostosis diffusing capacity for carbon monoxide dermatomyositis myotonic dystrophy type 1
00-PS Rheumatology-prelims-ccpp:prelims
viii
DMOAD DMPK dsDNA EBV EDTA EEG EGF eGFR ELISA EMG ENA eNOS EPA ESR ET FA FBC FDG-PET
GCA GDM GFR GI GMP GSD GTP GVHD H2RA HBA1C HBO2 HDL HELLP HIV HLA
HNPP
13:06
Page viii
Abbreviations
DM2 DMARD
FGF FKBP-12 FMS FVC FSH GAIT
27/3/08
myotonic dystrophy type 2 disease-modifying antirheumatic drug disease-modifying osteoarthritis drug myotonic dystrophy protein kinase double-stranded DNA Epstein–Barr virus ethylenediaminetetraacetic acid electroencephalogram epidermal growth factor estimated glomerular filtration rate enzyme-linked immunosorbent assay electromyography extractable nuclear antigen endothelial nitric oxide synthase eicosapentaenoic acid erythrocyte sedimentation rate endothelin fatty acid full blood count (18)-F-fluorodeoxyglucose-positron emission tomography fibroblast growth factor 12 kDa FK506-binding protein fibromyalgia syndrome forced vital capacity follicle-stimulating hormone Glucosamine/chondroitin Arthritis Intervention Trial giant cell arteritis gestational diabetes glomerular filtration rate gastrointestinal guanosine monophosphate glycogen storage disease guanosine triphosphate graft-versus-host disease histamine H2 receptor antagonist glycosylated haemoglobin hyperbaric oxygen high-density lipoprotein Haemolytic anaemia, Elevated Liver enzymes, Low Platelets human immunodeficiency virus human leukocyte antigen (genetic designation for human major histocompatibility complex) hereditary neuropathy with liability to pressure palsies
hnRNP HPRT HRCT HRT HSP HTLV-1 IBD IBM IFN Ig IGF-1 Iκβ IL IL-1ra IMPDH IMT INR IP IU JSN LBP LDL LFA-1 LFT LIFE LJM LORA LRP-5 LUMINA LH MCP MCP-1 MCTD MELAS MERRF MI MMF MMP MORE MPA
heterogeneous nuclear ribonucleoprotein hypoxanthine phosphoribosyltransferase high-resolution computed tomography hormone replacement therapy Henoch-Schönlein purpura human T-lymphotropic virus type 1 inflammatory bowel disease inclusion body myositis interferon immunoglobulin insulin-like growth factor-1 inhibitor of kappa-beta interleukin interleukin-1 receptor antagonist inosine monophosphate dehydrogenase intima-media thickness International Normalized Ratio inflammatory polyarthritis International Units joint space narrowing low back pain low-density lipoprotein lymphocyte function-associated antigen-1 liver function test Losartan Intervention for Endpoint reduction limited joint mobility late-onset RA LDL receptor-related protein-5 Lupus in minorities: nature versus nurture luteinizing hormone metacarpophalangeal monocyte chemoattractant protein1 (see also CCL2) mixed connective tissue disease Myopathy, Encephalopathy, Lactic Acidosis and Stroke Myoclonic Epilepsy with Ragged Red Fibres myocardial infarction mycophenolate mofetil matrix metalloproteinase Multiple Outcome of Raloxifene Evaluation microscopic polyangiitis
00-PS Rheumatology-prelims-ccpp:prelims
27/3/08
13:07
Page ix
Abbreviations MRI MRSA MSA MTOR MTP MUA NALP
NCS NFAT NF-κB NHANES NIH NO NOD NOS NOS-2 NOS-3 NSAID OA OCP 25(OH)D OPG OR PADAM PADI PAH PAN p-ANCA PCR PCT PDGF PET PG PGI2 PIP PM PM/DM PMR PP PPAR
magnetic resonance imaging methicillin-resistant Staphylococcus aureus myositis-specific antibodies mammalian target of rapamycin metatarsophalangeal manipulation under anaesthesia pyrin domain-containing proteins sharing structural homology with NODs nerve conduction studies nuclear factor of activated T lymphocytes nuclear factor-κ-beta National Health and Nutrition Examination Survey National Institutes of Health nitric oxide nucleotide-binding and oligomerization domain proteins nitric oxide synthase inducible nitric oxide synthase endothelial nitric oxide synthase (eNOS) non-steroidal anti-inflammatory drug osteoarthritis oral contraceptive pill 25-hydroxy-vitamin D osteoprotegerin odds ratio partial androgen deficiency in aging men peptidylarginine deaminase pulmonary artery hypertension polyarteritis nodosa perinuclear anti-neutrophil cytoplasmic antibody polymerase chain reaction plasma procalcitonin platelet-derived growth factor positron emission tomography prostaglandin prostacyclin proximal interphalangeal polymyositis polymyositis/dermatomyositis polymyalgia rheumatica pyrophosphate peroxisomal proliferator-activated receptor
PPI PPRP PRIMO PsA PTH PTNP22 PUFAs QALY RA RANK RANKL RCT REM RF RISC RNA RNP ROD ROS RR RS3PE RUTH SAPHO SE SELENA SERM SHBG SI sIL-6R SJC SLC22A4 SLE Sm SOBOE SOTI SPARC SPECT SRP SRRR SS SSc ssDNA
ix proton pump inhibitor 5¢phosphoribosyl 1-pyrophosphate Prediction of Muscular Risk in Observational conditions psoriatic arthritis parathyroid hormone protein tyrosine phosphate nonreceptor type 22 polyunsaturated fatty acids quality-adjusted life year rheumatoid arthritis receptor activator of NF-κB receptor activator of NF-κB ligand randomized controlled trial rapid eye movement rheumatoid factor RNA-induced silencing complex ribonucleic acid ribonucleoprotein renal osteodystrophy reactive oxygen species relative risk remitting seronegative symmetric synovitis with pitting oedema Raloxifene Use for The Heart Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis shared epitope Safety of Estrogens in Lupus Erythematosus National Assessment selective oestrogen receptor modulator sex hormone binding globulin sacroiliac soluble receptor for IL-6 swollen joint count solute carrier family 22 A4 systemic lupus erythematosus Smith antigen shortness of breath on exertion Spinal Osteoporosis Therapeutic Intervention secreted protein acidic and rich in cysteine single photon emission computed tomography signal recognition particle sibling recurrence risk ratio Sjögren’s syndrome systemic sclerosis single-stranded DNA
00-PS Rheumatology-prelims-ccpp:prelims
x STAT1 sTNFR SSRI TB TBF TGF-β Th1 Th2 TIMP TJC TLR TKA TMV TNF TNFR2 TRAP
27/3/08
13:07
Page x
Abbreviations signal transducer and activator of transcription-1 soluble receptor for TNF selective serotonin reuptake inhibitor tuberculosis thermal biofeedback transforming growth factor-β T helper 1 cells T helper 2 cells tissue inhibitor of metalloproteinase tender joint count Toll-like receptor total knee arthroplasty turnover, mineralization and volume tumour necrosis factor TNF-α receptor type 2 tartrate-resistant acid phosphatase
TROPOS TSH TxA2 U1RNP UA U/E UDP UK US UV VDR VEGF VIGOR WBC WHO WOMAC XO
Treatment Of Peripheral Osteoporosis Study thyroid-stimulating hormone thromboxane A2 uracil-rich 1 ribonucleoprotein uric acid urea and electrolytes uridine diphosphate United Kingdom United States ultraviolet light vitamin D receptor vascular endothelial growth factor Vioxx Gastrointestinal Outcomes Research study white blood cell World Health Organization Western Ontario and McMaster Universities xanthine oxidase
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
S E C T I O N
18/3/08
14:28
Page 1
O N E
01
General Rheumatology and Soft Tissue Rheumatism 01
New onset painful joints
02
An acutely swollen/hot joint
03
Painful shoulders – rotator cuff and frozen shoulder
04
Tennis elbow and golfer’s elbow
05
Carpal tunnel syndrome and other entrapment neuropathies
06
Fibromyalgia syndrome
07
Plantar fasciitis
P R O B L E M
01 New Onset Painful Joints
Case History June is a 32-year-old tour guide with an eight-week history of painful stiff hands and difficulty walking in the mornings. The symptoms usually last for 90 minutes. For the last six weeks she has been using diclofenac 50 mg bd with moderate benefit. Her mother has rheumatoid arthritis treated with methotrexate. What additional history will help to determine a diagnosis? What is the relevance of her family history? What aspects of the examination will be particularly relevant? Which investigations should be performed?
© Atlas Medical Publishing Ltd
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
2
18/3/08
14:28
Page 2
§01 General Rheumatology and Soft Tissue Rheumatism
Background History Obtaining a clear history of June’s symptoms will assist greatly in narrowing your initial differential diagnosis as a prelude to examination and investigations. Open questions that encourage the person to start with their initial symptoms provide chronology and the pattern of progression. Gentle prompting can, towards the end of consultation, be supplemented with specific questions. As you listen to the story, you will be assessing the impact of the symptoms on the individual’s life and its components of family, work and leisure. Specifically: 쎲 쎲 쎲 쎲 쎲
Are symptoms related to a musculoskeletal problem? Was there an identified trigger or precipitant? What has been the pattern or progression of symptoms? Are there features of systemic illness or inflammatory disease? Has anything helped the problem?
Pain and loss of function are primary presenting symptoms, but do not always coexist. Individuals differ in their descriptors of pain, its intensity and its impact. You will be told when the problem began and where. Is the pain in a joint; in a related joint structure such as tendon, ligament or bursa; or in a bone? What is the nature of the pain; when does it occur; and what is the effect of movement? Malignant pain is usually a dull, deep ache within a bone, occurring at night or when resting. Similar symptoms may occur with Paget’s disease or with a fracture. Differentiators of inflammatory from non-inflammatory/mechanical joint pain are summarized in Table 1.1. Table 1.1 Differentiators of joint pain Inflammatory pain
Non-inflammatory/mechanical pain
• • • • • •
• • •
Pain and stiffness predominant in morning and at end of day Stiffness greater than 30 minutes Symptoms lessen with activity Pain does not improve with rest Localized erythema, swelling, tenderness Systemic features – fatigue, weight loss
Short-lived joint stiffness Pain worsens with activity Pain improves with rest
Localization of pain requires clarification as to whether symptoms are recreated by contact or movement in the area, or whether the pain is referred from another site. Referred pain occurs when sensory perception externalizes nociceptive input from the sclerotome or myotome of an affected structure to the relevant dermatome. Table 1.2 shows common referred pain patterns. Onset of symptoms following trauma supports mechanical disruption of a joint, disruption of a joint’s surrounding capsule and ligaments, or fracture. Less obvious triggers to explore are infections (Table 1.3), vaccinations (Rubella) and recent travel. A tactful approach is required when soliciting information on genitourinary symptoms or a
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 3
01 New onset painful joints
3
Table 1.2 Common presentations of referred pain Area pain experienced
Origin of pain
Shoulder
Cervical spine
Biceps and lateral upper arm
Shoulder and rotator cuff
Groin, inner knee
Hip
Lateral thigh, buttock
Trochanteric bursa
Table 1.3 Common infections associated with arthritis Viral
Gastrointestinal
Genitourinary
Hepatitis B, C
Salmonella typhimurium
Chlamydia trachomatis
Rubella
Shigella flexneri
Parvovirus
Yersinia enterocolitica
Arbovirus *
Campylobacter jejuni
* Serology should be tested according to exposure.
history of a new sexual partner, as it is not obvious to a patient with arthritis as to why you would be asking such questions. A comprehensive family history is a key part of every clinical history. A familial pattern of a specific diagnosis such as rheumatoid arthritis (RA), ankylosing spondylitis or systemic lupus erythematosus (SLE) highlights that diagnosis, and may also raise related diagnoses that are particularly relevant for seronegative spondyloarthritides such as psoriasis or inflammatory bowel disease.
Examination Examination identifies the pattern and number of joints involved and extra-articular features (Table 1.4). Features of inflammation are sought: temperature, pulse and blood pressure are measured, and an assessment is made of localized erythema and warmth, tenderness, inflammation obscuring the joint margins, and reduced function. You should distinguish monoarthritis from oligoarthritis (≤4 joints) and polyarthritis (>4 joints), whether these joints are large or small, and whether there is spinal (particularly sacroiliac) involvement. Distal to the wrist and ankle there are at least 56 joints, so that as the number of joints increases, the greater the probability is of involvement of both hands and feet and of the pattern becoming increasingly ‘symmetrical’. Fingernails are assessed for pitting or onycholysis suggestive of psoriasis. The scalp, umbilicus, natal cleft and extensor surfaces of knee and elbow should be inspected. The presence of a malar rash or photosensitive rash in a young woman suggests SLE.
Investigations Investigations serve to: 쎲 Confirm or refute a diagnostic possibility
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
4
18/3/08
14:28
Page 4
§01 General Rheumatology and Soft Tissue Rheumatism
Table 1.4 Patterns of arthritis Pattern
Monoarthritis
Inflammatory spinal disease Sacroiliitis
Asymmetrical large joint arthritis
Symmetrical small joint arthritis (MCP, PIP, MTP)
DIP hands
Differential diagnosis
Trauma
Ankylosing spondylitis
Psoriatic arthritis
RA
Haemophilia Septic Gout Pseudogout
Psoriatic arthritis IBD
Reactive arthritis IBD
SLE Psoriatic arthritis
Inflammatory OA (if involves PIP and 1st CMC) Psoriatic arthritis
Review personal and family history HLA-B27
Review personal and family history Examine for conjunctivitis and urethritis, and scalp and buttocks for psoriasis Infection screen
Examine X-ray hands rheumatoid nodules Skin rashes, serositis or mucositis
Further X-ray investigations Aspirate for crystals and culture
X-ray lumbar spine and SI joints
Urinalysis RF, CCP antibodies, ANA X-ray hands and feet
ANA, antinuclear antibodies; CCP, cyclic citrullinated peptides; CMC, carpometacarpophalangeal; DIP, distal interphalangeal; IBD, inflammatory bowel disease; MCP, metacarpophalangeal; MTP, metatarsophalangeal; OA, osteoarthritis; PIP, proximal interphalangeal; RA, rheumatoid arthritis; RF, rheumatoid factor; SI, sacroiliac; SLE, systemic lupus erythematosus.
쎲 Monitor for known complications of the disease process or proposed treatment 쎲 Document a parameter that changes with disease activity or treatment The latter includes the inflammatory markers erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), which are non-specific markers. Whenever the possibility of a septic joint is considered, obtaining aspirate and culture from the joint is mandatory. Aspirated fluid is collected into a sterile container and an ethylenediaminetetraacetic acid (EDTA)-containing tube to enable a cell count, and is sent with a request for Gram staining, polarized light microscopy, culture and sensitivity, and cell count and differential cell count. If there will be a significant delay in the sample reaching the laboratory, fluid can be inoculated into a blood culture system. The early signs and symptoms of RA are not always typical. RA is characterized as autoimmune partly on the basis of the presence of rheumatoid factor (RF), an autoantibody (usually immunoglobulin M [IgM]) targeting the Fc portion of IgG. Its sensitivity is low, ranging from 60%–80%, and specificity is lower, the antibody being frequently present in other connective tissue diseases, which limits the diagnostic utility.
Recent Developments 1 RF is present in 70% of RA cases but is not specific, occurring in 5% of healthy individuals, and globally is more associated with chronic infection than rheumatic diseases. Non-RF antibodies were first described in the 1960s, with the target
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 5
01 New onset painful joints
5
epitopes now identified as citrulline residues, which are arginine residues modified by peptidylarginine deaminase (PADI). Assays are now available for the detection of antibodies to cyclic citrullinated peptides (anti-CCP antibodies), which are highly sensitive and specific for RA and are a poor prognostic marker of joint erosion, vasculitis and rheumatoid nodules.1 The specificity of anti-CCP in RA is >90% with sensitivity of 33%–87%. When combined with IgM-RF, antiCCP has positive predictive value of >90% for RA.2 A study of undifferentiated polyarthritis found that 93% of subjects positive for anti-CCP at first clinic visit progressed to RA compared to 25% who were anti-CCP negative.3 2 Smoking increases the risk of RA 2–4 fold and also influences the manifestations of the disease – with increased RF positivity and erosive disease, nodularity and vasculitis – similar to the findings noted with anti-CCP antibodies. Smoking may break immune tolerance by creating neo-epitopes on IgG and thus leading to RF development. Recent work has shown that smoking is associated with increased citrullination. The subsequent citrullinated antigens bind with more affinity to the HLA-DR4 shared epitope subtypes, leading to increased risk of RA.4
Conclusion Persistent arthropathy in a younger patient necessitates both accurate diagnosis and effective management. A working knowledge of local infectious triggers is required, with supplemental knowledge of the likely pathologies based on age and gender. History and examination need to include potential exposure to infectious triggers, along with personal and family history. Examination will confirm or exclude significant joint inflammation, and provide information on its pattern and severity (number of joints and functional impact). Targeted investigations will narrow the diagnosis, with the urgent investigation being exclusion of septic arthritis if there is clinical suspicion.
Further Reading 1
Mimori T. Clinical significance of anti-CCP antibodies in rheumatoid arthritis. Intern Med 2005; 44: 1122–6.
2
Schellekens GA, Visser H, De Jong BAW et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155–63.
3
van Gaalen FA, Linn-Rasker SP, van Venrooij WJ et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50: 709–15.
4
Gorman JD. Smoking and rheumatoid arthritis: another reason just to say no. Arthritis Rheum 2006; 54: 10–13.
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
6
18/3/08
14:28
Page 6
§01 General Rheumatology and Soft Tissue Rheumatism
P R O B L E M
02 An Acutely Swollen/Hot Joint
Case History You have been asked to see a 28-year-old man who presents with a 36-hour history of a red and very swollen right knee, upon which he is unable to weight bear. He has been previously well and has no relevant family history. The clinic nurse has recorded his temperature as 37.9°C and a random blood glucose is 7.3 mmol/l. What is your preliminary differential diagnosis? What additional history and examination is relevant? What are the key investigations? How should he be managed?
Background Differential diagnosis The knee is one of the most common joints affected by monoarthritis, which is fortunate since it is so easy to aspirate. The differential diagnosis of monoarthritis is listed in Table 2.1. Table 2.1 Differential diagnosis of monoarthritis Trauma – Meniscal or ligamentous tears ± haemarthrosis Sepsis – Gonococcal arthritis, Staphylococcus aureus, penetrating injury, foreign body Reactive arthritis – Following gastrointestinal or genitourinary infection Haemophilia Crystal arthritis – Gout, pseudogout Inflammatory – e.g. Rheumatoid, psoriatic
Trauma conjures images of motor vehicle accidents or dramatic tackles in rugby; however, much more mundane twisting injuries or valgus/varus strains when under load are common. A rapidly developing joint swelling within minutes of the injury is suspicious of an anterior cruciate ligament tear with involvement of the blood vessel running along its surface. If internal mechanical derangement is considered possible, then imaging or © Atlas Medical Publishing Ltd
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 7
02 An acutely swollen/hot joint
7
Table 2.2 Common errors in diagnosing acute monarthritis Error
Reality
The problem is the joint because the patient has ‘joint pain’
Surrounding soft tissues, including bursitis, may be the source of pain
The presence of intra-articular crystals excludes infection
Crystals can be present in a septic joint
Fever distinguishes infectious causes from other causes
Fever may be absent in septic monoarthritis, and in the immunocompromised patient. Acute crystal arthritis may cause fever
A normal serum urate makes gout unlikely, and a high level confirms gout
Serum urate is normal for 30% of acute gout attacks, and only 5% of those with hyperuricaemia develop gout each year
Gram staining and culture of synovial fluid are sufficient to exclude infection
Fastidious, slow-growing organisms, or fragile organisms, may not be identified in early infection. Liaison with the laboratory is required for specialist media and prolonged incubation
orthopaedic review is warranted. Table 2.2 highlights some common errors in diagnosing acute monoarthritis. The presence of fever suggests infection, and the patient should be questioned and examined to determine the likely source. Septic arthritis is usually exquisitely tender with resistance to joint movement. Staphylococci are the most common cause of musculoskeletal sepsis, with the prevalence of both streptococcal and mycobacterial infection increasing. For infections with staphylococci, streptococci, Gram-negative bacteria and anaerobes, only one joint is usually involved. Polyarticular involvement is more likely in the elderly or immunosuppressed, with infection by Haemophilus influenza, meningococci and Neisseria gonorrhoeae. Lyme disease can present with knee involvement, although the diagnosis can be quickly excluded if there has been no exposure to the tick vector of Borrelia burgdorferi. In young patients, gonococcal arthritis is the most common non-traumatic acute monoarthritis, and questioning regarding sexual partners and genitourinary symptoms is necessary. In addition to arthritis (often polyarticular), tenosynovitis and a pustular rash of the extremities should be sought. Gonococcal arthritis is 3–4 times more common in women, who often develop arthritis in the perimenstrual period. Men often experience a urethritis as dysuria, and may notice a morning discharge, whereas women may be asymptomatic. Reactive arthritis is a sterile arthritis, occurring distant in both time and place from an inciting infection (usually gastrointestinal or genitourinary). Lower limb asymmetric oligoarthritis is most common, with associated enthesitis such as Achilles tendinitis, and mucocutaneous features of conjunctivitis, pustular rash on the hands and feet and sterile urethritis. Common triggers are genitourinary infection with Chlamydia trachomatis and gastrointestinal infection with Salmonella typhimurium, Shigella flexneri, Campylobacter jejuni and Yersinia enterocolitica. Stool culture and collection of early morning urine for detection of chlamydia DNA by polymerase chain reaction (PCR) should be considered. Crystal arthritis is both dramatic and rapid in onset, with the most commonly implicated crystals being uric acid, calcium pyrophosphate and hydroxyapatite. Gout is
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
8
18/3/08
14:28
Page 8
§01 General Rheumatology and Soft Tissue Rheumatism unusual in the young and is usually preceded by more distal joint involvement, classically the first metatarsophalangeal joint (podagra). Pseudogout or calcium pyrophosphate dihydrate (CPPD) deposition disease is uncommon below the age of 50 years and the knee is most often involved, followed by wrist and shoulder. Basic calcium phosphate (hydroxyapatite) results in a calcific periarthritis, which most commonly affects the shoulder.
Aspirating a knee joint Every medical graduate should feel confident to undertake knee aspiration (Figure 2.1). The knee is exposed with the patient lying so that you can obtain access to either the medial or lateral aspect. The knee is generously cleaned with antiseptic and allowed to dry whilst you are preparing the aspiration syringes. The patella is pinched between thumb and index finger at its midpoint, which allows you to detect tension in the quadriceps muscles and also allows you to distract the patella upwards to increase the infrapatellar space. Local anaesthetic (5–10 ml) is infiltrated via a 21G or 23G needle at a point proximal and inferior to where you are holding the patella, noting that the pain-sensitive structures are the dermis and the thickened synovium as you enter the joint. When the anaesthetic has been given time to work, the joint is aspirated along the same needle track with a fresh 10–20 ml syringe and 18G needle. Afterwards, a dressing is applied firmly for several minutes to ensure haemostasis and to prevent synovial fluid leakage.
Figure 2.1 Arthrocentesis of the left knee – medial approach.
Only 1–2 ml of fluid is sufficient to complete all investigations; however, the joint should be aspirated of as much fluid as possible without increasing the trauma of the procedure. Substantial pain relief is achieved by aspirating a tense effusion, and while reaccumulation will occur, it buys some time while the preliminary investigation results are received. As the aspirate is removed, you should note its colour, viscosity and turbidity. Normal synovial fluid is similar to egg white (syn = resembling, ovium = egg) and is both viscous and acellular. As the degree of inflammation increases – from the negligible amount found in osteoarthritis to the mid-range of rheumatoid arthritis and the extreme of septic arthritis – the viscosity decreases and the cellularity and turbidity increase.
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 9
02 An acutely swollen/hot joint
9
Table 2.3 Synovial fluid characteristics Normal
Non-inflammatory
Inflammatory
Septic
Colour
Clear
Straw yellow
Yellow
Variable
Clarity
Transparent
Transparent
Hazy opaque
Opaque
Viscosity
High
High
Low
Low–Thick
WBC (¥ 106/l)
0–200
200–2000
2000–75 000
>75 000
Neutrophils
<25%
<25%
25%–50%
>75%
WBC, white blood cell.
Blood-coloured effusions suggest either trauma or CPPD deposition disease. Synovial fluid characteristics are shown in Table 2.3. It is suggested that approximately 2 ml of fluid is collected into a container plus anticoagulant, and the remaining fluid collected in a large-volume sterile container. Tests requested should include an urgent Gram stain, cell count and differential count, crystal examination using polarized light microscopy and culture. If gonococcal or fungal infections are suspected, this needs to be highlighted as it influences the culture medium and length of culture required. Analgesics, antipyretics and rest should be employed in the first instance, with the aspiration itself often affording a considerable pain relief. If septic arthritis is suspected, then intravenous antibiotics covering Staphylococcus aureus and N. gonorrhoeae should be commenced after the synovial fluid aspiration. The presence of bacteria on Gram staining or subsequent bacterial growth requires specialist medical and orthopaedic review to combine antibiotic therapy with joint lavage. Gout is confirmed by the presence of intracellular, negatively birefringent urate crystals, with intracellular pyrophosphate crystals confirming pseudogout. Both of these conditions are self-limited and spontaneously improve over a few days. Adequate hydration combined with analgesia and the introduction of a non-steroidal anti-inflammatory drug will generally suffice. Colchicine at a dose sufficient to impact on acute gout invariably causes diarrhoea. If you have confirmed the joint is sterile, then intra-articular corticosteroid injection provides excellent resolution.
Recent Developments 1 A prospective study of children presenting for investigation of possible septic arthritis of the hip concluded that oral temperature >38.5°C was the best predictor, followed by an elevated serum C-reactive protein (CRP), an elevated erythrocyte sedimentation rate, refusal to weight bear and an elevated white cell count.2 CRP >20 mg/l was a strong independent risk factor and a valuable tool for assessing and diagnosing septic arthritis of the hip. As the number of risk factors increases so does the predicted probability of septic arthritis, such that three to five factors present is associated with 83%–98% predictive probability.
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
10
18/3/08
14:28
Page 10
§01 General Rheumatology and Soft Tissue Rheumatism 2 Increased plasma procalcitonin (PCT) may be a useful marker for osteomyelitis but not septic arthritis. Procalcitonin is cleaved in neuroendocrine tissues – such as thyroid C cells, lung and pancreatic tissue – to calcitonin. During infection, large amounts of PCT are released. The source is probably monocytes stimulated by endotoxin, and hepatocytes stimulated by tumour necrosis factor or interleukin-6. The role of PCT measurement with a rapid immunoassay was investigated in children admitted with suspected osteomyelitis or septic arthritis.3 The authors reported specificity of 100% and sensitivity of 58% for osteomyelitis and the same specificity, but lower 27% sensitivity, in septic arthritis. 3 High-resolution magnetic resonance imaging (MRI) of soft tissues and joints is increasingly used prior to interventions such as arthroscopy. In a cohort of children, Luhmann and colleagues4 compared radiological interpretation of knee MRI with that of the surgeon who integrated the history, clinical examination, plain radiographs, MRI scans and radiologist report. The pre-operative diagnosis by the surgeon was better (P <0.05) than the formal radiology interpretation with respect to anterior cruciate ligament tear, lateral meniscal tear, osteochondritis dissecans and discoid lateral meniscus.
Conclusion An acutely hot, swollen joint is an urgent presentation. Exclusion of sepsis is mandatory, particularly in children and immunocompromised patients. Joint aspiration remains the investigation of choice. Subsequently, treatment will often include antibiotics, pending laboratory results, combined with judicious use of analgesia and anti-inflammatory medications. Analysis of synovial fluid is valuable in establishing the diagnosis of gout, particularly in joints other than the classical podagra of the great toe. Patients often interpret the doctor’s ‘it could be gout’ comment about their sore joint as either a definitive diagnosis or as a slur on an indulgent lifestyle, when neither may be intended.
Further Reading 1
Siva C, Velazquez C, Mody A, Brasington R. Diagnosing acute monoarthritis in adults: a practical approach for the family physician. Am Fam Physician 2003; 68: 83–90.
2
Caird MS, Flynn JM, Leung YL, Millman JE, D’Italia JG, Dormans JP. Factors distinguishing septic arthritis from transient synovitis of the hip in children. A prospective study. J Bone Joint Surg Am 2006; 88: 1251–7.
3
Butbul-Aviel Y, Koren A, Halevy R, Sakran W. Procalcitonin as a diagnostic aid in osteomyelitis and septic arthritis. Pediatr Emerg Care 2005; 21: 828–32.
4
Luhmann SJ, Schootman M, Gordon JE, Wright RW. Magnetic resonance imaging of the knee in children and adolescents. Its role in clinical decision-making. J Bone Joint Surg Am 2005; 87: 497–502.
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 11
03 Painful shoulders – rotator cuff and frozen shoulder
11
P R O B L E M
03 Painful Shoulders – Rotator Cuff and Frozen Shoulder
Case History Mr Lawrence, a 76-year-old retired driver, is having difficulty living independently after returning home following a recent myocardial infarction. On the day of discharge he fell heavily, landing on his left upper arm. His concern is a very painful left shoulder, especially at night and when he tries to move his left arm during the day. How would you determine whether he has adhesive capsulitis (frozen shoulder)? Is there a role for medical imaging, and if so, what modality? What treatment should be initiated?
Background Shoulder pain is an almost unavoidable life experience; in one study, 7% of an adult population aged 25–75 years reported at least one month’s shoulder pain in the previous year. The peak annual incidence of shoulder disorders is in the fourth and fifth decades, at a rate of 0.25%. A Dutch study found that 25% of all 85-year-olds in Leiden suffered from chronic shoulder pain and restriction. Community-based surveys concur with this high incidence of soft tissue lesions about the shoulder, with roughly equal sex incidence. Up to 20% of patients with chronic symptoms and 65% of all diagnoses relate to lesions of the rotator cuff. Rotator cuff disease is the most common cause of shoulder pain found in these studies. An ultrasound study found rotator cuff tears in 13% of 50–59-year-olds, 20% of 60–69-year-olds, 31% of 70–79-year-olds and 51% of subjects aged over 80 years, even when they were asymptomatic. Table 3.1 summarizes causes of shoulder pain. The pain-sensitive structures of the shoulder are mainly innervated by the fifth cervical segment (C5), so that pain from these structures is referred to the C5 dermatome creating the sensation of pain over the anterior arm, especially the deltoid insertion. The acromioclavicular joint is innervated by the C4 segment – pain arising here is felt at the joint itself and radiates over the top of the shoulder into the trapezius muscle and to the side of the neck.
Clinical assessment A history of trauma, marked night pain and weakness on resisted abduction strongly suggests a rotator cuff tear. The sleeping position that induces night pain is an important clue: © Atlas Medical Publishing Ltd
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
12
18/3/08
14:28
Page 12
§01 General Rheumatology and Soft Tissue Rheumatism
Table 3.1 Causes and clinical characteristics of shoulder pain Category
Cause
Clinical features
Extracapsular lesions
Rotator cuff and subacromial bursa (e.g. impingement Painful arc of abduction syndromes, calcific tendinitis, cuff tears, bursitis) Pain on resisted cuff muscle movements, with intact passive movement (allowing for pain and guarding) Pain on impingement manoeuvres as the inflamed rotator cuff tendons impinge on the inferior surface of the acromion and coracoacromial arch
Intracapsular lesions
Glenohumeral joint (inflammatory arthritis – RA, spondyloarthritis, pseudogout) Joint capsule (adhesive capsulitis) Bone disease (Paget’s disease, metastases)
Loss of both active and passive movement Reduced glenohumeral range Night pain Muscle strength, allowing for pain, is intact
Referred pain
Cervical spine (facet joint root impingement, discitis) Brachial plexus (brachial amyotrophy) Thorax (Pancoast’s tumour) Thoracic outlet syndrome Suprascapular nerve entrapment Subdiaphragmatic (abscess, blood, hepatic lesions)
Arm and hand pain with paraesthesia Marked muscle weakness and wasting Neck pain and stiffness Herpes zoster rash Systemic features with weight loss
shoulder pain that results in awakening when not lying on that shoulder is found in adhesive capsulitis and inflammatory arthritis; pain when lying on the affected shoulder is seen in acromioclavicular joint disease and rotator cuff disease. Prior shoulder problems suggest rotator cuff disease with chronic impingement, or calcific tendinitis. A history of marked shoulder joint swelling suggests inflammatory arthropathy with the presence of an anterior bulge in the shoulder usually secondary to a subacromial bursa effusion. Glenohumeral osteoarthritis (OA) is characterized by morning stiffness, pain with use and chronicity of symptoms. OA, however, is less common than rotator cuff dysfunction. Examination of the shoulder is best undertaken with the patient wearing the minimum of upper body clothing. The contours of the shoulder are examined for wasting, asymmetry and muscle fasciculation. Palpation should proceed from the sternoclavicular joint along the clavicle to the acromioclavicular joint, to the tip of the acromion and the humeral head beneath the acromion. The shoulder range of movement should be examined both actively and passively, with muscle strength and pain on resistance assessed. There are essentially three movements to test in the shoulder: abduction due to supraspinatus contraction; external rotation as a result of infraspinatus and teres minor movement; and internal rotation due to subscapularis movement (Box 3.1). Box 3.1 Practice Point Three positive clinical tests (supraspinatus weakness, weakness of external rotation and impingement) or two positive results for a patient older than 60 years are highly predictive of a rotator cuff tear.1 Complete rotator cuff tears will show no active abduction but near full-range movement when passively moved. During examination ask about a painful arc during abduction (Figure 3.1). When examining active and passive abduction you should stand behind the patient and place one hand over the shoulder and scapula. The scapula should not begin to
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 13
03 Painful shoulders – rotator cuff and frozen shoulder
13
Painful arc of abduction acromioclavicular joint
180°
Painful arc of abduction in rotator cuff 120°
70°
Figure 3.1 Painful arc: the patient slowly abducts the arm as high as possible, describing symptoms as the arm rises.
elevate or rotate until at least 90 degrees of abduction has been reached. Early scapulothoracic movement localizes the abnormality to the glenohumeral joint or capsule, as seen in frozen shoulder. You should examine external rotation at 0 degrees abduction, with the elbow beside the chest, and if external rotation is absent then a frozen shoulder is likely. Next re-examine both internal and external rotation at 90 degrees abduction; if both are restricted, a frozen shoulder is again likely. Bicipital tendinitis is examined by testing resisted flexion at 30 degrees external rotation, and feeling for tenderness in the bicipital groove. Shoulder impingement can be reproduced by internally rotating the arm held flexed at 90 degrees and bringing the inflamed rotator cuff against the anterior acromion. The ‘empty can’ test is suggestive of a rotator cuff tear: it shows pain on resisted elevation of the inverted arm held extended at 90 degrees, as if emptying a can of drink.
Rotator cuff disease The glenohumeral joint is, by virtue of its anatomical shape, inherently unstable, relying on the joint capsule as well as the rotator cuff muscles (supraspinatus, infraspinatus and subscapularis) for additional stability. Impingement of the rotator cuff between the proximal humerus and the acromioclavicular arch may occur from anomalies of the arch (structural impingement) and from instability due to joint hyperlaxity or weak rotator cuff muscles (functional impingement). Coracoacromial arch anomalies may be congenital, dependent on acromial shape. Three shapes have been described – flat, curved and
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
14
18/3/08
14:28
Page 14
§01 General Rheumatology and Soft Tissue Rheumatism hooked – although there is poor inter-observer agreement on identifying the shape. Acquired impingement occurs secondary to osteophytes growing from the acromioclavicular joint or calcification of the acromioclavicular ligament. Impingement occurs when the cuff becomes compressed in the subacromial space as the arm is elevated. As the humeral head rotates, the rotator cuff tendons are compressed between the greater tuberosity of the humerus and the anterior edge of the acromion, the coracoacromial ligament, the under-surface of the acromioclavicular joint and with the reactive inflammatory subacromial bursa. In addition to the impingement theory, a vascular theory has been proposed. With the arm at the side, it has been suggested that the supraspinatus tendon has a relative avascular area 1 cm proximal to its insertion at the greater tuberosity, directly beneath the impingement zone. This may be affected by the position of the shoulder and increases with age. However, the infraspinatus tendon has a similar vascular watershed area, suggesting that factors other than vascularity are important. Chronic irritation in the avascular region produces tendinitis, leading to local inflammation and further compression. Other causes of tendinitis include trauma, instability and possibly infarction of the cuff in patients with vascular disease. The vascular and impingement theories are not mutually exclusive and it is possible that the high incidence of supraspinatus pathology is the result of impingement in and around a critical zone of vascular supply. With time, wearing and attrition of the cuff leads to impaired action or rupture of the short rotators stabilizing the humeral head into the glenoid fossa, so that the deltoid pulls the humerus against the under-surface of the acromion and a vicious impingement cycle is established. Impingement-caused tears are usually incomplete in the supraspinatus and infraspinatus tendons and complete in the long head of biceps. Complications of impingement include a frozen shoulder, rupture of the rotator cuff tendons or long head of biceps and, in elderly patients with a long-standing tear, a feared end-stage lesion, ‘recurrent haemorrhagic shoulder of the elderly’. Treatment depends on the mechanism of impingement. Patients with functional impingement are treated with a resting sling for 24–36 hours, pendular exercises and fulldose non-steroidal anti-inflammatory drug (NSAID). Structural impingement is treated similarly but the surgical options of arthroscopic surgery to remove osteophytes or trim the acromion are available. Corticosteroid injection to the subacromial space can be combined with an initial 4–7 days of pendulum exercises and avoidance of abduction prior to a programme of shoulder-strengthening exercises. Infraspinatus strengthening may be important to provide stabilization of the humeral head to prevent superior subluxation on abduction. Studies of eccentric loading exercises have shown promising results, particularly in lesion of the Achilles tendon. Eccentric loading exercises involve a load being applied to a muscle in its contracted position and the muscle is lengthened under the load. In the shoulder, the supraspinatus would be contracted with the arm abducted and under load the arm would slowly return to the side. Exercise programmes require highly motivated people and there is concern that exercises can increase symptoms initially.
Frozen shoulder/adhesive capsulitis Initially described in 1872, this condition remains as ‘difficult to treat and difficult to explain from the point of pathology’ as Codman observed in 1934. This common disor-
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 15
03 Painful shoulders – rotator cuff and frozen shoulder
15
der (2% cumulative risk in an at-risk population annually) is frequently misdiagnosed and is characterized by painful restriction of all shoulder movements, both active and passive, with characteristic restriction in the glenohumeral range. There is marked reduction or absence of shoulder external rotation at 0 degrees abduction, reduction of both internal and external rotation at 90 degrees abduction, as well as prominent restriction of placing the hand behind the back on internal rotation. Frozen shoulder is characterized pathologically by fibrosis and retraction affecting predominantly the anterior and inferior structures of the glenohumeral joint capsule. Patients usually present in the sixth decade and onset before the age of 40 years is uncommon. Table 3.2 lists the diseases associated with frozen shoulder, diabetes being the most significant. Diabetes, particularly long-standing insulin-dependent diabetes, is associated with glycosylation of subcutaneous collagen and the development of soft tissue contraction – so called diabetic cheiroarthropathy. Table 3.2 Common disorders associated with frozen shoulder
• • • • • • • •
Acute shoulder trauma and shoulder immobilization Diabetes mellitus Thyroid disease (both hyper- and hypothyroidism) Cardiac disease, particularly after cardiac surgery Neurological disease with loss of consciousness or hemiplegia Pulmonary disease – tuberculosis and carcinoma Rotator cuff disease, especially cuff tear Acute glenohumeral joint inflammation
Three phases of frozen shoulder are recognized: 1 Painful inflammatory phase. Beginning insidiously, with often only a minor injury being recalled, nocturnal awakening pain develops. The pain may be constant and prevents the patient lying on the shoulder. Physiotherapy often aggravates symptoms at this stage and corticosteroid injections are of limited benefit. This phase lasts 2–9 months. 2 Frozen shoulder. With time, the night and rest pain eases, but the shoulder remains ‘frozen’. Mean duration is 4–12 months. 3 Recovery phase. After a mean delay of 5–26 months, shoulder limitation slowly recovers in the majority of patients towards normal range (usually a 10%–30% loss of motion, which is often undetected by the patient). The total duration of symptoms lasts 12–42 months, with mean disease duration of 30 months. In 10%–20% of patients a contralateral frozen shoulder develops, usually milder than the first, while the original shoulder is ‘thawing’. It is important to educate patients that the condition will spontaneously resolve and the stiffness will greatly reduce. NSAIDs and analgesics are used but there are no randomized controlled trials studying efficacy. A prospective study in frozen shoulder compared exercise within the limits of pain with intensive physiotherapy. Those who performed exercises within the limits of pain had better results, recorded as near-normal painless shoulder movement (64% of patients at 12 months, 89% at 24 months), compared to intensive physiotherapy (63% of patients at
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
16
18/3/08
14:28
Page 16
§01 General Rheumatology and Soft Tissue Rheumatism 24 months).2 An early meta-analysis by Hazleman on the use of intra-articular steroids reported that the outcome depended on the duration of symptoms and hence possible stage of disease. Patients who receive the injection earlier in the course of the disease recover more quickly.3 An extensive meta-analysis by Buchbinder et al. found a benefit for glenohumeral intra-articular corticosteroid injection for frozen shoulder compared with placebo.4 For those unable to tolerate the pain and disability of a frozen shoulder, manipulation under anaesthesia (MUA) is a reliable way to improve the range of movement. It is particularly indicated when disability persists after six months of non-operative therapy. More recently, arthroscopic release of the capsule has been advocated as a more controlled release of the capsule than MUA. Arthroscopic release also avoids the complications of MUA such as fracture of the humerus and iatrogenic intra-articular shoulder lesions.5
Imaging Imaging is undertaken primarily when considering referred pain or a malignant process. In the assessment of rotator cuff disease, no imaging may be required initially, and may only be undertaken subsequently if the clinical progression is not as expected. A plain Xray should then be the initial imaging modality, because if there is marked superior migration of the humeral head, there must be complete rotator cuff disruption. Either magnetic resonance imaging or ultrasound can confirm a possible full-thickness rotator cuff tear, although ultrasound is significantly cheaper and is preferred by patients. Suspected partial-thickness tears are best verified with an ultrasound scan.1
Recent Developments 1 Oral steroids may be useful in frozen shoulder, particularly during the early inflammatory phase. Buchbinder et al.6 undertook a randomized controlled trial on a series of 50 patients and found that oral steroid therapy initially improved the frozen shoulder but the effect did not last beyond six weeks. Their subsequent analysis of five small trials, in which all subjects received physiotherapy or an exercise programme, confirmed that oral prednisolone or cortisone when given for 3–4 weeks had a modest benefit on pain and disability and ability to move the shoulder.7 2 Recently, a neural aetiology for tendinopathy has been considered.8 Tendinopathy was proposed as an appropriate term for a symptomatic primary tendon disorder, as it made no assumption as to the underlying pathological process. Underlying the neural theory are four basic observations: tendons are innervated; substance P has been found in rotator cuff tendinopathy and is a pro-inflammatory mediator; the neurotransmitter glutamate is also present in tendinopathy; and tendon nerve cell endings are closely associated with mast cells. It has been tentatively postulated that neural stimuli secondary to overuse or mechanical irritation lead to mast cell degranulation and release of mediators that begin an inflammatory cascade.
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 17
03 Painful shoulders – rotator cuff and frozen shoulder
17
Conclusion Frozen shoulder is a common and painful condition that impacts adversely on an individual’s activities of daily living. Despite being self-limited, recovery is protracted and a high proportion of patients do not regain full function. As a condition, it is largely managed in the community by primary physicians, physiotherapists and occupational therapists. Treatments that aim to mechanically stretch or disrupt the joint capsule (MUA, arthroscopic release or hydrodilation of the capsule) are reserved for those with severe symptoms who have failed to progress with conservative therapy.
Further Reading 1
Diehr S, Ison D, Jamieson B, Oh R. Clinical inquiries. What is the best way to diagnose a suspected rotator cuff tear? J Fam Pract 2006; 55: 621–4.
2
Diercks RL, Stevens M. Gentle thawing of the frozen shoulder: a prospective study of supervised neglect versus intensive physical therapy in seventy-seven patients with frozen shoulder syndrome followed up for two years. J Shoulder Elbow Surg 2004; 13: 499–502.
3
Hazleman BD. The painful stiff shoulder. Rheumatol Phys Med 1972: 11: 413–21.
4
Buchbinder R, Green S, Youd JM. Corticosteroid injections for shoulder pain. Cochrane Database Syst Rev 2003; CD004016.
5
Dias R, Cutts S, Massoud S. Frozen shoulder. BMJ 2005; 331: 1453–6.
6
Buchbinder R, Hoving JL, Green S, Hall S, Forbes A, Nash P. Short course prednisolone for adhesive capsulitis (frozen shoulder or stiff painful shoulder): a randomised, double blind, placebo controlled trial. Ann Rheum Dis 2004; 63: 1460–9.
7
Buchbinder R, Green S, Youd JM, Johnston RV. Oral steroids for adhesive capsulitis. Cochrane Database Syst Rev 2006; CD006189.
8
Rees JD, Wilson AM, Wolman RL. Current concepts in the management of tendon disorders. Rheumatology 2006; 45: 508–21.
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18
18/3/08
14:28
Page 18
§01 General Rheumatology and Soft Tissue Rheumatism
P R O B L E M
04 Tennis Elbow and Golfer’s Elbow
Case History Simon is a 48-year-old labourer. His work has required a large amount of manual screwdriver use, and he presents with a three-month history of an increasingly painful elbow. He now has trouble grasping objects such as a cup. What is the difference between tennis elbow and golfer’s elbow? What are the characteristics of each condition, and what treatment is indicated?
Background Tennis elbow Tennis elbow or lateral epicondylitis is an overload injury, which occurs after minor or unrecognized microtrauma to the proximal insertion of the extensor muscles of the forearm – particularly extensor carpi radialis brevis. Tennis elbow is the most frequently diagnosed elbow condition (Box 4.1); it occurs commonly in middle life (age 35–55 years) and has an incidence in general practice of 4–7 cases per 1000. Despite its common name, most cases occur in non–tennis players and it is frequently a work-related enthesopathy affecting up to 15% of workers in at-risk industries. Operative specimens reveal tendon glycosaminoglycan infiltration and microtears, as well as new bone formation at the attachment site. Both traction injury and ischaemia play a role in its development. Flexion deformity is unusual, occurs late and is minimal. Loss of 20 degrees of extension cannot be attributed to tennis elbow and warrants investigation for arthritis, impingement at the olecranon fossa or a soft tissue mass in the posterior aspect of the elbow. Tennis elbow is usually self-limiting, having an average duration of six months to two years, with 90% of subjects recovering within one year. Various conservative interventions exist including pain-relieving medications, corticosteroid injections, physiotherapy, elbow supports, acupuncture, surgery and shockwave therapy (Box 4.2). Box 4.1 Diagnosis of tennis elbow 쎲 Lateral elbow pain with tenderness on palpation just distal to the lateral epicondyle 쎲 Worsening pain localizing to the lateral epicondyle on resisted wrist dorsiflexion 쎲 X-rays excluding calcific tendinitis, exostoses and osteoarthritis of the radio-ulnar joint © Atlas Medical Publishing Ltd
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 19
04 Tennis elbow and golfer’s elbow
19
Box 4.2 Treatment of tennis elbow 쎲 Structured physiotherapy consisting of elbow manipulation and exercise, supplemented with home exercises and self-manipulation 쎲 Practical advice booklet on self-management and ergonomics 쎲 Recommend avoidance of corticosteroid injections, as short-term benefit is offset by a poorer longer-term outcome
Most important in treatment is activities modification – both frequency and method of performance. In tennis players, common errors are inadequate conditioning, incorrect grip size, faulty backhand style and problems with the racquet and its stringing. In the work setting, a review by an occupational therapist is recommended, particularly focusing on pronation/supination movements and grip size. A physiotherapy programme that includes strengthening exercises for the entire upper limb and a graded resistive programme for wrist dorsiflexors is recommended. In the setting of localized tenderness it is tempting to inject the lesion. As noted in Box 4.2, the short-term gain may be offset by a poorer long-term outcome. The injection technique is a small volume of corticosteroid and local anaesthetic injected into the tendinous insertion of extensor carpi radialis brevis into the lateral epicondyle. As the injection is not into a potential space but into an already tender, dense area, the injection is against resistance and is both uncomfortable and has the risk of steroid tracking superficially to the subcutaneous tissues, leading to depigmentation and atrophy. In contrast to other painful overuse syndromes in which total tendon ruptures have been reported (Achilles, biceps, patella), the tendon of the extensor carpi radialis brevis is strongly connected and supported by other extensors of the wrist. A small number of patients have recalcitrant lateral epicondylitis and are considered for operative intervention – open, arthroscopic and percutaneous. Operative interventions followed for a minimum of two years demonstrate an improvement compared to pre-operative status, with no difference in outcome according to procedure technique.1
Golfer’s elbow Golfer’s elbow or medial epicondylitis is the mirror image of tennis elbow, and is thought also to relate to repetitive traction stress and microtears at the insertion of the forearm flexors (flexor carpi radialis) and pronator teres into the medial epicondyle. It occurs in both professional and amateur sports players, as well as manual workers such as bricklayers. It is much less common than tennis elbow, with approximately one-twentieth the incidence. Similar to tennis elbow, the diagnosis is clinical, with localized tenderness that worsens on resisted wrist flexion and forearm pronation (Box 4.3). Box 4.3 Golfer‘s elbow 쎲 Elbow pain at the medial epicondyle 쎲 Increasing symptoms on resisted wrist flexion and resisted forearm pronation 쎲 Treatment includes modification of activities, upper limb exercises and analgesics
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
20
18/3/08
14:28
Page 20
§01 General Rheumatology and Soft Tissue Rheumatism
Recent Developments A randomized controlled trial compared the effectiveness of physiotherapy, corticosteroid injections and a ‘wait and see’ approach in 198 patients with tennis elbow who were randomized to the three treatment arms.2 Physiotherapy was eight sessions of mobilization with movement and exercises plus home exercises and self-manipulation. Injection therapy with triaminolone acetonide (10 mg) and 1% lidocaine was the second study arm. The ‘wait and see’ approach consisted of ergonomic instruction and use of analgesics, heat, cold and braces if needed. At six weeks the main outcome measures (global improvement, pain-free grip strength, assessor’s rating of complaints, severity of elbow pain and elbow disability) were significantly better in the corticosteroid-treated group than in the other groups. However, all groups were improving and the benefit of the steroid injection was short-lived, such that a crossover occurred around twelve weeks, with the one-year results showing physiotherapy superior to corticosteroid injections for all outcome measures. Importantly, at one year, the injection-treated group was significantly worse on all outcomes compared with the physiotherapy group, and on two out of three measures compared with the ‘wait and see’ group. The corticosteroid injection group also had the most reported recurrences. A similar study with only seven weeks of follow-up confirmed the benefits of steroid injections in the short term.3
Conclusion Tennis elbow is a common problem in general practice and is best treated with the knowledge that it is a self-limiting condition, with the majority of patients improving in the medium term. Whilst corticosteroid injections offer short-term benefit, there is the potential for both short-term adverse effects and the possibility of a worse outcome at one year. Physiotherapy provides benefit that is slower in onset but is more sustained and allows patients to become self-reliant in their own management.
Further Reading 1
Szabo SJ, Savoie FH, Field LD, Ramsey JR, Hosemann CD. Tendinosis of the extensor carpi radialis brevis: an evaluation of three methods of operative treatment. J Shoulder Elbow Surg 2006; 15: 721–7.
2
Bisset L, Beller E, Jull G, Brooks P, Darnell R, Vicenzino B. Mobilisation with movement and exercise, corticosteroid injection, or wait and see for tennis elbow: randomised trial. BMJ 2007; 333; 939–45.
3
Tonks JH, Pai SK, Murali SR. Steroid injection therapy is the best conservative treatment for lateral epicondylitis: a prospective randomised controlled trial. Int J Clin Pract 2007; 61: 240–6.
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 21
05 Carpal tunnel syndrome and other entrapment neuropathies
21
P R O B L E M
05 Carpal Tunnel Syndrome and Other Entrapment Neuropathies
Case History Beatrix is a 33-year-old production-line worker. For the last four weeks she has been awakening with painful pins and needles in her left hand and a dull pain that radiates from her wrist to her elbow. Shaking the arm improves the symptoms and she sometimes sleeps with her arm hanging out of the bed. What are the clinical features of the carpal tunnel syndrome? What is the role for imaging and nerve conduction studies? What investigations are appropriate to determine the cause? How would you manage this problem?
Background Entrapment neuropathies are disorders where peripheral nerves are damaged by compression as they pass through a bony or fibrous canal. The disorders may be precipitated by repetitive motion or strain, and carpal tunnel syndrome (CTS) is by far the commonest entrapment neuropathy and the most common focal peripheral neuropathy. The median nerve, along with the flexor tendons, passes through the carpal tunnel, which is bridged by the transverse carpal ligament (Figure 5.1). CTS affects 3% of the population although there is an imperfect correlation between reported symptoms and electrophysiological findings. Women are three times more likely than men to be affected with CTS, and a number of predisposing conditions are recognized (Box 5.1). CTS causes pain, numbness and tingling in the distribution of the median nerve: i.e. anteriorly, in the lateral half of the ring finger to the median half of the thumb; and posteriorly, in the distal halves of the ring and middle fingers. If severe, the symptoms may radiate up the arm and they can often occur at night, thus disturbing sleep. In severe cases there is a loss of small muscle function, which impairs manual dexterity and can lead to wasting of muscles of the thenar eminence. The symptoms of CTS are common and clinical signs (Box 5.2) are not always present. Accurate diagnosis is one of the major determinants of successful treatment. The diagnosis should be confirmed wherever possible by nerve conduction studies. © Atlas Medical Publishing Ltd
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
22
18/3/08
14:28
Page 22
§01 General Rheumatology and Soft Tissue Rheumatism
Median nerve Tendon sheath
Carpal ligament
Bundle of tendons
Figure 5.1 Anatomy of the carpal tunnel.
Other common nerve entrapment syndromes Thoracic outlet syndromes These are due to compression of the brachial plexus and brachial vessels in the neck. Costoclavicular syndrome, due to a narrowing of the space between the clavicle and first rib, may arise from congenital abnormality or because of poor posture. Cervical rib syndrome is due either to an extra rib or to a fibrous band between the seventh cervical vertebra and the sternum. Compression of nerves and vessels occurs as they pass over the additional structures. Adson’s test may be positive: the patient looks to the affected side and takes a deep breath while the examiner lifts the arm to 90 degrees. If compression is present, the radial pulse may disappear.
Suprascapular neuritis The suprascapular nerve (cervical segments C5/C6) supplies sensation to the shoulder joint and motor supply to the infraspinatus and supraspinatus muscles. It can become compressed as it passes through the suprascapular notch and under the transverse ligament.
Ulnar neuritis Compression of the ulnar nerve usually occurs in the canal, where it is covered by the arcuate ligament. It may also occur between the two heads of flexor carpi ulnaris just distal to the elbow joint. The syndrome may occur as a result of direct trauma or fracture, repetitive
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 23
05 Carpal tunnel syndrome and other entrapment neuropathies
23
Box 5.1 Causes of CTS Overuse
Injury Arthritis
Wrist ganglion Increased canal volume
Infections
Metabolic
Repetitive flexion or extension of the wrist, particularly while gripping objects firmly Use of walking stick in patients with mobility disorders Occupational – use of power tools, assembly-line work Colles fracture Subluxation of the lunate bone Rheumatoid – tendon sheath inflammation Osteoarthritis Gout or pseudogout Outpouching of the wrist joint capsule Pregnancy Obesity Congestive cardiac failure Lipoma Septic arthritis Lyme disease Tuberculosis Diabetes Hypothyroidism Acromegaly Amyloidosis
Box 5.2 Clinical signs of CTS Tinel’s sign
Tapping over the median nerve elicits symptoms in the distribution of the nerve Phalen’s sign Place both hands together palm to palm, with the wrists extended to 90 degrees, and forearms horizontal and close to the chest. The affected hand will begin to tingle within 1–2 minutes Reverse Phalen’s As above, but with the hands placed back to back movements or rheumatoid arthritis affecting the elbow joint. It causes pain and tingling down the inside of the forearm to the little finger and medial aspect of the ring finger. The nerve gives rise to a sensory supply to the skin of the hypothenar eminence and a motor supply to muscles of the hypothenar eminence and other small muscles in the hand.
Median neuritis This is a much less common syndrome and is usually due to entrapment of the nerve at the elbow. Symptoms are similar to those of the carpal tunnel syndrome and may be exacerbated by pronation of the forearm.
Radial neuritis Again, this is relatively uncommon. Compression usually occurs at the elbow and causes sensory symptoms in the forearm bone to the base of the thumb.
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
24
18/3/08
14:28
Page 24
§01 General Rheumatology and Soft Tissue Rheumatism
Meralgia paraesthetica The lateral cutaneous nerve of the thigh passes through the femoral canal, where it is sharply angulated and liable to compression. The syndrome leads to sensory symptoms in the middle and lower part of the lateral aspect of the thigh. It is caused by obesity, direct trauma or by repetitive flexion of the thigh.
Anterior compartment syndrome This part of the lower leg contains the tibialis anterior and extensor digitorum muscles and the deep peroneal nerve (supplies skin between the first and second toes). The nerve may be injured by unaccustomed running, as a result of tibial or fibular fractures or through direct trauma.
Medial compartment syndrome This is the most common lower-leg nerve entrapment syndrome. The symptoms include pain and tenderness on the medial aspect of the shin (‘shin splints’). It is often precipitated by unaccustomed running on a hard surface.
Posterior compartment syndrome This compartment contains the soleus and gastrocnemius muscles, which join together to form the Achilles tendon and are responsible for plantar flexion. The syndrome is associated with calf pain precipitated by exercise and with altered sensation on the sole of the foot. The management of all of these nerve entrapment syndromes is somewhat similar: the patient should rest wherever possible and avoid movements or actions that exacerbate the symptoms; local injection with anaesthetic or steroid is indicated in some cases, and a minority of patients require surgical decompression of the affected nerve.
Management of CTS1,2 쎲 General measures include trying to relax the grip, using grip-adapted implements such as large pens, taking frequent breaks, keeping the hands warm and considering posture and position (e.g. if using a keyboard, this should be at elbow height). Conservative management with ultrasound has been advocated but there are limited trial data to support this therapy. 쎲 Splinting the wrist in neutral position may alleviate symptoms related to soft tissue swelling and is most effective when used soon after the onset of symptoms. Nighttime splinting is often sufficient. 쎲 Non-steroidal anti-inflammatory drugs are effective in some cases, although improvement may be short-lived. Oral corticosteroids are more effective (e.g. prednisolone 20 mg/day for 2–3 weeks, followed by reducing doses). Diuretics are widely used but are often disappointing in their effect. 쎲 The use of local injection of anaesthetic and steroid into the proximal carpal tunnel is supported by trial data. The outcome is probably comparable to that of systemic steroids, but the patient is not exposed to the risk of side effects associated with highdose steroid therapy. The injection may be directly into the carpal tunnel or proximal to the carpal tunnel. Benefit from local injection may last for up to three months and is increased by concurrent splinting. 쎲 For patients who have either severe symptoms or do not respond to conservative measures, surgery is required. This has traditionally been carried out by an open
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 25
05 Carpal tunnel syndrome and other entrapment neuropathies
25
Confirm symptoms are in median nerve distribution
History and examination to search for underlying causes Enquire about occupation and repetitive strain
Mild symptoms
Moderate symptoms with signs
Rest Remove precipitating cause Trial of splinting
NCS ± imaging
No further action
Confirmed diagnosis
Severe symptoms
Conservative measures
Local injection Systemic steroids
Repeat treatment at 3 months
Consider surgery • Open • Endoscopic
Figure 5.2 Investigation and management of CTS. Imaging is with high-resolution ultrasound or with MRI. NCS, nerve conduction studies.
procedure, which can be performed without admission to hospital. More recently, endoscopic carpal tunnel release through two small incisions has been used by many surgeons. This has the advantage of causing less scarring.
Recent Developments 1 Not all patients have ready access to nerve conduction studies. Several studies have shown that high-resolution ultrasound and magnetic resonance imaging (MRI) may be very accurate in diagnosing CTS.3,4 These methods can demonstrate altered
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
26
18/3/08
14:28
Page 26
§01 General Rheumatology and Soft Tissue Rheumatism anatomy and decreased volume of the carpal tunnel, and in patients with CTS show the median nerve is swollen distal to the compression. 2 Some familial cases of nerve entrapment are due to inherited anatomical abnormalities. Recently, the condition of hereditary neuropathy with liability to the pressure palsies (HNPP) has been described.5,6 This condition is inherited in an autosomal dominant manner and is due to a deletion at locus 17p11.2. HNPP is a slowly progressive condition, punctuated by episodes of acute peripheral neuropathy at sites that are liable to nerve entrapment. 3 Endoscopic surgery has revolutionized treatment of CTS. The two-portal endoscopic approach to managing CTS has been adopted in many centres. Although this approach is attractive, recent trials7,8 suggest that it has very little to offer over traditional open surgery. In general, surgical treatment is more successful than medical or conservative treatment in patients with proven CTS.9
Conclusion CTS is the most common form of entrapment neuropathy. Definitive diagnosis is by nerve conduction studies, but ultrasound and MRI are increasingly being used to confirm the diagnosis. It is worth routinely excluding hypothyroidism and diabetes as predisposing causes but there is not usually a treatable or identifiable underlying cause. A limited trial of conservative or medical measures is justified in mild cases but surgery is generally required for severe, progressive or unresponsive cases.
Further Reading 1
Viera AJ. Management of carpal tunnel syndrome. Am Family Physician 2003; 68: 265–72.
2
Ashworth N. Carpal tunnel syndrome. Clin Evid 2006; 15: 1–18.
3
Wiesler ER, Chloros GD, Cartwright MS, Smith BP, Rushing J, Walker FO. Use of diagnostic ultrasound in carpal tunnel syndrome. J Hand Surg 2006; 31: 726–32.
4
de Noordhout AM. Diagnosing entrapment neuropathies: probes and magnets instead of electrodes and needles? Clin Neurophysiol 2006; 117: 484–5.
5
Sander MD, Abbasi D, Ferguson AL, Steyers CM, Wang K, Morcuende JA. The prevalence of hereditary neuropathy with liability to pressure palsies in patients with multiple surgically treated entrapment neuropathies. J Hand Surg 2005; 30: 1236–41.
6
Koc F, Guzel R, Benlidayi IC, Yerdelen D, Guzel I, Sarca Y. A rare genetic disorder in the differential diagnosis of the entrapment neuropathies: hereditary neuropathy with liability to pressure palsies. J Clin Rheumatol 2006; 12: 78–82.
7
Rab M, Grunbeck M, Beck H et al. Intra-individual comparison between open and 2-portal endoscopic release in clinically matched bilateral carpal tunnel syndrome. J Plast Reconstr Aesthet Surg 2006; 59: 730–6.
8
Atroshi I, Larsson G-U, Ornstein E, Hofer M, Johnsson R, Ranstam J. Outcomes of endoscopic surgery compared with open surgery for carpal tunnel syndrome among employed patients: randomised controlled trial. BMJ 2006; 332: 1473–6.
9
Hui ACF, Wong S, Leung CH et al. A randomized controlled trial of surgery vs steroid injection for carpal tunnel syndrome. Neurology 2005; 64: 2074–8.
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 27
06 Fibromyalgia syndrome
27
P R O B L E M
06 Fibromyalgia Syndrome Case History Sandra is in her early 40s and is seeing you because she hurts from her scalp to her toes. This has been present for at least eight years and is ruining her life. She tires easily and aches with any activity. Her sleeping is restless, she awakes tired and she has an irritable bowel. There are no abnormalities on physical examination. What is fibromyalgia and how would you support this diagnosis? Are there any investigations that might help? What treatment, if any, would you suggest to Sandra?
Background Fibromyalgia syndrome (FMS) is a soft tissue musculoskeletal condition with many features in common with chronic fatigue syndrome, the major difference being the predominance of musculoskeletal features in FMS. Diagnosis of FMS is based on the American College of Rheumatology (ACR) criteria (1990): 쎲 쎲 쎲 쎲
Pain on both sides of the body Pain above and below the waist Pain in an axial distribution Local tenderness in at least 11 out of 18 defined trigger points (Figure 6.1)
The pain is often defined as ‘aching’ or ‘burning’ and varies in intensity and location from day to day. Other features of FMS are shown in Table 6.1. Table 6.1 Frequency of FMS symptoms Symptom
%
Symptom
%
Muscular pain
100
Paraesthesiae
52
Fatigue
96
Memory impairment
46
Insomnia
86
Leg cramps
42
Joint pains
72
Poor concentration
41
Headaches
60
Anxiety
32
Restless legs
56
Major depression
20
© Atlas Medical Publishing Ltd
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
28
18/3/08
14:28
Page 28
§01 General Rheumatology and Soft Tissue Rheumatism
Figure 6.1 Trigger points for the diagnosis of FMS. There are 18 points in total (nine identical locations on each side). Anterior: anterior aspects of C5, C6 and C7; second rib; lateral epicondyle; knee (medial fat pad). Posterior: suboccipital muscle insertions; supraspinatus muscle origin; trapezius (midpoint upper border); gluteal (upper outer quadrants); greater trochanter. Adapted with permission from Borg-Stein 2006.1
Musculoskeletal pain is the most consistent feature of FMS. Fatigue can be almost as debilitating. Disordered sleep is also a very frequent feature and contributes to fatigue and to the mood disturbances. Sleep abnormalities are strongly correlated with the alpha-electroencephalogram (EEG) abnormality and movement disorders including the periodic jerking of arms and legs, teeth grinding (bruxism) and restless legs. Gastrooesophageal reflux disease occurs with high frequency, as does irritable bowel syndrome. Headaches may be of the migraine or tension type. Facial pain is also relatively common, including discomfort related to temporomandibular joint dysfunction. Psychological and psychiatric morbidity are increased. There is high prevalence of anxiety disorders including obsessive-compulsive disorder and post-traumatic stress disorder.2
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
06 Fibromyalgia syndrome
Page 29
29
Epidemiology and aetiology A number of recent studies2–4 have examined incidence and prevalence of FMS. The estimated prevalence is between 1% and 4%. FMS is between two and six times more likely to occur in women. Incidence in the female population has been estimated at 11.3 per 1000 person-years. It can occur at any age but becomes more common with advancing years. FMS has been associated with other rheumatic disorders including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). There is clearly strong interplay between physical and psychological factors in FMS. The onset of illness may be triggered by physical illness (including viral diseases) or by trauma (including surgery). There is some suggestion that heredity may play a part, with components of the serotonergic and dopaminergic systems being potential candidates for involvement. Some of the symptomatology around the trigger points may be due to increased acetylcholine at the motor endplate causing contraction and shortening of the sarcomere. This may lead to increased energy consumption and increased local blood supply, with resulting local tenderness. A number of local and systemic mediators have been implicated. These include bradykinin, calcitonin gene-related peptide, substance P, tumour necrosis factor-a, interleukin-1, noradrenaline and serotonin.
Investigations Routine investigations – including full blood count and biochemistry, plus erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and other inflammatory markers – are within the normal range. Because thyroid disease is common, it is useful to include thyroid function tests. There are no specific endocrine abnormalities. X-ray, computed tomography (CT) and magnetic resonance imaging (MRI) scans are generally normal. There are no specific abnormalities on muscle biopsy, electromyography or nerve conduction studies. EEG or more formal sleep studies may be requested in patients who have marked sleep disturbance. This may reveal abnormalities including periodic limb movement disorder, rapid eye movement (REM) sleep disorder or sleep apnoea. The diagnosis of FMS is one of exclusion and is made clinically.
Prognosis, differential diagnosis and treatment The outlook for FMS is variable and the condition tends to become chronic. However, more widespread understanding and clearer definition, along with a more highly developed treatment flow, are beginning to streamline management and improve the outlook. There is a danger that over-enthusiastic investigation might contribute to making the condition more chronic. However, this should not deter the clinician from making a full investigation and the clinical picture warrants it. The major differential diagnosis is other connective tissue disorders, including rheumatoid disease, SLE and scleroderma. Major differential diagnoses of FMS and investigation of the condition are summarized in Figure 6.2. There is no specific treatment for FMS. Therapeutic measures include the following: 쎲 General: investigation and clear diagnosis; educating the patient as to the nature of the diagnosis and reassuring them; attention to psychological and social factors, and encouraging the patient to have a normal sleep pattern as well as to engage in physical activity consistent with their state of health and preferences.
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
30
18/3/08
14:28
Page 30
§01 General Rheumatology and Soft Tissue Rheumatism
Musculoskeletal pain
Associated symptoms
Limited Ix • FBC 1ESR • CRP • FT4 2ve 1TSH
1ve
Joint swelling or deformity
? Referred pain • Visceral • Skeletal
Further Ix • RF • ANF • Viral serology
Imaging • X-rays • CT scan • MRI scan
2ve Classic FMS (clinical diagnosis)
• Affecting the axial skeleton • Both sides of the body • Above and below the waist • At least 11/18 trigger points tender
2ve
1ve
Consider: • RA • Scleroderma • SLE • Lyme disease
Figure 6.2 Investigation of suspected FMS. - ve, negative; + ve, positive; ANF, antinuclear factor ; CRP, C-reactive protein; CT, computed tomography; ESR, erythrocyte sedimentation rate; FBC, full blood count; FMS, fibromyalgia syndrome; FT4, thyroxine; Ix, investigation; MRI, magnetic resonance imaging; RA, rheumatoid arthritis; RF, rheumatoid factor; SLE, systemic lupus erythematosus; TSH, thyroid stimulating hormone. Adapted from Schneider et al. 2006.5
쎲 Pain relief. This may range from simple analgesics such as paracetamol to more powerful agents. Inappropriate use of powerful opioid analgesics should be avoided as this may lead to dependence and seldom alleviates the symptoms in the long term. Non-steroidal anti-inflammatory drugs have marginal benefits over simple analgesics. Tramadol is a weak opioid with some action to inhibit the uptake of serotonin. 쎲 Antidepressants. Either tricyclic antidepressants or selective serotonin reuptake inhibitors are of benefit in many cases, even when there is not major evidence of depression. Dual inhibitors of both noradrenaline and serotonin uptake, such as duloxetine, may be of particular benefit. 쎲 a2-adrenergic agonists, such as clonidine or tizanidine, are of benefit to some patients and may act by preventing the action of neurotransmitters such as glutamate or substance P within the central nervous system. 쎲 Anticonvulsants may contribute to pain relief. There is increasing experience with newer agents such as pregabalin or gabapentin, which have proved to be of use in other painful neurological conditions.
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
06 Fibromyalgia syndrome
Page 31
31
쎲 Trigger point injection may be undertaken with local anaesthetic, steroid or botulinum toxin. The latter may be more effective than steroid injection; it may act by diminishing acetylcholine release, thus decreasing muscle activity and local ischaemia. 쎲 Postural training, exercise and ergonomic adjustments (particularly in the workplace) may help a patient to adapt to disability associated with FMS. 쎲 Stress reduction may be achieved by a variety of means including cognitive behavioural therapy, relaxation techniques and biofeedback methods. 쎲 Physical therapies including acupuncture, massage, transcutaneous electrical nerve stimulation and ultrasound may be helpful. These should always be performed by a suitably qualified and reputable practitioner.
Recent Developments 1 There is some discordance between the clinical diagnosis of FMS and the diagnosis using ACR criteria.6 In a survey of 206 patients, FMS was diagnosed in 49.0% while only 29.1% met ACR criteria. The authors of the report proposed a survey method for diagnosis of FMS that did not require clinical examination. 2 Improved understanding of the pathophysiological basis for the syndrome is not only lending credence to the diagnosis, but is also giving rise to more logical management.7 Patients are often mislabelled as having a purely psychological diagnosis, leading to the undertreatment or mismanagement of the physical symptoms. Increased activity of the hypothalamic–pituitary–adrenal axis and the sympathetic nervous system has been proposed to be responsible for some of the clinical features.8 3 More than 90% of patients have tried alternative or complementary treatments. Acupuncture has been widely used but not intensively studied. A recent randomized controlled trial of acupuncture in FMS9 reported greater improvements in the treatment group compared with the control group. Symptoms of fatigue and anxiety were particularly improved and the treatment is very well tolerated. These patients also experienced better pain relief. 4 Being overweight or obese is associated with a variety of physical and psychological symptoms, including many of the symptoms that form part of the FMS complex. Results of the recently published behavioural weight loss programme10 confirm that modest weight loss is associated with an improvement in FMS symptoms.
Conclusion Attempts should be made to establish the diagnosis in the above patient. This should include the exclusion of thyroid disease and connective tissue disorders. Thorough medical assessment should be undertaken, with care not to increase the patient’s anxiety. Once the diagnosis is established, this should be carefully explained to the patient and a realistic management plan should be agreed. This should include trying to manage pain and sleep disturbance with the minimum of pharmacological intervention. Physical activity should be encouraged within the limits imposed by her condition. Weight loss is
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
32
18/3/08
14:28
Page 32
§01 General Rheumatology and Soft Tissue Rheumatism important in the overweight patient for future health and may also help to alleviate the symptoms of FMS.
Further Reading 1 Borg-Stein J. Treatment of fibromyalgia, myofascial pain, and related disorders. Phys Med Rehabil Clin N Am 2006; 17: 491–510. 2 Raphael KG, Janal MN, Nayak S, Schwartz JE, Gallagher RM. Psychiatric comorbidities in a community sample of women with fibromyalgia. Pain 2006; 124: 117–25. 3 Weir PT, Harlan GA, Nkoy FL et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases 9th Revision codes. J Clin Rheumatol 2006; 12: 124–8. 4 McNally JD, Matheson DA, Bakowsky VS. The epidemiology of self-reported fibromyalgia in Canada. Chronic Dis Can 2006; 27: 9–16. 5 Schneider MJ, Brady DM, Perle SM. Commentary: differential diagnosis of fibromyalgia syndrome: proposal of a model and algorithm for patients presenting with the primary symptom of chronic widespread pain. J Manipulative Physiol Ther 2006; 29: 493–501. 6 Katz RS, Wolfe F, Michaud K. Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum 2006; 54: 169–76. 7 Dadabhoy D, Clauw DJ. Fibromyalgia: progress in diagnosis and treatment. Curr Pain Headache Rep 2005; 9: 399–404. 8 Sarzi-Puttini P, Atzeni F, Diana A, Doria A, Furlan R. Increased neural sympathetic activation in fibromyalgia syndrome. Ann NY Acad Sci 2006; 1069: 109–17. 9 Martin DP, Sletten CD, Williams BA, Berger IH. Improvement in fibromyalgia symptoms with acupuncture: results of a randomized controlled trial. Mayo Clin Proc 2006; 81: 749–57. 10 Shapiro JR, Anderson DA, Danoff-Burg S. A pilot study of the effects of behavioural weight loss treatment on fibromyalgia symptoms. J Psychsom Res 2005; 59: 275–82.
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 33
07 Plantar fasciitis
33
P R O B L E M
07 Plantar Fasciitis
Case History Shirley is aged 43 years and presents with exquisite pain beneath her left heel when walking. She is moderately obese (body mass index 32 kg/m2) and finds it hard to walk first thing in the morning. She prefers to wear open sandals. Should Shirley have X-rays to determine whether she has a plantar spur? What effect, if any, does Shirley’s weight have on her condition? What are the current supported therapies?
Background Plantar fasciitis commonly causes inferior heel pain and occurs in up to 10% of the United States population. It affects both active and sedentary adults of all ages, but is more likely to occur in persons who are obese, who spend most of the day on their feet or who have limited ankle dorsiflexion. Plantar fasciitis is a musculoskeletal disorder primarily affecting the fascial enthesis. Although poorly understood, development of plantar fasciitis is thought to have a mechanical origin. In particular, pes planus foot types and lower-limb biomechanics that result in a lowered medial longitudinal arch create excessive tensile strain within the fascia, producing microscopic tears. The roles of both chronic inflammation and arch mechanics in the aetiology of plantar fasciitis are controversial.1 Diagnosis is based on the history and physical examination (Table 7.1); the differential diagnosis is listed in Table 7.2. Unaccustomed walking in the sedentary or prolonged running in the athlete may induce fatigue tears of the plantar fascia and avulsion fracture may cause pain at the medial calcaneal tuberosity. The same area is involved in spondyloarthropathy (ankylosing spondylitis, psoriatic arthritis and reactive arthritis) as plantar
Table 7.1 Diagnosis of plantar fasciitis2
• • • • • •
Chronic inferior heel pain on weight bearing: throbbing, searing, piercing in character Pain worst with the first steps in the morning or after rest Pain reduces after mobilization, to recur with continued activity Walking barefoot, on toes or up stairs exacerbates pain Tenderness around medial calcaneal tuberosity at the plantar aponeurosis Bilateral plantar fasciitis is highly suggestive of spondyloarthropathy
© Atlas Medical Publishing Ltd
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
34
18/3/08
14:28
Page 34
§01 General Rheumatology and Soft Tissue Rheumatism
Table 7.2 Common causes of heel pain2,3
•
Posterior calcaneal pain – Superficial bursitis – Achilles tendonitis – Retrocalcaneal bursitis – Calcaneal epiphysitis (Sever’s disease) in adolescents
•
Plantar calcaneal pain – Central: fat pad atrophy (primary, or secondary to corticosteroid infiltration), obesity – Medial: compression neuropathy of nerve to abductor digiti minimi and medial calcaneal branch of the posterior tibial nerve; posterior tibialis tendonitis – Medial central: plantar fasciitis, avulsion fractures, fascial microtears – Lateral: calcaneal stress fracture, calcaneal cysts
fascia enthesitis. Insertional plantar fascia pain is typically increased by passive dorsiflexion of the big toe and is located centromedially at the medial calcaneal tuberosity. Heel pain may be caused by an entrapment neuropathy of the calcaneal branches of the posterior tibial nerve or the first branch of the lateral plantar nerve. Since encroachment occurs between the abductor hallucis fascia and the quadratus plantae muscle, maximal tenderness is in the medial border of the heel. Diagnostic imaging does not contribute unless another diagnosis is strongly suspected, such as calcaneal stress fracture. The latter may be diagnosed by plain X-ray or by isotope bone scanning for confirmation. Radiography may show calcifications in the soft tissues around the heel, or osteophytes on the anterior calcaneus (i.e. heel spurs). Fifty per cent of patients with plantar fasciitis and 20% of persons without plantar fasciitis have heel spurs. Plantar fasciitis is five times more likely to occur in obese individuals. Although the link between obesity and plantar heel pain is poorly understood, research to date has focused on the impact of adiposity of the subcalcaneal fat pad and the function of the medial longitudinal arch.4 The plantar fascia is the primary structure stabilizing the medial longitudinal arch of the foot. Both abnormal arch structure and movement have been implicated in the development of plantar fasciitis. In particular, pes planus or Table 7.3 Therapeutic recommendations2 Clinical recommendation
Evidence rating
Off-the-shelf (non-magnetic) insoles
B
Custom-made insoles are not more effective than fabricated insoles
B
Plantar fascia stretching more effective than calf stretching and should be recommended to all patients
B
Corticosteroid iontophoresis should be considered for short-term relief if initial therapy fails
B
Custom-made night splints
B
Extracorporeal shock therapy is not effective
B
Walking casts in those who have failed conservative therapy
C
Open or endoscopic surgery for those who have failed all conservative measures
B
B, inconsistent or limited quality evidence; C, consensus, usual practice or expert opinion.
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
07 Plantar fasciitis
Page 35
35
biomechanics that result in a lower longitudinal arch (i.e. foot pronation) increase tension within the plantar fascia and thereby increase the risk of fascial injury. The plantar fat pad is a specially organized and richly innervated adipose tissue that provides cushioning to the underlying foot structures of the heel, dampening impulses associated with heel strike. The heel pad is particularly receptive to detecting vibration, suggesting a role for detection of gait-induced shock waves. Consequently, changes leading to increased stiffness and reduced compressibility of the subcalcaneal fat pad have been linked to the development of plantar fasciitis, presumably by lowering the attenuation of impulse arising from heel strike. Most patients with plantar fasciitis eventually improve, albeit slowly; 80% of patients treated conservatively are in complete remission at four years. A variety of therapies are used in the treatment of plantar fasciitis and key recommendations, including exercises (Figure 7.1), are summarized in Table 7.3. Limited evidence supports the use of corticosteroid injections; the benefit is short-lived and may be associated with adverse effects such as fascial rupture. Corticosteroid-induced atrophy of the subcalcaneal fat pad may also exacerbate the underlying biomechanical predisposition.
Recent Developments 1 Foot orthoses are commonly used for plantar fasciitis but, if custom-made, require a period of weeks between initial consultation and use. Off-the-shelf orthoses are quicker and cheaper, but cost and availability may still be a barrier to use. Short-term treatments, such as supportive taping, are frequently used to alleviate symptoms initially. Low-Dye taping is one of the most frequently applied methods, and improves symptoms by reducing strain in the plantar fascia during standing and walking. Utilizing taping around both the midfoot and the level of the Achilles insertion into the calcaneum, comparison was made between individuals who received taping plus sham ultrasound and individuals receiving sham ultrasound only.5 The primary outcome was ‘first-step’ pain one week after tape application, and there was a statistically significant though clinically small reduction in pain with taping. The 12.3 mm reduction in a visual analogue scale for pain was greater than the 9–10 mm difference thought to be clinically meaningful. 2 The sensory nerve supplying the skin of the heel and the medial side of the sole is the medial calcaneal branch of the posterior tibial nerve; researchers have suggested that entrapment of this nerve might present as an important factor causing heel pain. Nerve conduction tests have confirmed latency in the medial calcaneal nerve in subjects with plantar fasciitis, but these subjects have normal conduction in their sural, medial and lateral plantar nerves and posterior tibial nerves.6
Conclusion Plantar fasciitis, if not treated, tends to follow a chronic course. Being overweight, the presence of bilateral symptoms and duration greater than six months are associated with poorer outcome. Treatment should be directed along biomechanical lines – weight
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
36
18/3/08
14:28
Page 36
§01 General Rheumatology and Soft Tissue Rheumatism
Figure 7.1 Recommended exercises for plantar fasciitis. (1) Before stepping down, especially after sleeping or resting, stretch the arch of the foot by stretching your legs out in front of you (do not bend the knee). Place a towel around the ball of the foot. Slowly pull on the ends of the towel, pulling the toes and ball of the foot back as far as is comfortable. Hold the foot in this position for ten seconds. Repeat at least ten times. You should feel a pull on the bottom of the foot, especially in the arch. This stretches the plantar fascia and reduces its pull on the heel. (2) Stand about two to three feet from a wall. Lean forward with your hands against the wall. With the painful foot behind, place the other foot forward. Press against the wall, shifting weight over the front foot, while straightening the back leg. Keep the heel of the back foot on the floor and feel the stretch in the heel, Achilles tendon and calf. Hold this position for ten seconds. Repeat at least ten times, and try to do this three times a day.
01-PS Rheumatology-cpp:01-PS Rheumatology-ppp.QXD
18/3/08
14:28
Page 37
07 Plantar fasciitis
37
reduction, orthoses and plantar stretching. Since there is limited evidence regarding the value of treatments, a reasonable approach is to start with patient-directed, low-risk, minimal-cost interventions, such as regularly stretching the calf muscles and the plantar fascia, avoiding flat shoes and walking barefoot, using over-the-counter arch supports and heel cushions, and limiting extended physical activities. A trial of non-steroidal antiinflammatory drugs is reasonable. More costly treatments, such as custom-made orthotics, night splints and immobilization with casts, may be options when the condition does not improve, although the value of these treatments is uncertain.
Further Reading 1
Wearing SC, Smeathers JE, Urry SR, Hennig EM, Hills AP. The pathomechanics of plantar fasciitis. Sports Med 2006; 36: 585–611.
2
Cole C, Seto C, Gazewood J. Plantar fasciitis: evidence-based review of diagnosis and therapy. Am Fam Physician 2005; 72: 2237–42.
3
Canoso JJ. Foot pain. In: Rheumatology in Primary Care. WB Saunders, Philadelphia, 1997; Chapter 29.
4
Wearing SC, Hennig EM, Byrne NM, Steele JR, Hills AP. Musculoskeletal disorders associated with obesity: a biomechanical perspective. Obes Rev 2006; 7: 239–50.
5
Radford JA, Landorf KB, Buchbinder R, Cook C. Effectiveness of low-Dye taping for the short-term treatment of plantar heel pain: a randomised trial. BMC Musculoskelet Disord 2006; 7: 64.
6
Chang CW, Wang YC, Hou WH, Lee XX, Chang KF. Medial calcaneal neuropathy is associated with plantar fasciitis. Clin Neurophysiol 2007; 118: 119–23.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
S E C T I O N
18/3/08
14:29
Page 39
T W O
02
Osteoarthritis 08
Causes and prevention
09
Non-pharmacological treatment
10
Drug treatment
11
NSAIDs – gastric side effects and protection
12
NSAIDs – cardiac complications
13
Joint replacement surgery
P R O B L E M
08 Causes and Prevention Case History John is a 48-year-old accountant who is overweight (body mass index 32 kg/m2). His general health has been good, but he has become concerned recently about twinges of pain in his knees. He was a keen road runner in his teens and 20s, but no longer takes regular exercise. He smokes and takes no regular medications. Both of his parents suffered from osteoarthritis, his father requiring knee replacements in his early 60s. What is the current thinking about the inheritance of osteoarthritis? Which environmental factors play a part in its progression? Can the disease be prevented in a predisposed individual?
Background Osteoarthritis (OA) is an increasing public health problem because of the rising prevalence of obesity and because of the increasing number of older people in the population.1 Currently, in the United States, 350 000 hip and knee replacements are performed each year. OA is markedly age related, affecting around 12% of those aged 55 years, 50% of © Atlas Medical Publishing Ltd
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
40
18/3/08
14:29
Page 40
§02 Osteoarthritis those aged 65 years and as many as 80% of those aged 75 years and over. Prevalence estimates have largely come from population-based X-ray surveys. However, there is a variable relationship between radiological features and symptoms. In clinical practice, OA is only diagnosed when clinical symptoms (pain and stiffness) coexist with evidence of structural damage to the joint. With age, the higher prevalence of OA in females becomes even more exaggerated. The hips, knees and hands are the most commonly affected joints, although almost any joint can be affected. Joint failure arises from a combination of systemic and mechanical factors, including weakness of supporting muscles and ligaments, growth of new bone, erosion of articular cartilage and loss of joint space. A simple grading system is presented in Box 8.1. OA may be primary or secondary; secondary causes are summarized in Box 8.2.
Box 8.1 Radiological severity scoring of OA Grade 0 1 2 3 4
None Possible Minimal Moderate Severe
No features Minimal osteophytes Osteophytes, normal joint space Diminution of joint space Decreased joint space, bony sclerosis
Box 8.2 Secondary causes of OA Anatomical Leg length inequality, joint malalignment Slipped femoral epiphyses, epiphyseal dysplasias Perthe disease Congenital dislocation of the hip Hypermobility syndromes Traumatic Occupational arthropathies Fracture through or near a joint Joint surgery Major external trauma Inflammatory Inflammatory arthropathies Septic arthritis Metabolic Crystal arthropathies Haemochromatosis Acromegaly Ochronosis, chondrodysplasias
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
08 Causes and prevention
Page 41
41
The traditional view is that OA is a simple mechanical condition, in which repeated or sustained stresses on the joint lead to articular cartilage damage and loss. The notion that the cartilage is the tissue primarily affected in patients prone to OA has been challenged. In fact, cartilage is a relatively inert tissue with no direct blood supply, nerve input or capacity to become inflamed. Severe OA can occur in rare genetic conditions – ochronosis and chondrodysplasias – but generally in OA, predisposed individuals do not appear to have an alteration in their cartilage structure or composition. In the early stages, changes in modelling of adjacent bone and in the collateral ligaments of the joint may precede the development of changes in cartilage and symptoms. Aging and postmenopausal changes in bone turnover are almost certainly important in the disease. From post-mortem and other studies, it seems clear that changes in the joint capsule and collateral ligaments can also precede the classic structural findings of OA. These changes may affect joint stability and alignment leading to increased mechanical forces on bone and cartilage. Furthermore, weakening of periarticular muscles further compromises joint stability and predisposes to malalignment. This is a particular factor in knee OA where quadriceps wasting and weakness leads to decreased joint stability. Loss of coordination, vision and proprioception with age contribute to the individual responding less well to unexpected stresses on the joint and thus increasing the impact of minor, potentially traumatic events. A genetic predisposition to OA was first suspected in the 1940s when prevalence of Heberden’s nodes was noted to be three times higher in first-degree relatives of OA patients. Several segments of the human genome have been identified as susceptibility loci, and at least twelve candidate genes have been studied. Genetic factors account for around 50% of the variance in susceptibility to OA. Twin studies suggest a concordance rate of around 0.65 for monozygotic twins and 0.4 for dizygotic twins.2 In a United Kingdom study,2 first-degree relatives of patients who had total hip replacement carried a relative risk of 1.9 for also requiring the procedure. The comparable figure for total knee replacement was 4.8. From genome-wide scans, susceptibility loci have been hypothesized at chromosomes 2q, 4q, 6p, 11q and 16p. The only candidate genes identified so far in these regions of the genome are the collagen genes COL29A1 and COL11A2. Other genes are COL2A1, which codes for collagen II (the major protein of cartilage), CRTL1 (coding for a cartilage link protein) and CRTM (coding for a cartilage matrix protein). Polymorphisms of the genes for the vitamin D receptor (VDR) and the oestrogen-a receptor have also been related to risk – both are major determinants of bone density. The COL2A1 and VDR genes are located closely together on chromosome 12q. Cartilageremodelling protein gene expression may also play a role; expression of the gene for matrix metalloproteinase-3 (MMP-3), which degrades collagen, and the gene for a disintegrin and metalloproteinase with thrombospondin motif-5 (ADAMTS-5) both increase cartilage breakdown in vitro. Levels of expression of these enzymes may be both genetically determined and increase in response to mechanical stress of cartilage. Obesity is by far the best-studied environmental factor, particularly with respect to increasing risk of knee arthritis. Several factors may underlie the association between obesity and OA. Mechanical stresses predispose to joint damage, although obesity also increases risk of OA in non-weight-bearing joints, and alterations in gait and predisposition to injury contribute to joint alignment. Hormonal changes are factors, including low local levels of androgens because of increased aromatase activity. Hyperglycaemia appears to be a risk factor – partly because of its association with obesity, but also because of other
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
42
18/3/08
14:29
Page 42
§02 Osteoarthritis metabolic factors including the inhibitory effect of advanced glycation end products on proteoglycan synthesis. The low-grade inflammation found in obese subjects and other pro-inflammatory states also predispose. Glucosamine blocks the effect of cytokines on nitric oxide synthesis and also increases glycosaminoglycan production. Other nutritional factors have been identified: low vitamin C intake and vitamin E as an antioxidant and determinant of collagen turnover have been implicated, as has low vitamin D status. Numerous studies have confirmed the increased risk of OA with obesity, particularly when obesity develops at a younger age.3–5 In the study by Dawson et al.,3 women who smoked heavily were also at increased risk. Even a modest increase in weight within the normal healthy range increases risk of developing OA.4 The latter observation was also confirmed in a national Swedish study,5 although a decreased risk of OA of the hip was reported in smokers. The effect of smoking on OA is therefore uncertain but appears unlikely to be marked. Occupational risk factors are well documented,6 with those who undertake manual labour being at increased risk. Repeated stress on the knee, particularly with the knee Genetic
• Strong family history • Joint replacement in first-degree relative • Premature onset
Secondary OA
Anatomical
Metabolic
Traumatic
Inflammatory
Primary OA
Overweight or obese
• Lose weight
Mechanical loading (± occupational)
• Avoid repeated strain • Support knee
Female gender
Age, post-menopausal
Others – Low vitamin C, D or E; neuromuscular weakness; low BMD
Figure 8.1 Risk factors for OA.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
08 Causes and prevention
Page 43
43
bent, increases mechanical stress on the patello-femoral compartment of the joint. Moderate sporting activity does not seem to pose a risk. Elite athletes are at increased risk. Having high bone mineral density (BMD) may predispose to development of osteophytes, but high bone turnover – as in post-menopausal osteoporosis – leads to microarchitectural deterioration around the joint. The bone in this area consequently becomes ‘stiff’ and less able to absorb shock, placing the patient at higher risk of OA. Hormone replacement therapy (HRT) has been said to be protective. This may relate to its protective effect on BMD, but it should be noted that use of HRT is associated with a variety of other lifestyle factors. Risk factors for OA are summarized in Figure 8.1. The risk factors for progression are similar and appear to operate more markedly on the knee. These include obesity, injury, crystal arthropathy, neuromuscular dysfunction and poor physical alignment of the joint.
Recent Developments 1 Levels of adiponectin, a hormone product of fat cells, are decreased in obesity. Low levels increase the risk of developing diabetes and vascular disease. High levels of adiponectin have recently been reported in synovial fluid from patients with OA.7 The hormone is thought to have a protective role by upregulating the tissue inhibitor of metalloproteinase-2 (TIMP-2) and by inhibiting interleukin(IL)-1–induced increases in matrix metalloproteinase-13 (MMP-13). 2 The rate of development of OA in women increases markedly after the menopause, suggesting that oestrogen may have a protective effect. In a large study,8 low plasma oestrogen and low urinary levels of its metabolites were associated with increased risk of OA. Measures to preserve exposure to oestrogen may protect the joints. 3 Biomarkers of disease activity could prove to be a considerable asset.9 Candidates include the urinary C-terminal peptide of collagen type II, serum hyaluronan and cartilage oligomeric matrix protein. Measurement of these markers could be combined with other clinical measures (e.g. C-reactive protein), symptom scores and genetic/molecular markers of risk to help focus programmes of treatment on patients who are either at high risk or have rapidly progressive disease.
Conclusion OA is a disorder with a strong genetic component. Patients with a first-degree relative who has a joint replacement, Heberden’s nodes or who has developed premature OA should be aware that they are at risk of developing OA. The major, modifiable risk factor is being overweight or obese. There is evidence that weight loss in those who are overweight improves OA symptoms and retards progression. It is important to identify factors that place increased strain on the joints, including occupational risks, repetitive injuries and joint malalignment. Simple measures may decrease the risk from physical factors. OA is one of the major degenerative diseases of aging. While we can delay the impact of the disorder on individual patients, we are not at a stage where OA can be routinely prevented.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
44
18/3/08
14:29
Page 44
§02 Osteoarthritis
Further Reading 1
Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006; 20: 3–25.
2
Loughlin J. Genetic epidemiology of primary osteoarthritis. Curr Opin Rheumatol 2001; 13: 111–16.
3
Dawson J, Juszczak E, Thorogood M, Marks SA, Dodd C, Fitzpatrick R. An investigation of risk factors for symptomatic osteoarthritis of the knee in women using a life course approach. J Epidemiol Community Health 2003; 57: 823–30.
4
Holmberg S, Thelin A, Thelin N. Knee osteoarthritis and body mass index: a population-based case-control study. Scand J Rheumatol 2005; 34: 59–64.
5
Järvholm B, Lewold S, Malchau H, Vingård E. Age, bodyweight, smoking habits and the risk of severe osteoarthritis in the hip and knee in men. Eur J Epidemiol 2005; 20: 537–42.
6
Rossignol M. Primary osteoarthritis and occupation in the Quebec national health and social survey. Occup Environ Med 2004; 61: 729–35.
7
Chen TH, Chen L, Hsieh MS, Chang CP, Chou DT, Tsai SH. Evidence for a protective role for adiponectin in osteoarthritis. Biochim Biophys Acta 2006; 1762: 711–18.
8
Sowers MR, McConnell D, Jannausch M, Buyuktur AG, Hochberg M, Jamadar DA. Estradiol and its metabolites and their association with knee osteoarthritis. Arthritis Rheum 2006; 54: 2481–7.
9
Kraus VB. Do biochemical markers have a role in osteoarthritis diagnosis and treatment? Best Pract Res Clin Rheumatol 2006; 20: 69–80.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
Page 45
09 Non-pharmacological treatment
45
P R O B L E M
09 Non-Pharmacological Treatment
Case History AP is a 58-year-old woman whose symptoms of osteoarthritis (OA) are beginning to limit her activity. She complains that she feels stiff. She takes paracetamol regularly but does not want to take other drugs. One of her friends recently suffered gastrointestinal haemorrhage while taking a non-steroidal anti-inflammatory drug (NSAID). What non-pharmacological interventions are available? Are natural treatments effective at decreasing symptoms and protecting joints? Is cartilage protection a valid treatment goal?
Background Effective analgesia and use of anti-inflammatory drugs can transform the lives of patients with OA. However, pharmaceuticals are not the sole mode of treatment for OA. Nonpharmacological approaches are often underused. Also many patients resort to natural products. Health practitioners need to understand these products and whether they work. Drug treatment should only be considered when lifestyle and non-pharmacological management has failed.
Body weight Being overweight or obese increases the risk of developing OA and accelerates progression of the disease.1 In the Framingham study, an increase in body mass index (BMI) of only 2 kg/m2 was associated with a 50% increase in the risk of developing OA in women.2 Studies documenting the benefit of weight loss have generally been short term, lasting no more than two years. Maintenance of a normal or near-normal body weight is also associated with other health benefits including prevention of diabetes and cardiovascular disease. While the cornerstone of weight management is diet and exercise, the role of drugs (including orlistat, sibutramine and rimonabant) should be considered. Weight reduction reduces mechanical stresses on the joints of the axial skeleton. Being overweight also increases the risk of joint malalignment. Some of the benefits of a weightmanagement programme may relate directly to the effects of exercise and to improved metabolic factors and lower levels of chronic inflammation. It is important that treatment goals are realistic and that the patient receives adequate support. The practitioner should always be alert to the possibility of psychological problems, including eating disorders. © Atlas Medical Publishing Ltd
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
46
18/3/08
14:29
Page 46
§02 Osteoarthritis
Exercise Physical exercise contributes to weight loss or at least to weight maintenance. Independently of this, it increases overall function and well-being, and decreases risk of falling. As well as protection from OA,1 exercise also lowers risk of osteoporosis, diabetes and cardiovascular disease. Exercise is of particular benefit in knee protection. Isokinetic exercises that utilize either flexion against resistance or extension against resistance are effective. Both aerobic exercise (low impact) and specific strengthening exercises for periarticular muscles have been found to be effective. Whichever form of exercise is used, there is benefit from the input of a qualified therapist; undue pain or discomfort should be avoided and the approach should be based on the patient’s ability and motivation, with only gradual increase in the effort required.
Glucosamine and chondroitin Glucosamine, available as sulphate or hydrochloride, is a hexosamine that is a natural constituent of keratin sulphate, the glycosaminoglycan of hyaline cartilage. It is frequently administered with chondroitin sulphate, another naturally occurring constituent of the cartilage matrix (being a constituent of aggrecan, which is the major proteoglycan of cartilage). Although studies have reported effects comparable with NSAIDs, results have been extremely variable. This may be partly because of differences between glucosamine hydrochloride and glucosamine sulphate. Studies using the former preparation have tended to show negative results whereas use of the latter compound tends to be more effective. This has been attributed by some to the fact that it is a source of sulphate, rather than because of the glucosamine per se. Glucosamine sulphate is given as a single, daily oral dose of 1500 mg and is well absorbed. Some of its effect is mediated through inhibition of cytokine-induced nitric oxide production and through inhibition of proteolytic enzymes. A Cochrane review in 2000 included 16 studies of patients (total 2029) who used glucosamine sulphate 1500 mg each day for six weeks.3 Sixty per cent of patients reported improved pain and 33% reported improved function. A more recent Cochrane review3 included 20 trials with 2570 patients and, overall, did not confirm improved pain and function with glucosamine. However, ten trials using one preparation (Rotta Pharmaceuticals) did show improvements. A recent study4 randomized 1583 patients with knee arthritis to glucosamine hydrochloride 1500 mg/day, chondroitin sulphate 1200 mg/day, glucosamine and chondroitin together, 200 mg celecoxib or placebo. Up to 4 g/day of paracetamol was allowed as rescue analgesia. Neither glucosamine, chondroitin, nor the combination was successful overall. The combination of the two was somewhat effective in patients with moderate to severe knee pain. It is noteworthy that glucosamine hydrochloride was used in this study.
Other nutritional components and supplements There is evidence that low vitamin C levels or status is related to the risk of developing OA and to the progression of the disease. The two major essential fatty acids are linoleic acid (18:2 n-6) and a-linolenic acid (18:3 n-3). These two fatty acids form eicosanoids through the action of cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2) and 5-lipoxygenase. When cell membranes comprise predominantly n-6 fatty acids (leading to prostaglandin E2 and leukotriene B4 production) a pro-inflammatory state exists,
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
Page 47
09 Non-pharmacological treatment
47
while the incorporation of predominantly n-3 fatty acids results in an anti-inflammatory state. There is considerable evidence for the benefit of n-3 fatty acid supplementation in management of OA. Patients with OA frequently use complementary and alternative medicines – up to 40% of patients were using such products in a recent survey.5 Fish oils, garlic extracts and celery extract are among the most commonly used products. This high level of usage reflects, to an extent, the fact that patients get incomplete relief from medical approaches, and also that many patients do not want to be reliant on pharmaceuticals.
Viscosupplementation Hyaluronic acid is a high-molecular-weight polysaccharide that contributes to the physical properties of synovial fluid and cartilage. Synovial fluid supplementation, or viscosupplementation, was developed in the 1980s as a treatment proposed to relieve pain in the short term and to restore the viscoelastic properties associated with hyaluronan in synovial joints. The products used are derivatives of hyaluronan and hylan and are given by intra-articular injection – sometimes weekly for the first three weeks, but then at intervals of at least four weeks for up to six months. A recent Cochrane review6 considered 76 controlled trials comparing viscosupplementation products, or examining their use with intra-articular steroids or NSAIDs. The conclusion was that viscosupplementation treatment was effective, especially at the 5–13-week period. Firm conclusions about the relative value of different products could not be made. Two recent studies have confirmed the potential benefits of viscosupplementation. Sun et al.7 administered hyaluronic acid to 75 patients with ankle OA. Patients reported increased pain relief and improved function. The effects were apparent both during treatment and for up to six months afterwards. In another study,8 intra-articular hyaluronic acid (three injections) was compared with an exercise regimen for patients with knee OA. Both treatments were effective and there was no statistical difference between the two.
Other measures Use of a walking stick (cane) may help. The stick should be used on the opposite side to the worst affected joints, with the hand holding the stick at the level of the greater trochanter, and the foot of the affected leg and the stick striking the ground more or less simultaneously. The importance of the joint being as well aligned as possible cannot be overemphasized. Shoe inserts, braces or taping of the affected joint may minimize the effect of malalignment including valgus (knees closer together than ankles) and varus (ankles closer together than knees) deformities. Local application of capsaicin cream (0.025%–0.075%), which acts as a counter-irritant, can be useful. Footwear should be chosen according to the following advice: 쎲 Thick, soft soles with maximum shock absorption 쎲 Minimum heel raise 쎲 Broad forefoot, allowing the toes to splay (thus improving balance and decreasing the likelihood of falls and injuries) 쎲 Soft uppers 쎲 Adequate depth of the shoe
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
48
18/3/08
14:29
Page 48
§02 Osteoarthritis
Recent Developments 1 Glucosamine has recently been studied in chondral and synovial cultures in vitro.9 In this study, glucosamine suppressed the secretion of matrix metalloproteinases (MMP-2 and MMP-9), key enzymes involved in cartilage degradation. Urokinase plasminogen activator has also been implicated in the development of OA, particularly where there are joint effusions. Again, levels of this enzyme were suppressed by glucosamine. 2 The hexosamine biosynthetic pathway may be a major cellular nutrient sensor.10 The first step in this pathway is the formation of glucosamine-6-phosphate from fructose-6-phosphate. The pathway leads to formation of uridine diphosphate (UDP)-N-acetyl-glucosamine, which becomes incorporated into the side chains of
Weight loss (if overweight/obese)
Weight maintenance
Exercise • Aerobic (general fitness) • Resistance (muscle bulk and function) • Strengthening (periarticular muscles)
Diet • Suitable calorie intake • Reasonable protein content • ? Vitamin C • ? Essential FA (n-3)
General measures • Accident/injury prevention • Sensible footwear • Taping or bracing affected joint • Orthotics (joint alignment) • Walking aids (stick etc.)
Capsaicin for pain relief
Glucosamine sulphate ± chondroitin sulphate
Viscosupplementation (hyaluronic acid)
Figure 9.1 Non-pharmacological management of OA. FA, fatty acid.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
Page 49
09 Non-pharmacological treatment
49
proteins and lipids. There is concern that increased flux through this pathway (including by glucosamine supplementation) may worsen insulin resistance and increase susceptibility to diabetes complications. 3 Some of the properties of mature cartilage depend on the charge of sulphate moieties of chondroitin sulphate. Dietary sulphate largely comes from high-protein foods, and low sulphate intake or low serum levels of sulphate have been associated with increased risk of OA. Blinn et al.11 have shown that prolonging the overnight fast or ingestion of calories without protein leads to lower serum levels of sulphate.
Conclusion Non-pharmacological management should be considered at the outset before drug treatments are initiated (Figure 9.1). The most important factors are weight management, exercises to increase general fitness and to increase strength around affected joints, measures to decrease stresses on joints, and improvement of the alignment of joints if need be. Current evidence favours the use of glucosamine sulphate (usually with chondroitin sulphate) and viscosupplementation with hyaluronic acid products. A number of nutritional factors, including antioxidant vitamins and essential fatty acids, are almost certainly important, but routine supplementation is not currently recommended.
Further Reading 1 Roddy E, Doherty M. Changing life-styles and osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 2006; 20: 81–97. 2 Felson DT, Zhang Y, Hannan MT et al. Risk factors for incident radiographic knee osteoarthritis in the elderly: the Framingham Study. Arthritis Rheum 1997; 40: 728–33. 3 Towheed TE, Maxwell L, Anastassiades TP et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; CD002946. 4 Clegg DO, Reda DJ, Harris CL et al. Glucosamine, chondroitin sulphate, and the two in combination for painful knee osteoarthritis. New Engl J Med 2006; 354: 795–808. 5 Zochling J, March LM, Lapsley H, Cross M, Tribe K, Brooks P. Use of complementary medicines for osteoarthritis – a prospective study. Ann Rheum Dis 2004; 63: 549–54. 6 Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006; CD005321. 7 Sun SF, Chou YJ, Hsu CW et al. Efficacy of intra-articular hyaluronic acid in patients with osteoarthritis of the ankle: a prospective study. Osteoarthritis Cartilage 2006; 14: 867–74. 8 Karatosun V, Unver B, Gocen Z, Sen A, Gunal I. Intra-articular hyaluranic acid compared with progressive knee exercises in osteoarthritis of the knee: a prospective randomized trial with long-term follow-up. Rheumatol Int 2006; 26: 277–84. 9 Chu SC, Yang SF, Lue KH et al. Glucosamine sulfate suppresses the expressions of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis. Clin Chim Acta 2006; 372 : 167–72.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
50
18/3/08
14:29
Page 50
§02 Osteoarthritis 10 Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab 2006; 290: E1–8. 11 Blinn CM, Biggee BA, McAlindon TE, Nuite M, Sibert JE. Sulphate and osteoarthritis: decrease of serum sulphate levels in an additional 3-h fast and a 3-h glucose tolerance test after an overnight fast. Ann Rheum Dis 2006; 65: 1223–5.
P R O B L E M
10 Drug Treatment
Case History Mrs GT is 67 years old. Since she developed osteoarthritis (OA) five years ago she has tried hard to control symptoms with diet, exercise and nutritional supplements. She is increasingly frequently requiring analgesics. She wants to discuss drug treatments for her OA. Her general health is good and she has no history of dyspepsia. Do non-steroidal anti-inflammatory drugs (NSAIDs) have an advantage over simple analgesia? How should drug therapy be approached? What are the prospects for disease-modifying drugs?
Background The first line of treatment for OA should always be non-pharmacological. When drug therapy is required, paracetamol in doses of up to 4 g/day is the usual first-line treatment. Zhang et al.1 conducted a meta-analysis of published controlled trials of simple analgesia for OA. The pain response to paracetamol was assessed along with the Western Ontario and McMaster Universities (WOMAC) OA index score, a score that focuses largely on functional symptoms. Combining data from the four trials identified, the pain response was classified as weak, while there was minimal functional improvement. Further trial data confirm that the effect of paracetamol is modest, while there is clear evidence from numerous trials that NSAIDs have at least a modest benefit in alleviating pain and © Atlas Medical Publishing Ltd
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
10 Drug treatment
Page 51
51
improving function.2 Paracetamol should be used only with caution in patients with liver disorders, but it seldom (except in overdose) causes hepatic dysfunction. Compared with aspirin and NSAIDs, paracetamol is relatively safe in patients with renal impairment. If paracetamol is of limited efficacy, do more potent analgesics have greater effect? The best-studied agent is tramadol. In addition to its opioid action, it is a weak central inhibitor of noradrenaline and serotonin uptake. There is no question from available trials that tramadol is moderately effective at decreasing pain and improving function (by WOMAC score) in patients with OA.3 A total daily dose of 200–300 mg is usual (given in divided doses), and the drug may be combined with paracetamol either to increase effect or to minimize the dose of each agent. Side effects include dizziness, somnolence, headache and constipation, but the drug is generally very safe, as well as being cheap. There is a range of alternatives including dextropropoxyphene and pentazocine. More potent opiates do not offer any advantage in terms of symptom relief and are more likely to cause side effects including dependence. The efficacy of tramadol is comparable to that of lower doses of NSAIDs or cyclooxygenase-2 (COX-2) inhibitors. Topical NSAIDs may be as effective as systemic administration.2 Since only up to 5% of the topical dose is absorbed systemically, risk of severe adverse drug reactions is substantially lower than with oral dosing. Side effects are usually limited to the site of administration – localized itching, burning or skin rash. The only concern with topical NSAIDs from trials is that their benefit may be relatively short-lived. OA is not primarily an inflammatory disorder. However, inflammation does contribute to symptoms and to disease progression. For knee OA in particular, intraarticular corticosteroid injection can be useful. The agents used are prednisolone, methylprednisolone, betamethasone and triamcinolone. The treatment leads to shortterm symptom relief but does not modify the long-term progression of the disease. From assessment of nearly 30 trials,4 the treatment is clearly superior to placebo for pain relief. It is comparable in effect to other pharmacological treatments for pain, but varying effects on functional improvement have been reported. There is a risk of introducing infection into the joint, and the treatment is not useful where there is substantial effusion in the joint. The focus of treatment in OA has been on symptom relief, but there is increasing interest in development of drugs that may modify the progress of the disease, and in approaches to reconstructing the cartilage matrix.5,6 Diacerein is an antagonist to interleukin (IL)-1b that has already been demonstrated to have some efficacy in controlled clinical trials. Other anti-inflammatory approaches include antagonists to tumour necrosis factor (TNF)-a. It appears most likely that local administration of disease-modifying agents may be preferred to avoid the systemic effects of immunosuppression. Local inhibitors of nitric oxide synthase (NOS) have the potential to decrease activation of cytokines and the COX-2 enzyme system. Colchicine has been proposed as a means of decreasing local inflammation within the joint. Both bisphosphonates and oestrogen treatment (in women) may impact favourably on the increased bone turnover that occurs around affected joints. Decreasing the turnover of the cartilaginous matrix is one of the goals of therapy. Twenty-eight matrix metalloproteinase (MMP) enzymes have now been identified and are key targets for disease-modifying drugs. Of these drugs, the tetracyclines – including doxycycline and minocycline – are the most widely studied agents. The joint space is a relatively easy target for locally administered gene therapy.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
52
18/3/08
14:29
Page 52
§02 Osteoarthritis Amongst gene targets studied have been the insulin-like growth factor-1 (IGF-1) gene and the gene for the IL-1 receptor antagonist. Experimental tissue-engineering approaches include the use of mesenchymal stem cells, autologous cartilage plugs, implantation of autologous chondrocytes and use of artificial cartilage matrix. Although unlikely to be as potent as pharmaceuticals and tissue-engineering approaches, there is considerable interest in the potential role of diets and supplements. These approaches are cheap, safe and popular with patients. Evidence relating to their effects and modes of action is accumulating. Various polyphenols, including the catechin group, have been studied because of their anti-inflammatory and chondroproliferative properties. The best-known supplement is green tea (epigallocatechin gallate), which is widely used as a herbal remedy. There is also considerable interest in ginger extracts and avocado/soybean non-saponifiables.
Diet Exercise Joint support and alignment
(Glucosamine ± chondroitin)
Paracetamol
Local measures • Capsaicin cream • NSAIDs • Methylsalicylate
Maximum dose 4 g/day
Tramadol
Low GI risk • NSAID
More potent opioids or analgesia 1NSAID
High GI risk • Add PPI • Misoprostol • COX-2
Intra-articular treatment • Steroids • Hyaluronan
Consider surgery
Figure 10.1 Drug treatments for OA. GI, gastrointestinal; PPI, proton pump inhibitor.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
Page 53
10 Drug treatment
53
Recent Developments 1 Doxycycline has been proposed as a disease-modifying drug for OA. Amongst its actions in the joint, the drug inhibits breakdown of type XI collagen and decreases activity of collagenase and NOS. A 30-month trial of doxycycline in women with radiologically proven knee OA7 showed 40% less reduction in the knee joint space in treated patients compared with placebo. While doxycycline appeared to slow the progression of joint disease in this study, its effects on symptom control were disappointing. 2 Nuclear factor-k-beta (NF-kB) is a transcription factor that plays an important part in modulating immunological and inflammatory responses. When the NF-kB pathway is activated, there is increased expression of inflammatory mediators and proteins involved in the regulation of apoptosis.8 The NF-kB pathway is inhibited by corticosteroids and a number of other immunomodulatory agents. There is a search for more specific agents. The pathway is involved in the pathogenesis of OA not only through regulation of inflammation but also through its involvement in regulation of cartilage turnover.
Conclusion A scheme for managing drug therapy in OA is proposed in Figure 10.1. Paracetamol is the most widely used analgesic and is often effective in alleviating pain without a major risk of side effects. The potential benefits of local treatments and more potent analgesics (including tramadol) are often forgotten before proceeding to NSAIDs. Progress is being made with disease-modifying drugs on a number of fronts. The most promising approaches are those that may downregulate the local increases in inflammation and cartilage turnover.
Further Reading 1
Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004; 63: 901–7.
2
Bannwarth B. Acetaminophen or NSAIDs for the treatment of osteoarthritis. Best Pract Res Clin Rheumatol 2006; 20: 117–29.
3
Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis. Cochrane Database Syst Rev 2006; 3: CD005522.
4
Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006; CD005328.
5
Fajardo M, Di Cesare PE. Disease-modifying therapies for osteoarthritis: current status. Drugs Aging 2005; 22: 141–61.
6
Baker CL, Ferguson CM. Future treatment of osteoarthritis. Orthopedics 2005; 28 (4 Suppl): s227–34.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
54
18/3/08
14:29
Page 54
§02 Osteoarthritis 7
Brandt KD, Mazzuca SA, Katz BP et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebocontrolled, double-blind trial. Arthritis Rheum 2005; 52: 2015–25.
8
Roman-Blas JA, Jimenez SA. NF-kb as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2006; 14: 839–48.
P R O B L E M
11 NSAIDs – Gastric Side Effects and Protection
Case History Mr JS is a 58-year-old carpenter. He was diagnosed as having rheumatoid arthritis at the age of 40 years. He is a smoker and is prone to dyspepsia. He does not currently require disease-modifying drugs. However, he does have pain and stiffness and is not able to work comfortably without symptomatic relief. To what extent do non-steroidal anti-inflammatory drugs (NSAIDs) cause gastrointestinal symptoms? Does the presence of dyspeptic symptoms influence the choice of agent? What strategies are available for gastric protection?
Background The NSAIDs are an important class of drug with analgesic, antipyretic and anti-inflammatory activities. They are among the most common drugs prescribed. NSAIDs account for around 3% of the total United States (US) drugs market, and it is estimated that 5%–10% of the population use NSAIDs on a regular basis (Box 11.1). In the US during 2001, 70 million prescriptions were issued for NSAIDs and 30 billion doses were bought over the counter. NSAIDs are weak acids (pKa 3–5) that are highly lipid soluble and readily absorbed from the stomach. In the plasma they are highly protein bound (>95%, mainly to albumin). They are metabolized and conjugated in the liver and mainly excreted in the urine. © Atlas Medical Publishing Ltd
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
Page 55
11 NSAIDs – gastric side effects & protection
55
Box 11.1 Uses of NSAIDs Osteoarthritis Rheumatoid arthritis Inflammatory spondyloarthropathies (ankylosing spondylitis, reactive arthritis, psoriatic arthritis) Post-operative pain Acute gout Soft tissue injuries (including sports injuries) Dysmenorrhoea Renal colic NSAIDs reversibly inhibit the cyclooxygenase (COX) enzyme, which catalyses the first step in the pathway that converts arachidonic acid to key regulatory prostaglandins. The enzyme exists in two isoforms: COX-1 is constitutively expressed in most tissues while COX-2 is an inducible enzyme, the expression of which is upregulated at sites of inflammation (Figure 11.1). The gastric side effects of NSAIDs relate to inhibition of COX-1 in the gastric mucosa, where prostaglandins increase gastric mucous and bicarbonate secretion, decrease gastric acid secretion and stimulate mucosal blood flow. COX-2 is not
Membrane phospholipids
Phospholipase A2
Arachidonic acid
COX-1 constitutive/inducible
COX-2 constitutive/inducible
PGs • GI cytoprotection • Platelet aggregation • Renal function (blood flow)
PGs • Inflammation − Fever − Pain − Headache • Carcinogenesis • Kidney, stomach, uterus • CNS and spine • Endothelium
Figure 11.1 Prostaglandin generation by COX-1 and COX-2. CNS, central nervous system; GI, gastrointestinal; PG, prostaglandin.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
56
18/3/08
14:29
Page 56
§02 Osteoarthritis
Box 11.2 Risk factors for gastric side effects High dose of NSAID Use of non-selective NSAID First three months of treatment Age >50 years Previous ulcer history
Use of multiple agents Concurrent use of aspirin, warfarin or steroids Previous ulcer history Helicobacter pylori infection General disability
normally expressed in the gastric mucosa. The beneficial, anti-inflammatory actions of NSAIDs are mediated through inhibition of COX-2. NSAIDs vary greatly in their relative COX-1 and COX-2 inhibitory activity. Aspirin, sulindac and piroxicam have much greater selectivity for COX-1. The mechanism of aspirin action differs from that of other NSAIDs in that it acts by irreversibly acetylating the active site of COX-1. Meloxicam, the first of the selective COX-2 inhibitors, is three times more potent on COX-2 compared with COX-1. COX-2 is not inhibited by aspirin but is downregulated by glucocorticoids. NSAIDs are generally very safe and well tolerated. However, because of the number of patients using them, adverse reactions are frequently encountered. By far the most common side effects relate to gastric mucosal injury (Box 11.2). Up to 20% of patients taking NSAIDs suffer gastrointestinal symptoms including heartburn, dyspepsia, nausea, vomiting and abdominal pain. In endoscopic studies, haemorrhagic reactions to the presence of the tablets in the stomach are almost universal, superficial erosions occur in 50% of subjects and 20% of regular users have chronic ulceration (i.e. ulcers that penetrate the muscularis mucosa). There is a variable relationship between symptoms and the changes in the mucosa visible on endoscopy. The gastrointestinal side effects of NSAIDs are a major cause for concern.1 Serious gastric side effects occur in less than 1% of patients. However, this is sufficient to account for 100 000 hospital admissions, contribute to 16 000 deaths and cost $1.5 billion in the US each year. Similarly in the United Kingdom, where there are around four million users with osteoarthritis, use of NSAIDs contributes to 2000 deaths each year. Hooper et al.2 conducted a review comparing gastric protection strategies in subjects receiving NSAIDs. In all, 112 trials with 74 666 participants were included; 248 serious gastrointestinal adverse drug reactions (ADRs) were reported and there were 138 deaths. Histamine H2 receptor antagonists proved to be ineffective at preventing any of the primary outcomes. Proton pump inhibitors significantly reduced symptomatic ulcers (relative risk [RR] 0.09; 95% confidence interval [CI] 0.02–0.47) and serious complications (RR 0.57; 95% CI 0.36–0.91). Misoprostol is a prostaglandin analogue that increases mucous protection and decreases acid-induced damage. It may be prescribed alone (Cytotec) or in combination with diclofenac (Arthrotec). A dose of 200 mg/day is usually sufficient, while higher doses may cause diarrhoea, abdominal pain and bloating. Misoprostol decreased the rate of symptomatic ulcers (RR 0.36; 95% CI 0.20–0.67) and serious gastrointestinal side effects (RR 0.57; 95% CI 0.36–0.91). Use of COX-2-selective agents was associated with lower rates of symptoms (RR 0.49; 95% CI 0.38–0.62) and serious gastrointestinal ADRs (RR 0.55; 95% CI 0.38–0.80). H2 receptor antagonists are effective at preventing symptoms and duodenal ulcers with NSAIDs but probably do not prevent gastric ulcers. They are probably more cost-effective than COX-2-selective drugs and their routine prescription with non-selective COX inhibitors may be justified.3
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
Page 57
11 NSAIDs – gastric side effects & protection
57
Helicobacter pylori infection is implicated in the pathogenesis of gastric and duodenal ulcers. It is not clear whether there should be routine screening for and eradication of this agent in patients starting NSAIDs. Screening can be undertaken using breath tests, serological testing for antibodies or endoscopy with gastric biopsy. Serology is cheap and convenient but a positive result does not necessarily indicate current infection and does not change after eradication. The Celecoxib Long-term Arthritis Safety Study (CLASS) and the Vioxx Gastrointestinal Outcomes Research (VIGOR) study each enrolled over 8000 patients and confirmed that COX-2 inhibitors were as effective as non-selective agents for patients with arthritis.1 Use of COX-2 inhibitors was associated with lower risk of symptomatic ulcers and serious gastrointestinal side effects. A number of studies have confirmed that COX-2-selective agents reduce the incidence of serious gastrointestinal side effects by 40%–50%. Their role in preventing dyspeptic symptoms has been less certain. Spiegel et al.4 recently reviewed 26 published studies comparing COX-2-selective with non-selective agents; the relative risk of dyspeptic symptoms was decreased by 12% and the absolute risk was decreased by 3.7% with a COX-2-selective agent. By contrast, compared with non-selective NSAIDs alone, NSAID plus concurrent proton pump inhibitor led to a relative risk reduction of dyspeptic symptoms of 66% and an absolute risk reduction of 9%. Aspirin and NSAIDs may be associated with decreased risk of cancers, including those of the gastrointestinal tract. Studies in vitro have shown that COX-2 inhibition may decrease the growth of gastric cancers, and COX-2 inhibitors have been suggested for the treatment of pre-cancerous gastric lesions in humans.5 Increased risk of myocardial infarction has been associated with use of high-dose, non-selective NSAIDs and with use of COX-2-selective agents (chapter 12). Renal side effects include salt and water retention, hypertension, acute renal failure, interstitial nephritis, nephrotic syndrome and acute tubular necrosis.6 Renal side effects are more likely when the patient is also taking angiotensin-converting enzyme inhibitors or diuretics. COX-2 is constitutively expressed in the kidney, and patients taking COX-2 inhibitors are as likely to experience renal side effects as patients taking non-selective agents. Other side effects are headache, dizziness, tinnitus and pruritus. Photosensitivity may occur with piroxicam or diclofenac. NSAIDs may cause increased liver enzymes and, occasionally, severe hepatitis.
Recent Developments 1 The role of COX isoenzymes in ulcer healing has recently been investigated in COX-1 and COX-2 knockout mice with induced gastric ulcers.7 The COX-1 enzyme apparently had no part to play in ulcer healing, while ulcer healing was impaired in COX-2 knockout mice or in wild-type mice treated with COX-2 inhibitors. Inducible nitric oxide synthase (NOS-2) and endothelial nitric oxide synthase (NOS-3) were upregulated in healing ulcers, suggesting that these enzymes might play a part in the healing process. Some of the potential benefit of selective COX-2 inhibitors in protecting against ulcer formation may be offset by their inhibitory effect on ulcer healing. 2 The proton pump inhibitors are widely used in prevention and treatment of gastric injury induced by NSAIDs and their use is well supported by trial
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
58
18/3/08
14:29
Page 58
§02 Osteoarthritis
Pain (e.g. from arthritis)
Simple analgesia (paracetamol)
NSAID indicated
Correct risk factors if possible • Smoking • Alcohol excess • Stress • Use of steroid, warfarin or aspirin
Previous ulcer
No ulcer
H. Pylori (screen and eradicate) Consider endoscopy/barium Estimate risk of GI side effects Warn patient of risks
Low risk
Medium risk
High risk
Lowest possible dose NSAID
COX-2-selective NSAID 1H2RA
NSAID 1 PPI NSAID 1 misoprostol
Careful follow-up
Figure 11.2 NSAIDs and risk of gastrointestinal side effects. The considerations shown take account of the relative costs of different drugs and combinations as well as their efficacy. COX-2, COX-2-selective agent; H2RA, histamine H2 receptor antagonist (e.g. cimetidine, ranitidine); NSAID, non-steroidal antiinflammatory drug (non-selective agent); PPI, proton pump inhibitor.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
Page 59
11 NSAIDs – gastric side effects & protection
59
evidence. Several non-acid-dependent mechanisms are also thought to be important in promotion of gastric ulcers. In a recent animal study,8 lansoprazole decreased oxidative stress within the gastric mucosa and this was thought to contribute to its effect in protecting from mucosal damage induced by NSAIDs. 3 The interaction between NSAIDs and H. pylori infection in the causation of gastric and duodenal ulcers is controversial. A recent study compared rates of gastrointestinal symptoms in patients positive and negative for H. pylori and treated with NSAID.9 Furthermore, the positive group was divided, with half being treated with H. pylori eradication therapy and half with placebo. Overall, there was no relationship between dyspeptic symptoms induced by NSAID and H. pylori status. These data do not favour routine screening for and eradication of H. pylori in patients who are being started on NSAIDs.
Conclusion NSAIDs represent one of the most commonly prescribed groups of drugs. Their use is frequently associated with gastrointestinal symptoms, and serious drug reactions occur in up to 1% of patients annually. The anti-inflammatory action of NSAIDs relates to inhibition of the COX-2 isoenzyme, while gastrointestinal side effects are due to inhibition of COX-1. Individual agents vary widely in their relative inhibitory activity for the two isoenzymes. COX-2-selective agents are much less likely than non-selective agents to cause dyspeptic symptoms. However, combining non-selective NSAIDs with proton pump inhibitors or misoprostol probably provides even greater protection. Recent data showing that the COX-2-specific agents in particular are associated with increased risk of myocardial infarction have limited the use of this class of drug and led to the withdrawal of some agents. Management of risk of gastric problems with NSAIDs is summarized in Figure 11.2.
Further Reading 1
Fennerty MB. NSAID-related gastrointestinal injury. Evidence-based approach to a preventable complication. Postgrad Med 2001; 110: 87–94.
2
Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal antiinflammatory drugs: systematic review. BMJ 2004; 329: 948–58.
3
Elliott RA, Hooper L, Payne K, Brown TJ, Roberts C, Symmons D. Preventing nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population? Rheumatology 2006; 45: 606–13.
4
Spiegel BMR, Farid M, Dulai GS, Gralnek IM, Kanwal F. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med 2006; 119: 448.e27–36.
5
Jiang XH, Wong BCY. Cyclooxygenase-2 inhibition and gastric cancer. Curr Pharm Des 2003; 9: 2281–8.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
60
18/3/08
14:29
Page 60
§02 Osteoarthritis 6
Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des 2005; 11: 1795–804.
7
Schmassmann A, Zoidl G, Peskar BM et al. Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and -2 knockout mice. Am J Physiol Gastrointest Liver Physiol 2006; 290: G747–56.
8
Blandizzi C, Fornai M, Colucci R et al. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol 2005; 11: 4052–60.
9
Schaeverbeke T, Broutet N, Zerbib F et al. Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study. Am J Gastroenterol 2005; 100: 2637–43.
P R O B L E M
12 NSAIDs – Cardiac Complications Case History Mrs JA is a 64-year-old lady who finds that her osteoarthritis symptoms are no longer controlled with simple analgesia. She has suffered from angina since the age of 57. She has never had a myocardial infarction (MI) and her angina is stable. Her exercise tolerance is not governed by angina and would be better if her arthritic symptoms were improved. Would you prescribe her a non-steroidal anti-inflammatory drug (NSAID)? Which agent would you choose? What is the current thinking about NSAIDs and the risk of cardiac events?
Background The cyclooxygenase (COX) enzymes catalyse the first stage in the formation of prostaglandins and thromboxanes from arachidonic acid. The COX-1 isoenzyme is constitutively expressed in most tissues, while COX-2 expression is induced at sites of inflammation. The major side effects of the NSAID group of drugs, including the effects on the stomach, are caused by COX-1 inhibition, while the beneficial effects are almost entirely due to COX-2 inhibition. A classification of drugs with NSAID action is shown © Atlas Medical Publishing Ltd
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
Page 61
12 NSAIDs – cardiac complications
61
Box 12.1 The non-steroidal anti-inflammatory drugs (NSAIDs) Salicylates Aspirin Benorilate Diflunisal 2-arylpropionic acids (profens) Ibuprofen Fenbufen Fenoprofen Naproxen Ketoprofen Flurbiprofen Coxibs Celecoxib (Celebrex) Parecoxib (Dynastat) Lumiracoxib (Prexige) Rofecoxib * Valdecoxib * * Drug withdrawn from the market.
Arylalkanoic acids Diclofenac Etodolac Indomethacin Sulindac Tolmetin Oxicams Piroxicam Meloxicam Tenoxicam Pyrazolidine derivatives Phenylbutazone Oxyphenbutazone Azapropazone N-arylanthranilic acids Mefenamic acid Tolfenamic acid
in Box 12.1. Paracetamol has analgesic but no anti-inflammatory properties. Unquestionably, endoscopic studies have shown that COX-2 inhibitors are less likely than traditional NSAIDs to produce gastric ulceration. In late 2004, emerging data from the Vioxx Gastrointestinal Outcomes Research (VIGOR) and Adenomatous Polyp Prevention on Vioxx (APPROVe) studies demonstrated that risk of MI was increased up to two-fold in patients treated with rofecoxib (Vioxx). This led to withdrawal of the drug and valdecoxib was withdrawn because of similar considerations. Activation of COX-1 in platelets leads to increased thromboxane A2 (TxA2) and consequent platelet aggregation, vasoconstriction and smooth muscle proliferation.1 This pathway is irreversibly blocked by aspirin. Recent studies suggest that non-selective NSAIDs including naproxen and ibuprofen, when given concurrently with aspirin, may interfere with this beneficial effect of aspirin and increase coronary events. COX-2 is expressed only at very low levels in healthy blood vessels but is abundantly expressed in atherosclerotic vessels. The enzyme is expressed in smooth muscle cells, macrophages/foam cells and in the endothelium. Secretion of prostacyclin (PGI2) by endothelial cells counteracts the effects of TxA2 released from platelets. This intrinsic protection mechanism is lost when the COX-2 enzyme is inhibited. Figure 12.1 depicts the proposed model of prothrombotic and antithrombotic balance for low-dose aspirin, traditional NSAIDs and selective COX-2 inhibitors. Recent data suggest that the adverse effects noted with rofecoxib are a class effect. A trial with celecoxib2 revealed a dose-dependent increase in fatal and non-fatal cardiovascular events. Deaths from cardiovascular events were three times more likely on 400 mg/day and six times more likely on 800 mg/day. Hazard ratios for any cardiovascular
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
62
18/3/08
14:29
Page 62
§02 Osteoarthritis
LOW-DOSE ASPIRIN
NORMAL PGI2 PGI2
TxA2 TxA2
Prothrombotic
Antithrombotic
Prothrombotic
Antithrombotic
SELECTIVE COX-2 ASPIRIN
NSAID
TxA2 PGI2 Prothrombotic
TxA2 Antithrombotic
PGI2 Prothrombotic
Antithrombotic
Figure 12.1 Dynamic balance of prostacyclin (PGI2) and thromboxane A2 (TxA2) under the influence of NSAIDs.
event were 1.5 and 1.9, respectively, for the two doses. Other studies with parecoxib (a pro-drug for valdecoxib) have confirmed an increased cardiovascular risk, even with short-term usage. Non-selective NSAIDs also inhibit COX-2 to a variable extent. Increased cardiovascular risk has been noted in patients taking diclofenac, ibuprofen or naproxen. Comparing COX-2 inhibitors with non-selective NSAIDs is difficult as the latter also have some COX-2-inhibitory activity. It is agreed that naproxen is the preferred drug to compare with selective COX-2 inhibitors. Some of the conditions for which NSAIDs are used are themselves associated with increased cardiovascular risk (e.g. rheumatoid arthritis and systemic lupus erythematosus). The low-grade inflammation associated with arthritic conditions may contribute to cardiovascular risk through increasing endothelial dysfunction, decreasing availability of nitric oxide within vessels and increasing the generation of reactive oxygen species. Since the withdrawal of the two coxib drugs at the end of 2004, there has been considerable activity to clarify whether safety concerns should include all selective COX-2 inhibitors and even extend to some non-selective agents. A large Canadian study3 included 113 927 elderly subjects starting COX-2 inhibitors and who did not have a history of MI. Rofecoxib was associated with increased risk of MI. The increased risk with low-dose rofecoxib was offset by concurrent use of aspirin. There was no increased risk associated with celecoxib or meloxicam use. Kearney et al.4 conducted a meta-analysis of trials published between 1966 and April 2005. Patients taking COX-2 inhibitors had increased risk of vascular events. The annual rates of serious cardiovascular events were 1.2% per year for patients taking COX-2 inhibitors and 0.9% per year for patients receiving placebo. There was no difference in event rate between COX-2-treated patients and
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
Page 63
12 NSAIDs – cardiac complications
63
those treated with non-selective COX inhibitors. There was, however, considerable heterogeneity amongst the latter agents: relative risk of an event (compared with placebo) was 0.92 (95% confidence interval 0.67–1.26) for naproxen, 1.51 (0.96–2.37) for ibuprofen and 1.63 (1.12–2.37) for diclofenac. Another meta-analysis of 114 controlled clinical trials5 has reported increased risk of renal toxicity and arrhythmias with rofecoxib but no increase with other coxib drugs.
Recent Developments 1 A Danish study6 has investigated rates of death and re-admission with MI in 58 432 patients discharged following acute MI. There was a trend towards increased hospitalization for use of both COX-2-selective and non-selective agents. The hazard ratios for death were 2.80 (95% confidence interval 2.41–3.25) for rofecoxib, 2.57 (2.15–3.08) for celecoxib, 1.50 (1.36–1.67) for ibuprofen, 2.40
Non-pharmacological treatments been fully explored?
Analgesia (paracetamol up to 4 g/day)
Low cardiac risk*
Angina
Previous MI or stroke
NSAID
NSAID 1 aspirin
Stronger analgesia (e.g. tramadol)
High gastric risk or symptoms
High gastric risk or symptoms Naproxen 1 aspirin
Or Add PPI or misoprostol
Add PPI or misoprostol COX-2
Review need for NSAID regularly (every 3 months)
Figure 12.2 Use of NSAIDs in patients with cardiovascular risk. * Measure lipids, blood glucose and blood pressure; it is useful to use a cardiovascular risk calculator. COX-2, COX-2-selective agent; NSAID, nonselective anti-inflammatory drug; PPI, proton pump inhibitor.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
64
18/3/08
14:29
Page 64
§02 Osteoarthritis (2.09–2.80) for diclofenac and 1.29 (1.16–1.43) for other NSAIDs. The risk of death was related to dose of drug taken. 2 A nationwide Finnish study7 examined the use of NSAIDs in 33 309 patients admitted with their first MI. These subjects were age- and gender-matched with controls. The apparent risk with NSAIDS for first MI was 1.40 (95% confidence interval 1.33–1.48). No difference was noted between non-selective agents, semiselective COX-2 inhibitors or selective COX-2 inhibitors. There was no suggestion that any of the drugs was protective against MI. 3 A study to compare etoricoxib with diclofenac is under way.8 This study in patients with rheumatoid arthritis or osteoarthritis should answer the question of whether the risk associated with use of COX-2 inhibitors is any greater than that for conventional NSAIDs. The study has enrolled nearly 35 000 patients.
Conclusion Over 30 million people worldwide take NSAIDs regularly. Recent studies have shown that use of these drugs is associated with increased risk of MI. If non-pharmacological means and simple analgesia fail to control the above patient’s symptoms, then it is reasonable to consider use of NSAIDs. It is probably best, initially, to use one of the conventional agents and naproxen is the drug of choice, the dose and duration of exposure being kept to a minimum. There is an argument for using higher-dose aspirin to overcome the effects of COX-2 inhibition. A scheme for considering NSAID use is presented in Figure 12.2. There is considerable heterogeneity of cardiovascular risk amongst both COX-2selective and non-selective NSAIDs, although it seems likely that increased risk is related to the ability of the individual drug to inhibit the COX-2 isoenzyme.
Further Reading 1
Hermann M, Ruschitzka F. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. Intern Med J 2006; 36: 308–19.
2
Solomon SD, McMurray JJ, Pfeffer MA et al; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med 2005; 352: 1071–80.
3
Lévesque L, Brophy J, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142: 481–9.
4
Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302–8.
5
Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomised trials. JAMA 2006; 296: 1619–32.
6
Gislason GH, Jacobsen S, Rasmussen JN et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Circulation 2006; 113: 2906–13.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
Page 65
13 Joint replacement surgery
65
7
Helin-Salmivaara A, Virtanen A, Vesalainen R et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006; 27: 1657–63.
8
Cannon CP, Curtis SP, Bolognese JA, Laine L. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 2006; 152: 237–45.
P R O B L E M
13 Joint Replacement Surgery Case History Mary has been passing on your advice on preventing osteoarthritis (OA) to the members of the local bowls club. The information may have come a little late for George who has severe right hip OA. He is now aged 62 years, is moderately overweight at 89 kg (body mass index 28.7 kg/m2) and has asked about a hip replacement. Will weight reduction delay George’s need for surgery? What are the indications for a knee or hip replacement? What are the options for joint replacement and what is their expected lifespan?
Background In the United States and United Kingdom (UK), the number and rate has doubled for knee replacements and tripled for hip replacements over the past decade. Future projections are that >750 000 of these procedures will be performed per year by the year 2030. A critical variable in these estimations is the low proportion of individuals who on the basis of symptoms warrant joint replacement but remain unwilling to consider the procedure.
Weight reduction Given that obesity is modifiable by conservative treatment such as weight loss, its importance in reducing the incidence of large joint OA is often advocated, yet determining the impact prospectively of weight reduction is more problematic.1 The effect of adult weight change on risk for total hip replacement resulting from primary OA was studied prospectively in a large Norwegian cohort whose weight had been recorded over a mean 14-year © Atlas Medical Publishing Ltd
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
66
18/3/08
14:29
Page 66
§02 Osteoarthritis period from age mid-30s to late 40s. With an average follow-up of nine years, there was no association of weight slope, absolute weight change or relative weight change between screenings with later total hip replacement.2 A number of studies have shown that after large joint replacement weight increases, from a small amount in the pre-operatively non-obese patient to an average 4.8 kg gain in the pre-operatively obese.3,4 Post-operative weight gain has been documented for both hip and knee replacement, with younger hip-replacement patients gaining a significant amount of weight.5 Obesity therefore needs to be treated as an independent disease that increases the risk of requiring major joint replacement, and is adversely impacted by surgery that is aimed at reducing pain and increasing a person’s exercise ability.
Exercise Exercise is beneficial for people with arthritis, and pre-operative functional status is positively related to post-operative functional status. Inclusion of both pre-operative and post-operative strength training in a total hip replacement programme improves physical function at 12 and 24 weeks post-operatively.6 The optimal type and the amount of exercise plus the timing of the pre-operative intervention need to be established.
Indications for hip or knee replacement These indications are summarized in Figure 13.1. Concerns about the timing of surgery surface for two primary classes of patients: the younger, active candidate and the older candidate. For the younger (less than 60 years of age), active patient, the long-term survival of the prosthesis is the major concern. While there are several studies on long-term outcome, most of these describe prosthesis survival for the more typical older and less active individual. Furthermore, as prosthesis design and materials improve, the newer prostheses will have longer survival. For the less active, older patient in whom long-term prosthesis survival is less of a concern, some information may be provided by comparing outcomes in patients with poor pre-operative symptoms versus those with better pre-operative symptoms as proxies for late versus early surgery. When followed at 6 and 24 months post-operation, those with poorer pre-operative status had poorer outcomes. Patients need to appreciate the small but real risk of perioperative complications and, for younger patients, the potential for revision surgery. However, they also should be appraised that likelihood of functional benefit is higher if they enter into surgery with a better functional status.
Perioperative preparations and complications Rheumatoid arthritis (RA) patients also benefit from joint replacement, and in these individuals their immunosuppressant therapy needs to be considered. Weekly methotrexate is the mainstay of most RA regimes, and can be continued up to the time of surgery and recommenced upon return of baseline fluid balance and renal function. In a prospective, randomized study of post-operative infection and surgical complications in 388 RA patients in the UK who underwent elective orthopaedic surgery, one group continued methotrexate and the other group ceased methotrexate two weeks pre-operatively and recommenced treatment two weeks post-operatively.6 Complication rates were compared between groups and with 228 RA patients not on methotrexate and undergoing elective orthopaedic surgery. No increase in the duration of early post-operative
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
Page 67
13 Joint replacement surgery
Indications:
67
Pain limiting function despite conservative therapy Nocturnal pain disrupting sleep Understanding of potential complications
Contraindications: Severe neurological or cognitive impairment that will impair rehabilitation Vascular disease/unstable angina/anaesthetic risk Chronic sepsis
Plain X-ray
Confirms significant joint pathology
No or mild X-ray changes
Review to exclude periarticular source of pain
Orthopaedic referral
Figure 13.1 Hip and knee joint replacement surgery.
infections or rate of complications was found. Patients who continued methotrexate had significantly fewer adverse events than either of the other two groups (P <0.003). Additionally, those who did cease methotrexate had a higher incidence of disease flares in the six weeks following surgery than those who continued the medication. The risk of death is approximately 1% in the 90 days following hip replacement and slightly less for knee replacement. Pulmonary embolism and myocardial infarction occur within 90 days in 1% of patients. Dislocation occurs in 3% of total hip replacements. Deep joint infection occurs in about 0.4% of total knee replacements and 0.2% of total hip replacements. While dislocation and infection remain potential complications over the longer term, the risk is much higher in the first 90 days than subsequently.
How long will it last? Long-term success of total hip arthroplasty is dependent on prosthetic component fixation and the amount of wear and debris generated by the bearing surface. Advances in
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
68
18/3/08
14:29
Page 68
§02 Osteoarthritis both femoral cementing techniques and the design of cemented stems have resulted in near-perfect (98%) survivorship at ten years and good survivorship (93%) at 25 years.7 Comparable survival rates have been reported using cementless techniques for the femoral component. In the acetabular component, ten-year survival rates are similar for cemented and cementless techniques (approximately 95%–98%); however, at 15 years, cementless technology supersedes cemented (85%–95% versus 70%–95%). Cemented total knee arthroplasty (TKA) is the current gold standard, with consistent long-term (10–14 years) survival rates of 94%–98%. Whilst some cementless TKA techniques have demonstrated good long-term survival, the majority have not reliably resulted in bone ingrowth. Long-term survival rates and functional abilities are comparable in cruciate-retaining and cruciate-substituting prostheses. To improve patient satisfaction and function, implants have an increased arc of flexion that may approach 150 degrees of knee flexion. Recent literature searches and meta-analyses suggest that resurfacing the patella at TKA likely improves outcomes and long-term, pain-free patella function.
Recent Developments 1 Ogonda et al.8 randomized patients to a standard 16 cm incision or a minimal (≤10 cm) incision for their hip replacement. They found that although the standard incision group had a higher estimated blood loss, there was no difference in mean units of transfusion or haematocrit at discharge. There were also no significant differences found in post-operative pain, timed 10 m walk on the second post-operative day, length of hospital stay or functional outcome. 2 Although TKA is currently the gold standard for knee joint replacement, unicompartmental arthroplasty has emerged as a suitable option for advanced medial compartment osteoarthritis, with outcomes comparable with those for TKA. The procedure is generally performed using a minimally invasive approach and leads to more rapid recovery, minimal bone loss, less pain and early discharge compared to TKA. The 10–15-year survival rates for unicompartmental knee arthroplasty are high and range from 95%–98%.9
Conclusion Total joint replacement should not be regarded as an intervention of last resort and should be offered to patients when their quality of life is compromised. Pre-operative functional status is the most significant predictor of post-operative functional status. Surgery should be considered when symptoms warrant it and when the intervention will contribute to a person’s post-operative life experience. As procedures, total hip and knee joint replacements (Figure 13.2) are costly, but total hip replacement is among the most cost-effective interventions in medicine. Long-term follow-up is available on older prostheses and relief of pain and restoration of function can be expected in over 90% of patients, with a complication rate that is rare and a mortality rate of <1%.
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
18/3/08
14:29
Page 69
13 Joint replacement surgery
69
(A)
(B)
Figure 13.2 Total hip and knee joint replacements. (A) An artificial hip joint with metallic femoral stem and ultra-high-molecular-weight polyethylene acetabular cup. An artificial knee joint in situ, with metallic femoral component and ultra-high-molecular-weight polyethylene bearing. (Both figures redrawn with permission from Fisher 2004.10).
02-PS Rheumatology-cpp:02-PS Rheumatology-ppp.QXD
70
18/3/08
14:29
Page 70
§02 Osteoarthritis
Further Reading 1 Powell A, Teichtahl AJ, Wluka AE, Cicuttini FM. Obesity: a preventable risk factor for large joint osteoarthritis which may act through biomechanical factors. Br J Sports Med 2005; 39: 4–5. 2 Flugsrud GB, Nordsletten L, Espehaug B, Havelin LI, Meyer HE. Weight change and the risk of total hip replacement. Epidemiology 2003; 14: 578–84. 3 Donovan J, Dingwall I, McChesney S. Weight change 1 year following total knee or hip arthroplasty. ANZ J Surg 2006; 76: 222–5. 4 Aderinto J, Brenkel IJ, Chan P. Weight change following total hip replacement: a comparison of obese and non-obese patients. Surgeon 2005; 3: 269–72. 5 Heisel C, Silva M, dela Rosa MA, Schmalzried TP. The effects of lower-extremity total joint replacement for arthritis on obesity. Orthopedics 2005; 28: 157–9. 6 Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001; 60: 214–17. 7 Jones DL, Westby MD, Greidanus N et al. Update on hip and knee arthroplasty: current state of evidence. Arthritis Rheum 2005; 53: 772–80. 8 Ogonda L, Wilson R, Archbold P et al. A minimal-incision technique in total hip arthroplasty does not improve early post-operative outcomes. A prospective, randomized, controlled trial. J Bone Joint Surg Am 2005; 87: 701–10. 9 Yang KY, Wang MC, Yeo SJ, Lon NN. Minimally invasive unicondylar versus total condylar knee arthroplasty – early results of a matched pair comparison. Singapore Med J 2003; 416: 559–62. 10 Fisher J. Surgery for arthritis: total hip and knee joint replacement. ARC Topical Reviews 2004, Number 3.
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
S E C T I O N
18/3/08
15:26
Page 71
T H R E E
03
Rheumatoid Arthritis 14
Causes
15
Laboratory and imaging investigations
16
Managing rheumatoid arthritis at onset
17
Evaluating the response to treatment
18
Pregnancy and rheumatic diseases
19
Diet and arthritis
20
Polyarthritis in the elderly
P R O B L E M
14 Causes
Case History Steve’s rheumatoid arthritis (RA) has been managed for the past four years with a combination of methotrexate, hydroxychloroquine and sulphasalazine. He is rheumatoid factor (RF) positive and has significant joint damage. He wishes to explore with you why he may have developed RA. His daughter, aged 24 years, has recently been told that she is RF positive. What genetic factors influence the development or severity of RA? What environmental factors are known to be involved? How does being RF positive influence the likelihood of developing RA?
Background RA is a chronic inflammatory disease affecting the synovium and leading to joint damage and absorption of adjacent bone. Peak age of onset is in the fifth decade and females are © Atlas Medical Publishing Ltd
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
72
18/3/08
15:26
Page 72
§03 Rheumatoid Arthritis two to three times more likely to be affected, although the sex distribution becomes less apparent with increasing age. Apart from the disability caused by the disease, it also has a significant impact on life expectancy, with RA patients living on average three to ten years less than unaffected individuals. The overall incidence of the condition is 20–50 per 100 000 per year. This may have decreased since the 1960s. The prevalence varies in different countries:1 쎲 0.5%–1.1% in Northern Europe and North America 쎲 0.3%–0.7% in Southern Europe and other warmer countries 쎲 0.5% in developing countries In the pre-clinical phase of RA, immunoglobulin G (IgG) may be elevated and RF (polyclonal antibodies directed at the Fc fragment of IgG) and anti-cyclic citrullinated peptide (anti-CCP) antibodies may be detected. Citrullination is a post-translational modification of arginine by peptidylarginine deaminase enzymes. Specific diseasemodifying treatment is not indicated at this early phase of the disease.
Genetics of RA The importance of genetic factors is clear from family studies: prevalence is 2%–12% in first-degree relatives of RA sufferers – i.e. approximately ten times that of the background population. Concordance rate is 10%–30% in monozygotic twins and 5%–10% in same-sex dizygotic twins. The genetic component of RA has been studied by genomewide linkage analyses and by study of individual candidate genes.2 The major susceptibility gene for RA is the DRB1 gene located in the class II histocompatibility region on chromosome 6p. Risk of RA is associated with the alleles HLA-DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0408, DRB1*0101 and DRB1*0102. These alleles have similar or identical sequences at the third hypervariable region in the b chain between amino acid positions 70 and 74. According to the shared epitope (SE) hypothesis, this sequence is directly involved in the immunopathogenesis of RA, although the precise mechanism is not clear. The human leukocyte antigen (HLA) component accounts for around 30% of the genetic risk. The susceptibility alleles linked to RA are present in around 70% of patients but also in 40% of the general population. Thus genotyping is not currently useful in clinical practice. Other genes associated with RA include: 쎲 Tumour necrosis factor (TNF)-a located in the class II part of the histocompatibility complex on 6p. Polymorphisms influence the level of TNF-a expression 쎲 The TNF-a receptor type 2 gene (TNFR2) located at 1p36. The 196R allele of this gene is linked with RA 쎲 Peptidylarginine deaminases (PADIs), also located at 1p36. These enzymes catalyse the citrullination of arginine residues and, therefore, determine the level of citrullinated peptides 쎲 SLC22A4 (solute carrier family 22 A4) at chromosome 5q31 – also implicated in Crohn’s disease 쎲 PTNP22 (tyrosine phosphate non-receptor type 22) at 1p13 – also linked with type 1 diabetes and autoimmune thyroid disease
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
15:26
Page 73
14 Causes
73
Environmental factors These triggers may begin to operate long before clinically apparent disease develops. The pre-clinical phase of RA may last for up to 15–20 years. During this phase the prevalence of autoantibody markers increases amongst susceptible individuals as the onset of clinical disease approaches. IgA rheumatoid factors are probably the first markers to appear in most patients. Neither RF nor anti-CCP antibodies are entirely sensitive, but together the markers are reasonably specific – 85% to 90% for RF and 98% for anti-CCP. Markers of inflammation – including total IgG, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) – may be increased during the clinical phase. The patient may experience symptoms of malaise and fatigue and intermittent joint symptoms (palindromic rheumatism). Risk factors for RA are summarized in Figure 14.1. Environmental triggers may be more important than genetic factors.3 Some studies have shown much higher association than this in families but it is difficult to disentangle genetic influences from social and other environmental influences.
Susceptibility
Subclinical
Environmental
Diet
Disease onset
Progression
• Family history • Other autoimmune disease • HLA-DRB1 SE etc. • Female gender
Genetic
Occupation
Protective
• Smoking • Infections (EBV etc) • Low UV (vitamin D) Aggravating
Omega-3 Red meat Mediterranean Caffeine ? diet Fruit Vitamin C • Agriculture • Postal and print • Silica • Mineral oil
Smoking Aging Oestrogen withdrawal Decreased androgen levels Periodontal disease
Figure 14.1 Development of rheumatoid arthritis. EBV, Epstein–Barr virus; UV, ultraviolet light.
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
74
18/3/08
15:26
Page 74
§03 Rheumatoid Arthritis Smoking is probably the most potent environmental trigger, with smokers at two- to four-fold increased risk of RA. The risk is dose dependent with heavy smokers being at higher risk than light smokers. A number of mechanisms could account for the link between smoking and RA – these include the immunomodulatory effect of tobacco components, oxidative stress and oestrogenic effects, and the effect of smoke in promoting peptide citrullination. Smoking also increases the risk for anti-double-stranded DNA (anti-dsDNA)-positive systemic lupus erythematosus. Smoking is associated with more severe rheumatoid disease: erosive arthropathy, rheumatoid nodules and vasculitis. The Nurses Health Study was a large cohort study investigating the effect of aspirin and vitamin E in preventing cardiac disease. In a prospective study of 103 818 women from this cohort followed from 1976 to 2002,4 there were 680 new cases of RA. Women with a history of ten pack-years or more were at increased risk, and the risk of RA was related both to the intensity and duration of smoking. The increased risk persisted for up to 20 years after cessation of smoking. Oestrogen exposure in women has a protective effect. This is consistent with increased risk of the disease after the menopause and the slight protective effect of using hormone replacement therapy. It is not clear why the prevalence of RA is so much higher in women compared with men. As with other autoimmune diseases, pregnancy is protective, with the incidence during pregnancy being 70% lower than that for age- and sex-matched controls. However, there is a rebound increase after pregnancy with risk increased by as much as five-fold in the months after delivery. Breast-feeding also appears to increase risk. This may be due to the low-oestrogen state or to pro-inflammatory actions of prolactin. The relationship between sex steroid status and susceptibility to autoimmune disease is complex.5 The influence of social, employment and educational status does not seem to be great in RA. The disease is more prevalent in urban populations, but this could be partly due to migration of patients with chronic RA to metropolitan centres. Certain occupations do seem to have increased risk: men who work in agriculture and in the paper and transport industries, and female printer and postal workers, appear to be at increased risk. Workers exposed to silica dust (e.g. from drilling or crushing rock) are at up to three-fold increased risk. Mineral oil exposure has been noted to increase risk of a number of autoimmune diseases including RA. Low intake of fruit and vitamin C relates to increased risk, while high intake of red meat carries a high risk. Regular consumption of oily fish (a source of omega-3 fatty acids) is protective, as is adherence to a Mediterranean diet. Low vitamin D status is probably a risk factor for RA, but there is no evidence that vitamin D supplementation protects against the disease. Some immune-mediated diseases, particularly type 1 diabetes and multiple sclerosis, are more common in latitudes where there is lower exposure to ultraviolet light.6 While vitamin D status is the most plausible explanation for this association, other metabolic factors may equally be involved. The notion of an infectious trigger for RA is appealing. Evidence in favour of this includes the decreasing incidence of the condition and the associations with previous blood transfusion and pet ownership. There is no evidence for a seasonal incidence of the condition. Amongst candidate organisms are Epstein–Barr virus (EBV), rubella, parvovirus and Borrelia burgdorferi. Of these, the strongest evidence is with EBV, the glycoprotein of which has cross-reactivity with the HLA-DRB1 SE. Increased incidence and
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
14 Causes
15:26
Page 75
75
levels of EBV DNA have been reported in peripheral blood mononuclear cells and synovial fluid of RA patients and the virus is well documented to have immunomodulatory properties.
Recent Developments 1 Two recent studies7,8 have pooled data from the United Kingdom and United States to demonstrate that there are important susceptibility loci at chromosomes 6q and 16p. There appears to be an interaction between these loci and HLA determinants. Further study of the genes at these loci may shed more light on the pathogenesis of RA. 2 In a recent Swedish case–control study,9 positive immunostaining for citrullinated peptides was found in the cells from bronchoalveolar lavage of smokers. Furthermore, there was a strong association between smoking status and the presence of anti-citrulline antibodies. There was a positive interaction between anticitrulline autoimmunty and the presence of SE in the HLA-DR region. Individuals who smoked and had double copies of the HLA-DR SE had a 21-fold increased risk of RA. 3 In a mouse model of RA, oestrogen deficiency by oophorectomy accelerated the development of arthritis and increased levels of RF, anti-dsDNA and anti-collagen antibodies.10 4 Periodontal disease is mainly caused by infection with Gram-negative anaerobes. These lead to increased production of cytokines that damage gingival connective tissue and increase resorption of dental alveolar bone. Marotte et al.11 have shown that the presence of HLA-DR SE correlates with increased periodontal bone destruction. Furthermore, periodontal bone destruction strongly correlated with wrist bone resorption in patients with RA.
Conclusion RA has a significant genetic component but perhaps not as strong as was once thought. The most powerful genetic influence is the HLA-DRB1-related SE. Of known environmental triggers, smoking is the most powerful. Women are more prone to the disease but low oestrogen status appears to increase susceptibility. The presence of RF is not absolutely specific for the disease but is generally highly predictive. The antibody does occur in a proportion of the general population and may occur in other autoimmune connective tissue disorders. A long pre-clinical phase with positive RF and anti-CCP antibodies, sometimes with mild and variable symptoms, is common in RA.
Further Reading 1 Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005; 4: 130–6.
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
76
18/3/08
15:26
Page 76
§03 Rheumatoid Arthritis 2 Dieude P, Cornelis F. Genetic basis of rheumatoid arthritis. Joint Bone Spine 2005; 72: 520–6. 3 Oliver JE, Silman AJ. Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol 2006; 35: 169–74. 4 Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006; 119: 503.e1–9. 5 Cutolo M, Lahita RG. Estrogens and arthritis. Rheum Dis Clin North Am 2005; 31: 19–27. 6 Ponsonby AL, Lucas RM, van der Mei IAF. UVR, vitamin D and three autoimmune diseases – multiple sclerosis, type 1 diabetes, rheumatoid arthritis. Photochem Photobiol 2005; 81: 1267–75. 7 Etzel CJ, Chen WV, Shepard N et al. Genome-wide meta-analysis for rheumatoid arthritis. Hum Genet 2006; 119: 634–41. 8 John S, Amos C, Shepard N et al. Linkage analysis of rheumatoid arthritis in US and UK families reveals interactions between HLA-DRB1 and loci on chromosomes 6q and 16p. Arthritis Rheum 2006; 54: 1482–90. 9 Klareskog L, Stolt P, Lundberg K et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38–46. 10 Yoneda T, Ishimaru N, Arakaki R et al. Estrogen deficiency accelerates murine autoimmune arthritis associated with receptor activator of nuclear factor-kB ligandmediated osteoclastogenesis. Endocrinology 2004; 145: 2384–91. 11 Marotte H, Farge P, Gaudin P, Alexandre C, Mougin B, Miossec P. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheum Dis 2006; 65: 905–9.
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
15:26
Page 77
15 Laboratory and imaging investigations
77
P R O B L E M
15 Laboratory and Imaging Investigations Case History Joan is a 52-year-old schoolteacher who you have diagnosed with rheumatoid arthritis (RA). You have discussed a range of treatment options with her and also discussed with her a number of investigations. She is keen to know about the monitoring and investigation required for different medications and what information will be gained from other scheduled investigations. What investigations should be undertaken at the onset of RA? What investigations help with monitoring the activity of the condition? How should follow-up be planned?
Background Making a diagnosis of RA Joan has an inflammatory arthritis; it is established as a chronic problem, having extended beyond eight to ten weeks, which makes a post-viral arthropathy unlikely. The American College of Rheumatology classification for RA requires four of seven criteria to be met, with the clinical features of arthritis being present for at least six weeks: 쎲 Morning stiffness of greater than one hour duration 쎲 Objective evidence of joint inflammation, such as soft tissue swelling or fluid in 3 of 14 defined joint areas (right or left proximal interphalangeal [PIP], metacarpophalangeal [MCP], wrist, elbow, knee, ankle and metatarsophalangeal joints) 쎲 At least one of the joint areas demonstrating inflammation must be in the hands 쎲 Simultaneous involvement of the same joint area bilaterally in at least one pair 쎲 Rheumatoid nodules 쎲 A positive rheumatoid factor (RF) using a method that is positive in <5% of normal subjects 쎲 Typical changes of RA in hand and wrist X-rays, which must include erosions or unequivocal periarticular osteopenia RA is one of the most common autoimmune diseases, affecting 1% of the population. Other diagnoses, such as psoriatic arthritis or systemic lupus erythematosus (SLE), could present with the same clinical scenario and the history and examination undertaken will have considered these in the differential diagnosis. © Atlas Medical Publishing Ltd
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
78
18/3/08
15:26
Page 78
§03 Rheumatoid Arthritis
Investigations for RA RF is a polyclonal antibody predominantly of the immunoglobulin M (IgM) and IgG classes, which targets the Fc region of the IgG. Whilst commonly thought to have diagnostic significance by both doctors and patients, it has a very poor predictive value, being present in only 70% of RA cohorts and also present in 5% of the normal population. RF positivity increases with age and is positive in any circumstance with prolonged antigen stimulation, so that chronic infections such as malaria and tuberculosis account for the bulk of RF positivity globally. Similarly in individual patients, age and chronic sepsis need to be considered in addition to the pattern of joint disease before attributing a positive RF with a diagnosis of RA. RF positivity associates with increased joint erosions and vasculitis. Radiographs of the hands and wrists, feet and cervical spine were historically undertaken at baseline and then one- to two-yearly to monitor for erosive disease. Fortunately, the model of therapy has changed so that the goal is suppression of inflammation as soon as possible after diagnosis is established; this is combined with the knowledge that joint erosions detected by magnetic resonance imaging (MRI) or musculoskeletal ultrasound occur up to 18 months before their detection on plain X-ray. In Joan’s case, radiographs will add little, demonstrating the soft tissue swelling that was observed on clinical examination and therefore reinforcing the clinical pattern noted. In later disease, different patterns of involvement can be noted for psoriasis, SLE and RA. Psoriasis classically develops ‘pencil in cup’ erosions of both PIP and distal interphalangeal joints with the proximal phalanx narrowing to the sharpened pencil, burrowing into the cup-like, widened distal phalanx. SLE is almost always a non-erosive disease. X-ray changes in RA mirror the joints clinically involved, primarily affecting the hands, the PIP, MCP and wrists. Soft tissue swelling occurs early, with periarticular osteopenia noted, and subsequently there is symmetrical joint space narrowing. Erosions when they occur begin at the site of synovial lining of the joint capsule reflecting onto the cartilage/periosteum junctions, so that they occur slightly distant from the joint surface. Joan’s erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) will both be increased and will act as a means to monitor therapy, with the goal being their normalization. Both ESR and CRP are measures of acute phase proteins produced in the liver in response to monocyte-derived cytokines. CRP testing is more expensive than ESR but is the preferred measurement for monitoring success in suppressing joint inflammation, particularly in RA. The situation is more complex in SLE, with some individuals having a cytokine pattern resulting in an elevated CRP, and others whose disease pattern is not associated with a rise in CRP.1 The blood film commonly shows an inflammatory thrombocytosis, with more established disease showing a normochromic normocytic anaemia; this can eventually mimic the hypochromic microcytic picture of iron deficiency, due to the inflammatory process inhibiting the utilization of iron stores. Concomitant therapies such as non-steroidal anti-inflammatory drugs (NSAIDs) may cause genuine iron deficiency through gastrointestinal blood loss. Corticosteroids induce a neutrophil leukocytosis. The presence of lymphopenia in Joan would have caused a reconsideration of the diagnosis of SLE. Clinical examination should include urinalysis, with the presence of proteinuria or leukocytes warranting further microscopy and evaluation. Proteinuria would suggest glomerular inflammation. If SLE remains part of the differential diagnosis, an antinuclear antibody (ANA) test can be requested. A significant positive result is a titre of 1:160
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
15:26
Page 79
15 Laboratory and imaging investigations
79
or greater, and again in itself has poor diagnostic or prognostic value unless interpreted as part of the clinical presentation. Evaluation of electrolytes, renal function and liver function should be undertaken. NSAIDs may exacerbate hyperkalaemia and impair renal function, with several of the disease-modifying agents notable for their potential to cause hepatitis with elevation of transaminases.
Safety monitoring of RA medications A guide to the safety monitoring for the agents used for treatment of RA is shown in Table 15.1. Methotrexate, alone or in combination with other agents, is the basis of most RA regimes. Biological agents that target specific cytokines such as tumour necrosis factor (TNF) and interleukin-1, or that block cell-to-cell signalling (such as cytotoxic lymphocyte-associated antigen linked to immunoglobulin [CTLA4-Ig; abatacept]) are becoming increasingly used in those who do not respond quickly to ‘standard’ therapy. Screening for hepatitis B and C is recommended, although a positive result is not an absolute contraindication to therapy. Recent studies have suggested an enhanced hepatitis C antiviral effect of interferon and ribavirin in the setting of concomitant etanercept. Table 15.1 Guide to safety monitoring of commonly used antirheumatic medications NSAIDs
Methotrexate +
Sulphasalazine
Leflunomide
Anti-TNF therapy Chest X-ray, hepatitis B & C serology; screen for latent TB as per local guidelines
Baseline
BP, oedema, K , creatinine
Chest X-ray, FBC, LFT hepatitis B & C serology, FBC, LFT, chest auscultation
Chest X-ray, hepatitis B & C serology, FBC, LFT, chest auscultation
Periodic
K+ and creatinine at one week; BP and oedema at each clinical visit
FBC, LFT at four- to six- FBC, LFT monthly ¥3, weekly intervals; then three-monthly chest auscultation at each clinical visit
FBC, LFT at four- to As clinically indicated six-weekly intervals; chest auscultation at each clinical visit
BP, blood pressure; FBC, full blood count/screen; K+, serum potassium; LFT, liver function tests; TB, tuberculosis.
Liaison between specialist and primary care practitioner A close collaboration and correspondence flow is required. The management plan will be developed between Joan and her specialist, but much of its implementation will be with her general practitioner. They will need to consider the impact that any new illness will have on her RA management, and also the impact of her RA management on intercurrent illness as well as preventative activities such as vaccinations. Common points of ambiguity are who will undertake prescribing and who will monitor and communicate with Joan about any abnormalities detected on periodic screening. Joan should be encouraged to attend her general practitioner regularly and this eventually should allow alternating visits between the two physicians, with specialist attendance four- to six-monthly.
Recent Developments 1 Detection of antibodies to cyclic citrullinated peptides (CCP) has a sensitivity similar to RF, but specificity is much higher in the range of 95%–99%.2,3 In patients with early undifferentiated arthritis, the presence of anti-CCP antibodies has an odds
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
80
18/3/08
15:26
Page 80
§03 Rheumatoid Arthritis ratio of 38 for subsequent development of RA, and is an adverse prognostic marker for both clinical disease and radiological progression. Repeated measurement currently has no clinical utility, with therapeutic intervention leading to only modest reduction in levels that do not correlate with clinical indicators. 2 Anti-TNF therapy appears to protect against joint damage but may have little influence on systemic inflammatory markers such as ESR and CRP.4 High-sensitivity CRP measurement can generate specific values lower than the previous threshold in RA subjects with a normal CRP; subjects with high-sensitivity CRP values 2–8 mg/l had higher disease activity scores, less remission rates and greater depression and helplessness than those with values <2 mg/l. High-sensitivity CRP also performs consistently better than ESR at predicting other disease activity variables.5 A patient’s joint count is, not surprisingly, a good marker of activity and subsequent prognosis. In subjects with early arthritis of less than one year’s duration, a joint count of greater than seven actively diseased joints accurately predicted subsequent performance and function.6 3 Detailed radiological imaging and scoring has been undertaken in trials of biological therapy, which suggest that progression can be halted and that joint erosions can mature with regrowth of cortical bone and infilling. Plain radiographs of the hands and feet remain quick and affordable imaging modalities, but erosions can be detected by more sensitive imaging techniques around 18 months before they are detected on plain films. Imaging modalities that can be used include ultrasound, MRI and computed tomography (CT). Most erosions at the wrist will be detected by both CT and MRI, although CT will detect more erosions particularly at the metacarpal bases, possibly because of its ability to delineate cortical bony margins.7 High-resolution ultrasound requires good apposition of the probe and an ability to access the bone surface. As a consequence, wrist examination is suboptimal, with MCP joints 2 and 5 exhibiting better correlation with MRI than ultrasound of MCP 3 and 4, which can only be accessed in two planes.8
Conclusion A clear and positive approach is needed as you discuss the investigations that will assist in confirming the diagnosis, and in determining disease activity and its current impact on function. The shared care between specialist and primary care physician is aimed at inhibition of the inflammatory process and therefore halting the local and systemic impact of the disease. Involving the patient in the goal setting at the start is helpful in gaining their understanding of the strategies you are using to bring the disease under control. A clear goal of the absolute minimum number of tender and swollen joints, lowering of inflammatory markers and improvement in a patient’s quality of life is critical. Antirheumatic medications are highly effective in bringing disease under control, and that should always be the opening when discussing any new medications: to clearly put the benefits so that this can be weighed against the potential adverse events, which themselves are discussed in the context of how to minimize them and how to detect them early. RA remains a chronic disorder that, while not curable, is eminently treatable with an increasing range of options and flexible delivery systems to maintain a high quality of life in nearly all patients.
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
15:26
Page 81
15 Laboratory and imaging investigations
81
Further Reading 1
Liou LB. Different monocyte reaction patterns in newly diagnosed, untreated rheumatoid arthritis and lupus patients probably confer disparate C-reactive protein levels. Clin Exp Rheumatol 2003; 21: 437–44.
2
Riedemann JP, Muñoz S, Kavanaugh A. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis – a systematic review. Clin Exp Rheumatol 2005; 23 (5 Suppl 39): S69–76.
3
Zendman AJW, van Venrooij WJ, Pruijn GJM. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology 2006; 45: 20–5.
4
Smolen JS, van der Heijde DM, St Clair EW et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54: 702–10.
5
Dessein PH, Joffe BI, Stanwix AE. High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis. J Rheumatol 2004; 31: 1095–7.
6
Gerber LH, Furst G, Yarboro C, el-Gabalawy H. Number of active joints, not diagnosis, is the primary determinant of function and performance in early synovitis. Clin Exp Rheumatol 2003; 21 (5 Suppl 31): S65-70.
7
Perry D, Stewart N, Benton N et al. Detection of erosions in the rheumatoid hand; a comparative study of multidetector computerized tomography versus magnetic resonance scanning. J Rheumatol 2005; 32: 256–67.
8
Szkudlarek M, Klarlund M, Narvestad E et al. Ultrasonography of the metacarpophalangeal and proximal interphalangeal joints in rheumatoid arthritis: a comparison with magnetic resonance imaging, conventional radiography and clinical examination. Arthritis Res Ther 2006; 8; R52.
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
82
18/3/08
15:26
Page 82
§03 Rheumatoid Arthritis
P R O B L E M
16 Managing Rheumatoid Arthritis at Onset
Case History Jason, aged 48 years, has returned for his second visit with suspected rheumatoid arthritis (RA). He has a three-month history of increasing pain involving his hands, wrists and feet. He is a non-smoker. You note active synovitis affecting most of his proximal interphalangeal joints and metacarpophalangeal joints, both wrists and his metatarsophalangeal joints. Erythrocyte sedimentation rate (ESR) is 63 mm/h, serum C-reactive protein (CRP) 26 mg/l. He has strongly positive rheumatoid factor (RF) and elevated anti-cyclic citrullinated peptide (anti-CCP) antibodies. What medications would you recommend to Jason? Will providing Jason with educational material and support impact on his RA?
Background To impact on the morbidity of RA, long-term management of patients is required, based not only on drug treatment, but also on non-pharmacological approaches such as physiotherapy and psychosocial support. The pharmacological treatment of RA is still problematical and as yet there are no reliably curative or disease-remitting therapies, although considerable gains have been made recently with the advent of biological therapies. However, RA often progresses to disability. It is hoped that the full application of the older disease-modifying antirheumatic drugs (DMARDs) together with the newer DMARDs and biological agents can improve this outlook. First-line pharmacological therapy for all of the inflammatory arthritic diseases includes the non-steroidal antiinflammatory drugs (NSAIDs). These are useful symptomatically but have no clear effect on the progression of RA, with virtually all patients requiring additional treatment with a DMARD.
Omega-3 oil supplementation Inflammation contributes to a range of acute and chronic human diseases and is characterized by the production of inflammatory cytokines, arachidonic acid-derived eicosanoids (prostaglandins, thromboxanes, leukotrienes), reactive oxygen species and adhesion molecules. Long-chain omega-3 fatty acids – eicosapentaenoic acid and © Atlas Medical Publishing Ltd
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
15:26
Page 83
16 Managing rheumatoid arthritis at onset
83
docosahexaenoic acid – have anti-inflammatory properties when taken in doses greater than 2.7 g daily and are of proven benefit in RA, providing reduced morning stiffness, decreased tender joint count and a lessened need for NSAIDs. At sufficiently high intakes, long-chain n-3 polyunsaturated fatty acids (PUFAs), as found in oily fish and fish oils, decrease production of inflammatory eicosanoids, cytokines and reactive oxygen species and decrease the expression of adhesion molecules. Long-chain n-3 PUFAs act both directly (e.g. by replacing arachidonic acid as an eicosanoid substrate and inhibiting arachidonic acid metabolism) and indirectly (e.g. by altering the expression of inflammatory genes through effects on transcription factor activation). Long-chain n-3 PUFAs also give rise to a family of anti-inflammatory mediators termed resolvins. The required dose of omega-3 fish oil can be taken using a large number of fish oil capsules (more than nine standard fish oil capsules containing oil from eviscerated fish bodies [30% omega-3] daily); however, the cost can be prohibitive. A less expensive alternative is to take about 10–15 ml of bottled fish body oil daily. The palatability and hence long-term acceptance of fish oil can be improved by using a ‘two-glass technique’. This involves ‘floating’ the dose of fish oil on 30 ml of fruit or vegetable juice in a small glass. The contents are swallowed without contact with the lips, avoiding the fish oil taste. This is followed by slowly sipping a further 40 ml of juice (from a separate glass) to rinse the mouth. Reflux of the fish oil can be avoided by taking it immediately before a solid meal – and without any extra fluid – to encourage mixing of the fish oil with the food and its transport from the stomach into the small intestine. Passage of the oil from the stomach can also be facilitated by lying on the left side for 15 minutes after the dose, or by dividing the daily dose and having each half immediately before the morning and evening meals.1
DMARDs A recent change in the use of DMARDs is that they are generally commenced as soon as a diagnosis of an inflammatory arthritis is made, in order to have the maximal effect on slowing the progress of the disease.2 The rationale for early initiation of therapy is the demonstration of rapid functional decline, and evidence that many of the deleterious effects of RA, such as erosions of bone, occur within the first one to two years of disease. This approach contrasts to the older disease-management regimens in which DMARDs were only commenced on the appearance of bony erosions on joint X-rays. Many patients with RA and other inflammatory arthritic diseases are also administered intra-articular and/or low-dose oral corticosteroids. They are frequently administered as bridging therapy until the effect of a DMARD is fully established. In some patients they are used long term with a DMARD, in order to satisfactorily suppress the disease. Corticosteroids may also be used alone for disease control in the elderly if this can be achieved with a daily dose equivalent of 7.5 mg prednisolone or less.
Biological agents These are inhibitors of either tumour necrosis factor (TNF) or interleukin-1. These drugs produce rapid control of RA in a high percentage of cases, and joint destruction may be halted and even reversed in some patients. There are, however, potential problems with the biological agents, particularly the activation of infections, as well as very high financial costs.
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
84
18/3/08
15:26
Page 84
§03 Rheumatoid Arthritis The most recent strategy to optimize treatment of RA has been the introduction of initial combination therapy. This approach is based on the experience of oncologists, with the combination of different mechanisms of action leading to additive or synergistic effects without significantly increasing toxicity. Studies in which one arm receives intermediate- to high-dose corticosteroids have demonstrated a clinical superiority that becomes less noticeable, however, as the steroid dose reduces or is withdrawn. Interestingly, in these studies a radiographic benefit does continue to be seen for several years, suggesting that the initial, rapid clinical and laboratory improvement does retard or halt the structural damage that is otherwise occurring.3 The first-line choices of a single agent in RA consist of methotrexate, leflunomide and sulphasalazine. Methotrexate is currently the gold standard DMARD, with doses accelerated to achieve 20 mg/week within 6–8 weeks of commencement, with folic acid supplementation of 5 mg/week. Objective outcomes need to be recorded including swollen and tender joint counts, inflammatory markers (ESR, CRP) and a quality of life/functional index. Failure to achieve remission of disease activity after a maximum of 3–4 months of therapy should result in an escalation or switching of therapy. An algorithm of treatment is suggested in Figure 16.1.
Patient education Patient education is thought to be beneficial in helping patients cope with their disease and cooperate with its complex management. The focus is to teach patients to adjust their daily activities as dictated by disease symptoms. In addition to teaching patients what they should do, patients are also instructed on how to approach situations and to make adjustments that are appropriate for each individual and their needs. However, it is not clear which educational interventions are most effective in improving health status for patients with chronic disease. A systematic review of randomized controlled trials focused on the effects of patient education on pain, functional disability, joint counts, patient and physician global assessment, affect scores and measures of acute phase reactants.4 The quality of studies identified was not very high, with issues of randomization and concealment impacting adversely on their quality. At first follow-up there is a small but significant beneficial effect, particularly for functional disability. The magnitude of the effect is small, however, similar to that gained from the use of the weaker DMARDs. The duration of effect is also brief, being lost at follow-up 3–14 months later. Therefore strategies to preserve and extend the initial beneficial effects of education over a longer time need to be explored.
Recent Developments 1 The clinical response to treatment of RA can be assessed by the proportion of patients who have a 70% or greater improvement according to seven clinical and laboratory measures of disease activity; this is designated as having an American College of Rheumatology (ACR)-70 response. ACR-70 responses were found in 19%–21% of patients receiving methotrexate monotherapy in trials in early RA but in 33%–40% of those receiving TNF inhibitors with methotrexate. In established RA, ACR-70 responses occurred in fewer than 5% of patients receiving methotrexate monotherapy but in 10%–27% of those receiving the
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
15:26
Page 85
16 Managing rheumatoid arthritis at onset
85
Establish RA diagnosis or • RF 1 unclassified oligoarthritis/polyarthritis or • RF 2 unclassified oligoarthritis/polyarthritis .3 months duration
Document baseline disease activity
• • • • •
Patient education on disease and its therapy Commence analgesia, NSAID as needed Omega–3 oil supplementation Consider low-dose steroid Start DMARD and safety monitoring
Methotrexate 20–25 mg/wk plus folate
Evaluate at 10–12 weeks
Adequate response
Inadequate response
Periodic review
• Combination therapy • Biological agents
Figure 16.1 Antirheumatic therapy in early RA. (Adapted with permission from the American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines 20025 and Smolen et al. 2005.6)
combination. TNF inhibitors substantially reduce the erosive damage assessed on X-ray and magnetic resonance imaging. They also decrease the self-assessed disability measured using the Health Assessment Questionnaire and improve the quality of life assessed using SF-36.7 2 Cigarette smoking remains the most important lifestyle risk factor and one that is modifiable. Males are three times more likely to develop RA if they smoke, with the risk increasing 13-fold in both sexes for heavy smokers (41–50 pack-years). The influence of smoking is substantially greater in those with a background HLA-DRB1
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
86
18/3/08
15:26
Page 86
§03 Rheumatoid Arthritis shared epitope genetic susceptibility. Stopping smoking can reduce this risk, although the benefit is not seen until at least ten years after quitting, when the increased risk halves.8
Conclusion Early recognition of RA and prompt disease suppression with DMARDs and prednisolone is the key to the initial improvement of patients’ quality of life and to minimizing subsequent progressive joint damage. Methotrexate retains its key role in the early treatment of RA, and whilst there remains controversy over unequivocal demonstration of the superiority of combination therapy, several studies do support the concept. Some of the best evidence in support of combination therapy is that of TNF blockers when combined with methotrexate, in which the combination is superior to monotherapy with either agent with respect to clinical, functional and radiographic outcome. The strategy of aiming for tight disease control with rapid switching of regimens if patients do not improve when assessed against measurable and recorded outcome is also a key advance. The literature also suggests that the addition of intermediate- to high-dose prednisolone to DMARDs, whether as monotherapy or combination therapy, is beneficial if introduced early in the course of RA.
Further Reading 1
Cleland LG, James MJ, Proudman SM. Fish oil: what the prescriber needs to know. Arthritis Res Ther 2006; 8: 202–10.
2
Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004; 43: 906–14.
3
Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? Arthritis Rheum 2005; 52: 2975–83.
4
Riemsma RP, Taal E, Kirwan JR, Rasker JJ. Systematic review of rheumatoid arthritis patient education. Arthritis Rheum 2004; 51: 1045–59.
5
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 2002; 46: 328–46.
6
Smolen JS, Aletaha D, Machold KP. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005; 19: 163–77.
7
Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006; 355: 704–12.
8
Oliver JE, Silman AJ. Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol 2006; 35: 169–74.
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
15:26
Page 87
17 Evaluating the response to treatment
87
P R O B L E M
17 Evaluating the Response to Treatment
Case History Charles and Dianna are a married couple who have been under your care for some years. Charles is aged 43 years with a 20-year history of ankylosing spondylitis (AS), and Dianna is aged 48 years and has had rheumatoid arthritis (RA) for eight years. You have noted that they are increasingly restricted in their activities. As part of your ongoing commitment to care, you want to implement a method of recording the impact of your treatment. What measures are available for monitoring disease activity? How can function and quality of life be quantified?
Background The benefit of any therapeutic intervention must outweigh the cost, with cost most easily measured in monetary terms. More difficult to measure is the cost to the individual in terms of convenience of use, monitoring and adverse effects – both actual and potential. Similarly it can often be difficult to measure benefit, and this particularly applies to rheumatic disease, where a hard end-point such as mortality is rarely the outcome measure. Patients with rheumatic disease experience pain and impaired function, but over time they adapt to these circumstances and symptom-reporting alters, so that quietly and without complaint function is lost. RA and AS are contrasting diseases. In Table 17.1 the demographic and clinical characteristics are compared, providing insight into the different outcome measures that need to be evaluated for each disease process. Table 17.1 Characteristics of RA and AS
Gender
Rheumatoid arthritis
Ankylosing spondylitis
F>M
M>F
Age
Middle age onwards
Late teens onwards
Peripheral disease
Predominant with involvement of hand and feet
Unusual, with occasional involvement of hip and shoulder
Spinal disease
Cervical inflammation
Ascending spinal restriction with impaired posture
F, female; M, male.
© Atlas Medical Publishing Ltd
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
88
18/3/08
15:26
Page 88
§03 Rheumatoid Arthritis Outcome measures vary according to the situation and purpose for which they are being evaluated, often differing significantly when being used in routine clinical practice and research trials. A pragmatic approach is required if they are to be utilized by the average practitioner who either does not have specialist knowledge or lacks specialist equipment. In broad terms, the outcomes of interest in rheumatic disease are: 쎲 Laboratory evidence of inflammation recorded as erythrocyte sedimentation rate or serum C-reactive protein 쎲 Clinical joint inflammation recorded as the number of tender or swollen joints on examination 쎲 Clinical examination of spinal function 쎲 Patient’s self-reported experience of pain, fatigue or functional consequence of their disease 쎲 Radiological progression
Laboratory markers of disease activity Laboratory investigations, by themselves, can be misleading. It is not unusual for a person to have normal inflammatory markers despite a small number of inflamed peripheral joints; similarly, elevated markers may be caused by incidental illness such as urinary tract infection. RA, with its distinct synovial inflammation, often leads to elevated inflammatory markers, whereas the spondyloarthropathies (in which enthesial inflammation at the tendon–periosteal interface predominates) have much lower and often normal values.
Physical evaluation of disease activity Counting a patient’s tender and swollen joints is a quick and easy way of both examining the patient and evaluating the extent of their disease activity. While you could examine every joint, examining the easy-to-access 18 joints of upper limbs and knees has been shown to be a valid measure of disease activity (Figure 17.1). The joints examined are the interphalangeal joint of the thumb, proximal interphalangeal joint of the fingers, the metacarpophalangeal joints, wrists, elbows, shoulders and knees – totalling 18 joints. The method of examination is to palpate the joint in two directions – applying sufficient pressure to blanch the distal third of the nail bed of your thumb – to determine separately the presence of swelling and tenderness. The tender joint count (TJC) and swollen joint count (SJC) can be recorded both within the clinical record and in correspondence to other practitioners (i.e. SJC = 4/18, TJC = 6/18). This allows a quick analysis for trends over time and also provides an indicator of absolute disease severity. A count of six to eight indicates moderate severity, sufficient for entry into many trials of new therapeutic agents. Assessing spinal function requires a fuller examination and exposure of the patient but does allow serial evaluations, which are valid in detecting progressive loss of function and potentially act as patient motivation for their ongoing exercise programme. An index of spinal movement – the British Ankylosing Spondylitis Metrology Index (BASMI) – provides a score of relative severity for any outcome and allows serial comparison. Tables 17.2 and 17.3 describe both the scoring system and method of measurement relating to
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
15:26
Page 89
17 Evaluating the response to treatment
Figure 17.1 Mannequin showing the 28 easily accessible joints for evaluation in routine practice (highlighted).
Table 17.2 BASMI scoring system Score
0
1
2
Tragus to wall (cm)
<15
15–30
>30
Lumbar flexion (cm)
>4
2–4
<2
Cervical rotation (degrees)
>70
20–70
<20
Lumbar side flexion (cm)
>10
5–10
<5
Intermalleolar distance (cm)
>100
70–100
<70
Adapted with permission from Irons and Jeffries 2004.1
89
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
90
18/3/08
15:26
Page 90
§03 Rheumatoid Arthritis
Table 17.3 Obtaining BASMI measurements Measure
Starting position
Method
Tragus to wall
Standing with back to wall, outer edges of feet 30 cm apart
Patient draws chin in as far as possible. Examiner measures distance between tragus and the wall with a rigid ruler
Lumbar flexion (modified Schober)
Outer edges of feet 30 cm apart. Examiner marks midpoint of line level with iliac crests; a second point is marked 10 cm above and a third 5 cm below
Patient flexes forward from waist with knees fully extended. Distance between upper and lower marks is measured, and then 15 cm is subtracted
Cervical rotation (performed for each side)
Patient supine on bed
Patient rotates head as far as possible. Angle between neutral position and rotation is measured with goniometry
Lumbar side flexion (performed for each side)
As for tragus to wall
Measure from tip of middle finger to floor with rigid 1 m ruler. Patient side-flexes without forward flexion or knee flexion. Remeasure from tip of middle finger to floor. Calculate difference between two measurements
Intermalleolar distance Patient lies supine on floor
Keeping knees straight, patient moves legs as far apart as possible. Distance between medial malleoli is measured
Modified with permission from Irons and Jeffries 2004.1
AS. The ability to comment to a patient on the progress of their disease is important, and can also be a motivating force for compliance with interventions, particularly exercise and physiotherapy.
Evaluating quality of life As medical practitioners, it is readily acknowledged that for many patients physicians are not able to cure them of their disease but aim instead to improve their ‘quality of life’. The latter has many domains, and in practice physicians are primarily aiming to influence those areas related to a person’s health that impact on their global well-being – socalled health-related quality of life. Even within this more circumscribed area there are instruments that measure this in a generic way, thus allowing the same instrument to be used in different disease states providing comparisons that may be used to support health resource distribution decisions. Disease-specific instruments also exist and often provide greater insights into an individual disease and may respond quicker to interventions for that illness. Some self-reported questionnaires available for RA and AS are listed in Table 17.4, and can be accessed via internet search. Table 17.4 Self-reported health-related quality of life questionnaires RA
AS
Health Assessment Questionnaire (HAQ)
AS Quality of Life (ASQOL)
RA Quality of Life (RAQOL)
BAS Disease Activity Index (BASDAI) BAS Functional Index (BASFI)
BAS, British Ankylosing Spondylitis.
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
15:26
Page 91
17 Evaluating the response to treatment
91
An important domain to consider in patients with RA and AS is that of fatigue. Unlike normal tiredness, fatigue is chronic and typically is not related to over-exertion and is not relieved by rest. Fatigue is a frequent complaint in many chronic diseases and can be assessed via visual analogue scales and also by dedicated questionnaires. As an outcome it has a strong relationship with the other joint symptoms in RA and AS, and is negatively influenced by sleep disorders. Regular physical activity helps alleviate fatigue and improves quality of life.
Recent Developments 1 There are conflicting data regarding survival in patients with AS. A broad population-based study from Rochester, Minnesota, showed no difference in mortality between men with AS and the general population. Other studies indicate that mortality amongst AS patients seen in specialist referral centres is higher – standardized mortality ratio of 1.7 – with a linear relationship between mortality and disease severity. Furthermore, mortality in AS may be related to disease duration. Mortality risk ratios relative to the general male population are 4.0 for gastrointestinal disease, 1.3 for circulatory diseases and 1.2 for cerebrovascular disease. Smoking is a dose-dependent risk factor for the development of atherosclerosis, but it is unknown whether or not AS patients smoke more than the general population. However, smoking is associated with worse clinical, functional and radiological outcomes in AS.2 2 The inflammatory processes in AS may affect various structures of the heart; the most characteristic conditions are conduction defects and aortic insufficiency and, less commonly, pericarditis, cardiomyopathy and mitral valve disease. Conduction disturbances may occur in AS due to inflammation and fibrosis of the interventricular septum thereby affecting the atrioventricular node. Aortic insufficiency develops because the inflammatory process affects the aortic wall directly behind and above the sinuses of Valsalva. This leads to scarred, fibrotic, thickened and shortened aortic valve cusps and to a dilated aortic root, resulting in aortic regurgitation. The occurrence of conduction disturbances in patients with AS varies from 1% to 33%, and of aortic insufficiency from 1% to 10%, and increases with age, disease duration and the presence of peripheral arthritis. Impaired ventricular relaxation leading to diastolic dysfunction is being increasingly recognized in AS, even in subjects with clinically mild disease. Yildirir and colleagues examined 88 AS patients and 31 healthy controls and found that diastolic function of the left ventricle was significantly disturbed in AS patients compared to controls. 3 3 It is now recommended that three domains be assessed in the clinic for therapeutic responses in RA: patient-reported measures of physical function and/or global disease activity; physician-reported measures of physical function and/or global disease activity; and imaging of the hands and/or feet on a biannual basis.4 In practice, a 10 cm visual analogue scale can be used by both patient and physician for the global disease activity. Radiographic images should be compared over time, and may require the assistance of your local radiologist. Measures of improvement for individually relevant physical activities need to be defined for each patient.
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
92
18/3/08
15:26
Page 92
§03 Rheumatoid Arthritis
Conclusion A range of practical and relevant measures exists for measuring meaningful outcomes in patients with arthritis – particularly AS and RA. These neatly combine laboratory, objective clinical and subjective physician and patients’ measurements to provide a multidomain assessment that provides information on current disease activity and its impact on the person’s quality of life, and allows you to evaluate the utility of interventions that the patient is receiving.
Further Reading 1
Irons K, Jeffries C. The Bath Indices. Outcome Measures for use with Ankylosing Spondylitis Patients. National Ankylosing Spondylitis Society, East Sussex, United Kingdom, 2004. http://www.nass.co.uk/bath_indices.htm [Accessed November 2007]
2
Doran MF, Brophy S, MacKay K, Taylor G, Calin A. Predictors of longterm outcome in ankylosing spondylitis. J Rheumatol 2003; 30: 316–20.
3
Yildirir A, Aksoyek S, Calguneri M, Oto A, Kes S. Echocardiographic evidence of cardiac involvement in ankylosing spondylitis. Clin Rheumatol 2002; 21: 129–34.
4
Zatarain E, Strand V. Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials. Nat Clin Pract Rheumatol 2006; 2: 611–18.
P R O B L E M
18 Pregnancy and Rheumatic Diseases Case History Jane is a 32-year-old lawyer who has been treated for rheumatoid arthritis (RA) for the past four years. Her symptoms are well controlled on methotrexate 20 mg/week and diclofenac 50 mg bd as needed. She and her partner would like to start a family. She wishes to discuss the effect a pregnancy would have on her arthritis and vice versa. What are the beneficial and adverse effects of pregnancy on RA? Does she need to change her treatment? Will RA affect her chances of becoming pregnant?
© Atlas Medical Publishing Ltd
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
15:26
Page 93
18 Pregnancy and rheumatic diseases
93
Background RA tends to improve in pregnancy, with 80% of patients enjoying virtually complete remission. The disease remains active in the remainder but only worsens in a small minority. Most causes of inflammatory polyarthritis (IP) follow this pattern. A small proportion of patients with systemic lupus erythematosus (SLE) experience flares during pregnancy. These are now less common with more effective therapy before pregnancy and with planning of pregnancy. Previously, pregnancy flares of SLE may have been largely due to withdrawal of drugs in patients with disease that was still quite active. Prolactin is a pro-inflammatory hormone and may contribute to some cases of IP worsening in pregnancy and in the post-partum. RA is an autoimmune inflammatory disease in which CD4+ T lymphocytes have a prominent role in the underlying pathological process. CD4+ T cells can be divided into two subsets: T helper 1 cells (Th1) and T helper 2 cells (Th2). Th1 cells produce interferon-g, interleukin (IL)-2, tumour necrosis factor (TNF)-b and IL-12. Activation of this cell type and dominance of the Th1 cytokine pattern facilitates cell-mediated immunity. The Th2 cell pattern leads to secretion of IL-4, IL-10 and IL-13, which facilitates humoral immunity. Of the two T-cell patterns, the Th1 cell-mediated immunity pattern is more consistent with active autoimmune diseases. In general terms, pregnancy is associated with a shift towards a Th2 humoral pattern of immunity.1,2 Furthermore, circulating antagonists to Th1-type cytokines are increased, both during normal pregnancy and in pregnancies of patients with autoimmune diseases. These antagonists include interleukin1 receptor antagonist (IL-1ra) and the soluble receptors for TNF and IL-6 (sTNFR and sIL-6R). The cytokine pattern in pregnant patients with rheumatic diseases does not differ markedly from that of normal pregnant women. Increased levels of oestrogen, androgens and progesterone may all contribute to the shift away from the pre-pregnant Th1 pattern, and this leads to decreased cell-mediated immunity. Impairment of antigen-presenting function and neutrophil activity may also be relevant, as these are the initial steps that lead to normal activation of lymphocytes. It is noteworthy that remission of inflammatory conditions is more likely if the mother and foetus are dissimilar in HLA determinants, suggesting that the more active pregnancy-related immunosuppression occurs in women where there is the most marked HLA disparity between themselves and their foetus.
Fertility in rheumatic diseases Women with RA are more likely to be nulliparous or to have a smaller family than their non-RA counterparts. There is, however, no evidence of a general decrease in fertility among patients with RA.3 Their general debility and drug treatment (including steroids) may decrease sexual desire and the frequency of intercourse. They may also be concerned about potential effects of disease-modifying antirheumatic drugs (DMARDs) on their baby, and about their ability to deal with pregnancy and to care for a young child. Concerns about worsening symptoms during pregnancy and afterwards may also play a part. Paradoxically, while normal women often experience marked decrease in physical function and increase in symptoms (including pain) during pregnancy, many women with RA feel better and experience less pain. There is an increased rate of fetal loss related either to the underlying disease states or to drug treatments, including non-steroidal anti-inflammatory drugs (NSAIDs).
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
94
18/3/08
15:26
Page 94
§03 Rheumatoid Arthritis Cyclophosphamide is rarely needed in the management of RA but is used in the management of severe SLE, particularly for nephritis or vasculitis. Its use in women over the age of 35 years generally renders them infertile, with its effects on younger women being more variable. The effects of cyclophosphamide on the ovary can be diminished by use of a high-oestrogen oral contraceptive preparation or with gonadotrophin-releasing hormone agonists or antagonists. Alternatively, oocyte recovery with cryopreservation can be used. In men, sperm count is decreased with methotrexate, cyclophosphamide or sulphasalazine. The count usually recovers when the drug is stopped but, if there is concern, sperm can be stored. Fertility treatment is possible for women with RA and SLE – care should be taken with SLE as hormone treatments may increase disease activity.
Disease during pregnancy The risk of increased activity of SLE may be less than was once thought. With modern treatment, more women start pregnancy with the disease in remission. Also, we have become comfortable with using some of the disease-modifying drugs in pregnancy so that the disease can be effectively treated throughout. Flares of lupus during pregnancy are generally mild. However, disease activity in pregnancy increases risk of intrauterine death, fetal growth retardation, pre-eclampsia and premature rupture of membranes leading to early delivery. Lupus flares in pregnancy are less likely if the disease is well controlled at conception. Unplanned pregnancies, however, can lead to worsening of skin rash, increased joint symptoms, mucosal ulceration, anaemia and thrombocytopenia, hypertension and proteinuria, renal casts and increasing levels of anti-double-stranded DNA (anti-dsDNA) antibodies with decreased complement (C3 and C4). The risk of thromboses, particularly venous thromboses, is increased two- to fourfold during normal pregnancy and in the six weeks post-partum, and is particularly high after Caesarean section. The risk of both venous and arterial thrombosis is increased in women with antiphospholipid syndrome (APS), and all women with lupus or a history of pregnancy loss should be screened by testing for lupus anticoagulant and anti-cardiolipin antibodies. APS is present in 37% of patients with SLE, but can occur in other autoimmune disease and in the absence of autoimmune disease.4 APS also increases the risk of pre-eclampsia, premature labour and HELLP (Haemolytic anaemia, Elevated Liver enzymes, Low Platelets). The effect of pregnancy on the spondyloarthropathies is more variable – the peripheral manifestations (arthropathy and uveitis) tend to improve, while spinal symptoms often worsen. Vasculitides are relatively rare and there are few systematic studies during pregnancy. Like SLE, these conditions may flare up (particularly in the first and second trimesters). Patients with Behçet’s disease are at increased risk of thrombosis in pregnancy. Lupus nephritis and renal vasculitis can be difficult to distinguish from preeclampsia. The latter is more likely to be associated with hypertension and improves rapidly following delivery. Systemic sclerosis does not appear to be at particular risk of progressing during pregnancy.
Effect on the foetus Transplacental passage of immunoglobulin G (IgG) antibodies, including anti-SSA/Ro and anti-SSB/La, can lead to neonatal lupus syndrome and congenital heart block (CHB). The former can cause a transient photosensitive rash, hepatic dysfunction and bone
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
15:26
Page 95
18 Pregnancy and rheumatic diseases
95
marrow depression. CHB occurs in the offspring of mothers who are anti-SSA/Ro positive, and most infants born with this complication require a pacemaker before the age of one year. It is rare, occurring in only 2% of infants of such mothers, and in 1 in 22 000 of the general population. Ideally, all young women with an inflammatory arthropathy such as SLE or RA should be screened for lupus anticoagulant, anti-cardiolipin antibodies and anti-SSA/Ro prior to them considering a family, or they should be tested early in their pregnancy. The rash of neonatal lupus resolves over the first three to five months of life, as the maternally derived IgG is cleared from the baby’s circulation. SLE disease activity at conception and the presence of antiphospholipid antibodies are the major determinants of fetal outcome. Fetal loss occurs in up to 30% of patients with active lupus. All inflammatory arthropathies increase the risk of premature delivery. However, with modern obstetric monitoring and neonatal management, the risk to the child has been markedly decreased in recent years.
Drugs None of the drugs used in IP (except simple analgesics) is entirely safe during pregnancy. Methotrexate, cyclophosphamide, azathioprine, gold and cyclosporine should all be stopped at least three and preferably six months before pregnancy. Leflunomide has a very prolonged functional half-life (several months) due to its enterohepatic recirculation and is also very teratogenic. Prior to its prescription to a young woman, it is advisable to discuss the time frame of possible pregnancies and to clearly state that pregnancy should not occur within two years of ceasing the medication, unless the drug has been washed out using cholestyramine and a plasma drug level obtained that confirms elimination. NSAIDs should be stopped if possible before pregnancy as they may increase risk of early pregnancy loss. Later adverse effects on the infant include premature closure of the ductus arteriosus with resulting pulmonary hypertension, cutaneous and intracranial bleeding and impaired renal function leading to oligohydramnios. If NSAIDs are required in pregnancy, older agents with a short half-life are best – indomethacin, ibuprofen and diclofenac. Corticosteroids are relatively safe in pregnancy if the dose is kept below the equivalent of 20 mg/day prednisolone. If it is considered necessary to treat mother and foetus, then dexamethasone or betamethasone should be used. Otherwise, hydrocortisone, cortisone or prednisolone should be used; less than 10% of these are delivered to the foetus (the remainder that crosses the placenta is inactivated by 11bhydroxysteroid dehydrogenase). Side effects of steroid therapy mainly affect the mother and include hypertension, oedema, pre-eclampsia and gestational diabetes. The most extensively documented teratogenic effect is with methotrexate, which can also induce miscarriage even with normal foetuses. The drug may cause a range of congenital abnormalities including limb anomalies, craniofacial anomalies and a range of nervous system anomalies including anencephaly and hydrocephalus. Sulphasalazine has been extensively used throughout pregnancy in patients with both RA and inflammatory bowel disease and is considered safe. Where immunosuppression is required, azathioprine is a reasonable choice. The foetus cannot convert it to its active metabolite, 6-mercaptopurine, and it is therefore relatively free of teratogenic effect. It has, however, been associated with growth retardation and premature rupture of membranes.
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
96
18/3/08
15:26
Page 96
§03 Rheumatoid Arthritis
Recent Developments 1 In a national (United States) study with access to data from over four million deliveries, Chakravarty and colleagues5 showed that, compared with the background pregnant population, women with RA or SLE were more likely to develop a hypertensive disorder, spend more time in hospital and to have a Caesarean delivery. The prevalence of hypertensive disorders was highest in patients with SLE and was comparable in these patients to the prevalence of hypertensive disorders in gestational diabetes (GDM). There was increased risk of premature rupture of membranes and of intrauterine growth retardation in both RA and SLE. The Caesarean section rate was not as high as in patients with GDM. 2 There are fewer data available on Sjögren’s syndrome (SS) in pregnancy than for RA or SLE. A recent case–control study6 investigated reproductive problems in patients with SS. Complaints of vaginal dryness were found twice as commonly as in controls and affected over 50% of SS patients. The previously documented association between SS and endometriosis was confirmed. Fertility was not decreased in SS, but women chose to have fewer children because of their disease.
Conclusion The patient should stop methotrexate at least three months before pregnancy, which should be carefully planned wherever possible. Careful monitoring of the condition in the months before pregnancy should be achieved, which will determine the level of therapy required. Clearly the latter should be kept to a minimum before and during pregnancy. One would not expect a major reduction in fertility in the above patient.
Further Reading 1
Gordon C. Pregnancy and autoimmune diseases. Best Pract Res Clin Rheumatol 2004; 18: 359–79.
2
Østensen M, Förger F, Villiger PM. Cytokines and pregnancy in rheumatic disease. Ann NY Acad Sci 2006; 1069: 353–63.
3
Katz PP. Childbearing decisions and family size among women with rheumatoid arthritis. Arthritis Rheum 2006; 55: 217–23.
4
Tincani A, Bompane D, Danieli E, Doria A. Pregnancy, lupus and antiphospholipid syndrome (Hughes syndrome). Lupus 2006; 15: 156–60.
5
Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 899–907.
6
Haga HJ, Gjesdal CG, Irgens LM, Østensen M. Reproduction and gynaecological manifestations in women with primary Sjögren’s syndrome: a case– control study. Scand J Rheumatol 2005; 34: 45–8.
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
15:26
Page 97
19 Diet and arthritis
97
P R O B L E M
19 Diet and Arthritis
Case History Michelle is 37 years old and has had rheumatoid arthritis (RA) for four years. She is compliant with her medication and has achieved near-remission but does not like taking tablets. She has a body mass index of 27.6 kg/m2 and is seeking advice on whether there are any effective diets or supplements. What is the effect of being overweight or obese on rheumatic diseases? Are there pro- or anti-inflammatory components of the diet? What simple, risk-free advice might she be given? Is there a place for food supplements?
Background Pharmacological measures to improve symptoms and drugs to modify disease activity have transformed the management of rheumatic diseases. Dietary measures have a much less certain place but emerging evidence is beginning to point to a role in disease prevention in patients who are at high risk of developing the diseases, and in controlling symptoms or preventing relapse in patients who have diagnosed disease. There is increasing pressure on health professionals to be knowledgeable about dietary factors as patients are increasingly informed. The increased predisposition to osteoarthritis amongst patients who are either overweight or obese is now well documented, as is the importance of various dietary components in RA.
Diet as a susceptibility factor for RA The cause of RA is unknown but is likely to involve both genetic susceptibility and environmental factors such as diet, and may involve interplay of both factors. Available data suggest that at least one-third of RA susceptibility is explained by environmental variation. The possibility that diet may play a role in both the onset and persistence of RA is a frequently reported experience and there is a growing literature in support of this hypothesis.1 A large prospective study was performed in the United Kingdom using RA cases registered from the Norfolk Arthritis Register. A number of dietary factors emerged as being of possible relevance.2 Low fruit and vitamin C intake was associated with a doubling in the risk for RA, with the highest daily intake of the antioxidants b-cryptoxanthin and zeaxanthin having the lowest risk for RA. It was suggested that one glass of freshly © Atlas Medical Publishing Ltd
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
98
18/3/08
15:26
Page 98
§03 Rheumatoid Arthritis squeezed orange juice per day would be sufficient to offer protection. A high intake of red meat had a modest risk for RA, which is independent of any lowering of fruit and vegetable intake, and may be explained by red meat providing a dietary source of omega-6 oils. The reported effects of decaffeinated/caffeinated coffee, tea or total caffeine consumption are internally inconsistent and conflicting, making a real effect unlikely.2 Alcohol consumption and the risk of developing RA has only been studied in women. The results are conflicting, at best suggesting a modest protective effect in women consuming the most alcohol.1
Fruit, vegetables and antioxidants Monocytes, macrophages and granulocytes at the site of an inflammatory process generate reactive oxygen species. These, in turn, lead to increased production of inflammatory mediators. This process, which is partly mediated by increased local nitric oxide production, can potentially be inhibited by antioxidants, which scavenge reactive oxygen species.3 Interestingly, in patients with RA, blood markers of antioxidant nutritional status are lower than in normal controls. Fruit and vegetables are the main source of antioxidants in the diet, including retinoids, vitamins C and E, carotenoids, selenium and lutein. Lower intake of vitamin C is associated with increased risk of inflammatory polyarthritis.4
Essential fatty acids and the Mediterranean diet The Mediterranean diet is characterized by less red meat and more fish, with olive oil as the primary fat source, an abundance of plant food and moderate wine consumption. High levels of omega-3 fatty acids may protect against inflammation by substituting for omega-6 fatty acids. Polyunsaturated fatty acids contain two or more double bonds, with the omega-3 or omega-6 classification according to the site of the double bond proximal to the methyl terminus. Mammals do not possess the enzyme necessary to introduce double bonds at the 3 or 6 positions – they are therefore essential fatty acids and must be obtained from the diet. The Western diet is abundant in omega-6 fatty acids due to the abundance of linoleic acid in soybean, safflower, sunflower and corn oil.5 Fish oil contains the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These compete with arachidonic acid for cyclooxygenase (COX)-1, COX-2 and lipoxygenase enzymes, and their metabolism leads to incorporation of anti-inflammatory prostanoids and leukotrienes in cell membranes. Olive oil is rich in oleic acid, which can be metabolized to eicosatrienoic acid, similar to omega-3 polyunsaturated fatty acid from fish oil. Stamp et al.5 have extensively reviewed the role of dietary oils in RA. In combination with non-steroidal anti-inflammatory drugs (NSAIDs)/aspirin, omega-3 oil produced a novel family of bioactive lipids known as resolvins, named for their antiinflammatory effect and tendency to resolve inflammation at the site of study. Fish oil supplementation reduced expression of the antigen-presenting class II HLA-DR molecule on human monocytes, with a reduced ability to present antigen after culture with EPA and DHA. The risk of RA has been documented to be lower in those who consume higher amounts of olive oil or oily fish.6 These observations are consistent with several randomized controlled trials showing modest antirheumatic benefit of omega-3 fatty acid supplementation, including reduced early morning stiffness, tender joint count and use of NSAIDs (Box 19.1).
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
15:26
Page 99
19 Diet and arthritis
99
Box 19.1 Effects of omega-3 oils on the manifestations of RA 쎲 쎲 쎲 쎲
Modest clinical improvement when used with standard pharmacotherapy Deterioration in symptoms after discontinuation Ability to decrease or cease NSAIDs and hence reduce associated gastrointestinal and cardiovascular risk Reduce sudden cardiac death
Dietary supplements and RA In all studies of fish oils, the benefits were observed against a background of standard therapy of NSAIDs, disease-modifying agents and immunomodulators. Collectively, these studies have established that fish oil supplementation that delivers 2.6 g or more per day of the long-chain fatty acids EPA plus DHA reduces symptoms after a latent period of three months. The latency can be reduced with higher doses of fish oil. For antiinflammatory effect it is recommended to take 2.6–4.0 g of EPA and DHA per day. The required dose of fish oil can be taken either as fish oil capsules or from bottled fish body oil, with patient preference relating to cost and palatability. In addition to oil supplements, patients should be encouraged to review their background diet so as to minimize omega-6 oil intake and maximize omega-3 intake (Box 19.2). Elemental diets provide food in the most basic forms – i.e. free amino acids, medium chain triglycerides and small sugars – and are proposed as being hypoallergenic. General benefit has not been evident in several trials. Vegetarian and vegan diets have been reported to improve symptoms. Many of the studies commence with a fast with resultant improvement in clinical and biochemical parameters, which is not always sustained in the longer term when caloric intake in its modified form is reintroduced. Fasting has been shown to reduce both clinical and laboratory markers of inflammation, possibly by redirecting scarce resources away from inflammatory pathways and reducing disease activity but compromising immune defences. It is important to ensure that sufficient calories and nutrients are being provided to ensure well-being. Elimination diets seek to remove foods that are putatively allergenic from the diet. Studies demonstrate that a proportion of patients improve when putative allergenic foods are eliminated, with worsening of symptoms at some point when foods are sequentially reintroduced. Box 19.2 Diet in rheumatoid arthritis 쎲
쎲 쎲
쎲
Diet as a risk factor – Low fruit, vitamin C, b-cryptoxanthin, zeaxanthin – High meat Diet as a protective or therapeutic factor – High consumption of oily fish, olive oil, cooked vegetables Conflicting data – Caffeine, decaffeinated coffee, tea – Vitamin D and dairy products Doubtful benefit – Elemental diet
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
100
18/3/08
15:26
Page 100
§03 Rheumatoid Arthritis
Recent Developments 1 Turmeric has been used for centuries in Ayurvedic medicine as a treatment for inflammatory disorders including arthritis. In an animal model of arthritis, a curcuminoid-containing turmeric extract demonstrated efficacy in preventing joint swelling and destruction as determined clinically, histologically and by measurement of bone mineral density.7 The putative mechanism of action was further elucidated by analysis of turmeric’s effect on articular transcription factor activation and microarray analysis of articular gene expression. Treatment in vivo prevented local activation of nuclear factor-k-beta (NF-kB) and the subsequent expression of NF-kB-regulated genes mediating joint inflammation and destruction, including chemokines, COX-2 and receptor activator of NF-kB ligand (RANKL). Consistent with these findings, inflammatory cell influx, joint levels of prostaglandin E2 and periarticular osteoclast formation were all inhibited by turmeric extract. Other researchers using curcumin have documented antiproliferative, anti-inflammatory and immunosuppressive activities, as identified by inhibition of neutrophil activation, synoviocyte proliferation and angiogenesis.8 2 Polyphenols are secondary metabolites of plants and are generally involved in the defence mechanism against ultraviolet radiation and insects, but have antiinflammatory activity when consumed. Classified into four groups – flavonoids, stillbenes, lignas and phenolic acids – these naturally occurring plant compounds can have potent effects on reducing chronic disease in animal models.9 Flavanols (one of the flavonoids) have been extensively studied, and there is an estimated daily consumption of 20–25 mg/day in the United States. The potential mechanisms of their anti-inflammatory activities include inhibition of COX and lipoxygenase enzymes, as well as nitric oxide synthase, and inhibition of the transcription factors NF-kB and PPARs (peroxisomal proliferator-activated receptors). In collageninduced arthritis (a mouse model of RA, which is triggered by tumour necrosis factor [TNF]-a) the oral administration of flavonoids improves the arthritis even when the disease has become established.10 Dietary sources of flavonoids include tea, red wine, fruits, vegetables and legumes. Flavanones are in citrus, isoflavones in soy products, anthocyanidins in wine and bilberry, and flavans are in apples and tea. Citrus flavonoids are found in citrus fruits, rutin in buckwheat, epigallocatechin gallate in green tea and naringenin in grapefruit. Oligomeric proanthocyanidins are found in grape seeds and skins. Quercetin is found in onions, tea and apples. Polyphenols are the most abundant group of compounds in fresh tea leaves and are found in green and black tea beverages as 30%–42% and 3%–10% of the total dry matter, respectively. Many medicinal plants contain bioflavonoids, such as ginkgo biloba, hawthorn and Chinese skullcap.
Conclusion ‘Does my diet affect my arthritis?’ is a question familiar to all rheumatologists and primary care practitioners. One-third to three-quarters of RA patients believe that food plays an important role in their symptom severity, and up to half will have tried dietary manipulation to improve their quality of life. The most consistent link between diet and
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
18/3/08
15:26
Page 101
19 Diet and arthritis
101
Table 19.1A Omega-3 friendly foods FATS AND OILS Use either canola, sunola or olive oil spread, mayonnaise and salad dressing instead of your usual oil products Flaxseed oil can be used in salad dressings or mixed with sunola or olive oil and used in baking BREADS AND CEREALS Choose breads, crispbreads and cereals that have added linseed NUTS Macadamias, hazelnuts, cashews and almonds can be enjoyed every day in limited amounts (one handful) Peanuts (and peanut paste) and pistachios – one handful 2–3 times a week MEAT Use lean cuts of meat FISH Choose oily fish, i.e. mullet, flathead, snook, trevally, fresh tuna, canned pink salmon, canned sardines FRUITS AND VEGETABLES Eat freely CONVENIENCE FOODS Frozen chips (these are pre-cooked in canola oil) McCain – Healthy Choice; Straight Cut or Country Style Birds Eye – Steak House, Crinkle Cut, Home Style, French Fries, Flavour Crisp (Seasoned Crunchy Wedges only) SNACK FOODS & CONFECTIONERY Most potato crisps are cooked in omega-6 fats, which may prevent the omega-3 fats going into your body Kettle Chip Company chips are cooked in sunola oil FAST FOODS Pizza Haven and Fasta Pasta use canola oil Based on a pamphlet developed by Dr E Mantzioris, Dr MJ James and Prof LG Cleland, Royal Adelaide Hospital, Australia.
Table 19.1B Foods to avoid FATS AND OILS Avoid all other oils, cooking sprays, dressings, mayonnaise, lards, dairy blends, drippings, cooking margarines and spreads NUTS & LEGUMES Brazil nuts, pecan nuts, pine nuts, walnuts, sesame seeds (tahini paste, houmous), sunflower seeds FISH Packaged frozen fish such as fish fingers CONVENIENCE FOODS All other varieties of frozen chips. Avoid those fruits or vegetables that are canned in dressings (e.g. potato salad) SNACK FOODS & CONFECTIONERY Health food bars – sesame bars, nut bars, muesli bars
arthritis to date remains that of polyunsaturated omega-3 oils. Additional potential mechanisms are under exploration, and it is prudent advice to any patient with inflammatory polyarthritis that they aim to alter their omega-3/omega-6 balance (Table 19.1). This should occur in parallel with the use of single and preferably combination diseasemodifying agents. There is limited evidence for benefit of restrictive or elimination diets and any benefits are likely to be individual and not transferable to the next patient.
03-PS Rheumatology-cpp:03-PS Rheumatology-ppp.QXD
102
18/3/08
15:26
Page 102
§03 Rheumatoid Arthritis Research into the dietary polyphenols may open up new areas of dietary manipulation in the treatment of chronic inflammatory disease.
Further Reading 1 Pattison DJ, Harrison RA, Symmons DPM. The role of diet in susceptibility to rheumatoid arthritis: a systematic review. J Rheumatol 2004; 31: 1310–19. 2 Oliver JE, Silman AJ. Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol 2006; 35: 169–74. 3 Pattison DJ, Symmons DPM, Young A. Does diet have a role in the aetiology of rheumatoid arthritis? Proc Nutr Soc 2004; 63: 137–43. 4 Pattison DJ, Silman AJ, Goodson NJ et al. Vitamin C and the risk of developing inflammatory polyarthritis: prospective nested